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Chapter 1
Introduction and outline of the thesis
Chapter 1
Introduction
Microorganisms are everywhere. We are surrounded by microorganisms and we 
have to discriminate between the majority of the harmless colonizing 
microorganisms and a handful of harmful pathogens. The impact that infections 
have on everyday life was painfully apparent during the history of mankind, both 
before and after Louis Pasteur, who identified the cause of the infection in his 
microbial theory1. In the era before the discovery of antimicrobial drugs, 66 years 
ago, life expectancy at birth was much lower in western countries than nowadays2. 
Pasteur's microbial theory and the discovery of antimicrobial agents were major 
breakthroughs in medical science that paved the road for both the understanding 
and the treatment of infectious diseases. Despite these breakthroughs, a major 
question remained, namely, why is there a difference in susceptibility between 
individuals that are exposed to the same environment of microbial pathogens?
In order to understand the differences in susceptibility to infections between 
different individuals, one needs to consider the mechanisms responsible for the 
recognition and clearance of harmful pathogens. In vertebrates, specialized cells 
such as macrophages, neutrophils, dendritic cells, natural killer cells and basophils 
perform this task. These cells express specialized receptors named pattern 
recognition receptors (PRR) that recognize specific evolutionary preserved structures 
of bacteria, viruses, protozoa and fungi, named pathogen-associated molecular 
patterns (PAMPs). Recognition of PAMPs by PRRs activates cellular signaling 
pathways and induces an inflammatory response characterized especially by the 
production of inflammatory mediators such as proinflammatory cytokines. In turn, 
cytokine release is crucial for the inflammatory response against pathogens, through 
the recruitment and activation of leukocytes at the site of infection. Recent research 
has shown that there are four distinct families of PRR: Toll-like receptors, C-type 
lectins, Nod-like receptors and Rigl-helicases, and has identified the specific PAMP 
ligands that initiate the innate immune response through these receptors (an 
overview of these receptor families and some of the most important family
8
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members is presented in Table 1). The genetic blueprint of the receptors and 
signaling pathway molecules involved in the activation of the innate immune system 
is determined during fertilization. As a consequence, differences in the susceptibility 
between individuals in the same pathogenic environment could be caused by genetic 
variation in the innate immune system.
Table 1. Classes of Pattern recognition receptors (PRRs) and the pathogen- 
associated molecular patterns (PAMPs) ligands.
P RR PAMPs
Toll-like receprors TLR1 Triacyl lipopeptides
TLR2 Lipoprotein/lipopeptides, Peptidoglycan
TLR3 Double-stranded Ribonucleic acid
TLR4 Lipopolysaccharide, mannans
TLR5 Flagellin
TLR6 Lipopeptides, lipoteichoic acid, zymosan
TLR7 Single-stranded Ribonucleic acid
TLR8 Single-stranded Ribonucleic acid
TLR9 Cytosine—phosphate—Guanine Deoxyribonucleic acid sites
C-type lectin receptors Mannose Receptor Mannan, Fucose
DC-Sign Mannan, gp-120 (human immunodeficiency virus-1)
Dectin-1 Beta-glucan
Dectin-2 Mannan of hyphae
Nod-like receptors NOD1 Muramyl tripeptide, meso-diaminopimelic acid, FK156, FK565
NOD2 Muramyl dipeptide
NALP1 Muramyl dipeptide, lethal toxin
NALP3 Bacterial Ribonucleic acid, Adenosine-5'-triphosphate, Uric acid crystals
NLRC4 Flagellin
NAIP Flagellin
RigI Helicases Mda5 Viral Ribonucleic acid
RIG-1 Viral Ribonucleic acid, Poly ( I :C )
Abbreviations: T LR ; Toll-Like Receptor
DC-Sign; Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin 
NOD; Nucleotide-binding Oligomerization Domain 
NALP; NACHT Leucine-rich-repeat Protein
NLRC; Nod-Like Receptor fam ily , Card domain (NLRC4 is also known as IPAF)
NAIP; Nod-like receptor fam ily , Apoptosis Inhibitory Protein 
Mda; Melanoma Differentiation-Associated gene 
R IG ; Retinoic acid Inducible Gene
A major challenge in the genetics of human infectious diseases is to identify the 
genetic variation of the innate immune system between individuals and populations. 
Most genetic variation between genes in general, and those of the innate immune 
system in particular, is located at the level of single nucleotide polymorphisms 
(SNPs). SNPs are differences in the DNA occurring between individuals in a single 
nucleotide. Depending on the location in the genome, a SNP can either change the 
structure and modify the function of the protein, it can influence the splicing or 
transcription of a gene, or can have a neutral effect on the protein function ("no­
9
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effect"). In order to understand the impact that differences in the genetic make-up 
of a given gene could have on susceptibility to disease, an important step is 
represented by the assessment of the phenotypic consequences that genetic 
variations may induce (Figure 1).
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Figure 1. Effect of genetic variation in DNA. A mutation in a nucleotide (A, T, G or C) of the DNA can occur. Detection of the mutations can be 
analyzed by comparing DNA sequences of various individuals, as shown in panel A. When one nucleotide is altered, the change is called a single 
nucleotide polymorphism (SNP). On the DNA there are areas that contain nucleotide sequences that are transcripted and will lead to the 
synthesis of a protein. This areas of DNA involved in protein synthesis consist of an 5'UnTranslated Region (UTR) involved in the mRNA 
transcription, exon regions that contain the nucleotide sequences that represent the protein structure, intron regions between the exons and a 
3'UTR indicating the end for transcription (panel B). Nucleotides in the exon region are translated into amino acids during translation. Three 
nucleotides together code for one amino acid and is called a triplet. SNPs on the DNA can change the aminoacid sequence of a protein, as 
indicated by the SNP of the black star where the arginine (R) aminoacid is changed into a glycine (G). These change of nucleotides by a SNP are 
know as nonsynonymous. Most of the SNPs do not change the aminoacid structure, such as the SNP indicated by the white star. More effects of 
SNPs are known, and when located at the 5'UTR, 3'UTR and intron region they can influence the transcription of mRNA or splicing of the 
protein.
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Outline of the thesis.
In this present thesis, I describe our investigations into the genetic variation in genes 
of the innate immune system and the functional effect of specific genetic variations 
on the susceptibility to infections. The major aim of this thesis was to assess the 
effect of genetic variation in the innate immune system on the immune response, 
and to gain insight in genetic variations that change human susceptibility to 
infections.
The focus of the first part of the thesis is on the translation of genetic variation that 
is involved in the recognition of bacteria. After pathogenic bacteria have gained 
entrance to the host, recognition of these bacteria by the innate immune system will 
activate the inflammatory host defense mechanisms and clear the pathogen. 
Insufficient recognition and clearance will lead to outgrowth of bacteria, and may 
lead to sepsis. Bacterial sepsis is a severe clinical condition in which the bacterial 
growth is accompanied by a whole-body inflammatory state called systemic 
inflammatory response syndrome (SIRS), that may, in turn lead to shock, organ 
dysfunction and even death within a short period of time. Sepsis is still a major 
causes of death especially in intensive care units3. In this thesis, I have focused on 
understanding how genetic variations in two genes of the innate immune system, 
the toll-like receptor 4 (TLR4) and the anti-inflammatory protein Caspase-12, play a 
role in susceptibility to infections and in the pathogenesis of sepsis. In these studies, 
we have combined functional (phenotypic) and genetic (genotypic) approaches to 
understand the impact of TLR4 and caspase-12 polymorphisms on infections.
TLR4 is an extracellular innate immune receptor and one of the first PRRs discovered 
in humans. The function of TLR4 is well established4,5. The main ligand recognized by 
TLR4 is bacterial lipopolysaccharide (LPS, endotoxin), which is found in the cell 
membrane of Gram-negative bacteria. After the recognition of LPS by TLR4, an 
intracellular signaling pathway is triggered that leads to the transcription of 
proinflammatory cytokines, such as Tumor Necrosis Factor (TNF) and Interleukin-1
12
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beta (IL-1ß). These cytokines are responsible for the initiation of the immune 
response and clearance of the intruding Gram-negative bacteria. Several studies 
have assessed genetic variation of TLR46, and they have shown the presence of two 
SNPs in the recognition domain: Asp299Gly and Thr399Ile. Besides the change of the 
protein structure, it was also claimed that the Asp299Gly and Thr399Ile SNPs have 
an effect on the function of the TLR4 signaling7. To understand the TLR4 signaling 
and the effect of these two polymorphisms on the TLR4 function during sepsis, I 
present in Chapter 2 an overview of the TLR4 signaling pathway and of the literature 
focused on the functional consequences of polymorphisms in this gene.
Based on the information reviewed in Chapter 2, we hypothesized that TLR4 SNPs 
have important consequences for the susceptibility to infections, and subsequently 
affect the distribution of these genetic variants. In Chapter 3, we have assessed the 
distribution of TLR4 Asp299Gly and Thr399Ile SNPs by using an evolutionary 
approach. A first step was to assess differences in the distribution of the TLR4 
genotypes in populations from Africa, Asia and Europe, which might be caused by 
phenotypic changes in the susceptibility of Gram-negative infection. Hypothetically, 
individuals with TLR4 genetic variants that provide resistance to sepsis were more 
likely to survive and pass those variants onto their offspring during evolutionary 
history. In environments with high prevalence of Gram-negative infections, one 
would expect that the genetic signals due to this infectious pressure result in an 
effect on the prevalence of certain TLR4 genotypes. A second approach to this 
research question was to assess the functional consequences (the phenotype) that 
resulted from the presence of TLR4 SNPs. In in-vitro experiments we assessed 
cytokine production capacity of cells of the innate immune system stimulated with 
the TLR4 ligand LPS. After stimulation, cytokines were measured to give insight in the 
possible differences between the TLR4 genotypes.
An additional angle to the function of TLR4 pathway is studied in Chapter 4, where I 
investigated genetic variation in the adaptor molecule Mal (also known as TIRAP). 
Mal is a signaling adaptor molecule involved in the mediation of both TLR2 and TLR4 
signaling. TLR2 is a PRR involved in the recognition of lipopeptides and lipoteichoic
13
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acids of Gram-positive bacteria. The Ser180Leu Mal/TIRAP SNP has been reported to 
play an important role in the protection of individuals against a broad range of 
infections, such as malaria, tuberculosis, bacteremia and pneumococcal disease8. 
Although this effect of the Mal genotype on the susceptibility to infections was 
described at a genetic level, the insight in the phenotype induced by this SNP lacked. 
Therefore, using an in-vivo approach in healthy individuals receiving an LPS infusion, 
we assessed the differences between the individuals bearing different Mal/TIRAP 
genotypes in terms of cytokine production capacity.
Although TLR4 is the main PRR for LPS, it is also involved in the innate immune 
response against Mycobacterium tuberculosis9, the agent of tuberculosis. Regarding 
tuberculosis, an unsolved question remains why only a minority of the infected 
patients develops active tuberculosis. Even in the growing cohort of patients co­
infected with HIV and Mycobacterium tuberculosis in sub-Saharan Africa, who have a 
strongly suppressed immune system, not all develop active tuberculosis. This 
suggests a possible role for genetic variation of the innate immune system that 
influences susceptibility to mycobacteria. In Chapter 5 we investigated a possible 
effect of the TLR4 Asp299Gly SNP on the susceptibility to tuberculosis.
One of the best known examples proposed to be the result of evolutionary selection 
on the innate immune system by sepsis is that of the anti-inflammatory protein 
caspase-1210. Caspase-12 is an inhibiting enzyme of the caspase-1 and NOD2/RIP 
pathways11-13. Population genetic studies have identified an early stop codon SNP in 
caspase-12 that causes the truncation of the enzyme, resulting in the loss of its 
inhibitory effect on the caspase-1 and NOD2/RIP pathways. It was proposed that 
evolutionary pressure on human populations due to sepsis has selected against the 
active caspase-12 in Europe and Asia10. In Chapter 6, I investigated the differences in 
the phenotype of individuals with either the inactive or the active form of caspase- 
12, especially in relation to its effect on cytokine release induced by Yersinia pestis, 
the bacterium that causes plague. The plague epidemics of the Middle Ages have 
been proposed to represent the explanation of the selection on the inactive form of 
caspase-12 in Europe and Asia. In contrast with the Eurasian continental mass, the
14
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active form of caspase-12 is still found in Africa10,14. In Chapter 7 I investigated the 
hypothesis that the presence of malaria in Africa is responsible for the persistence of 
an active caspase-12 in the genome of African individuals.
In the second part of the thesis, I will assess, in even more detail, the relationship 
between the genotypic variation and the phenotypic consequences, by using either a 
clinical/immunological or an evolutionary approach (Figure 2). Using the first 
approach, clear phenotypic differences in terms of clinical presentation or 
immunological abnormalities are present in certain individuals. The challenge is to 
translate this phenotypic knowledge into the underlying genotype. In contrast to the
Figure 2. The clinical and evolutionary approach. Distinction between the clinical- 
and evolutionary approach lay in the starting point at which a research is initiated. In 
the clinical approach the research questions origin lays in the observation in 
physiological differences of patients with a similar disease. Hereby the patients have 
a different phenotype that is causing the change. By functional studies a better 
understanding of the phenotype can lead to indications that a specific genotype is 
responsible for the observed phenotype. The evolutionary approach starts with 
detection of specific genotypes that show signatures of selection. For evolutionary 
approach functional studies will lead to the understanding of the phenotype that is 
caused by the observed genotype.
15
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clinical approach, the evolutionary approach uses genotype analysis in populations 
to look at signatures of selection. These signatures indicate certain genotypes with 
potential beneficial effects that may have been selected during evolution. In this 
approach, the first step of the identification of genetic variants must be 
accompanied by a second step that assesses the possible phenotypic differences.
Firstly, the clinical approach is shown in Chapter 8 by the description of a non­
responder phenotype to beta-glucans. Beta-glucans are fungal PAMPs that are 
recognized by the dectin-1 receptor. In some patients with mucocutaneous fungal 
infections, it was observed that cells isolated did not release cytokines after 
stimulation with beta-glucans. We assessed the possible genotypic causes of this 
defect and the clinical phenotype of these patients.
Secondly, the evolutionary approach is highlighted in Chapter 9. In Genome Wide 
Association Studies (GWAS) many immunological disorders have been investigated in 
order to understand the genotypic basis of the diseases. One of the successfully 
studied diseases by the GWAS approach is celiac disease (CD), which is an intestinal 
inflammatory disorder due to gluten intolerance15. For many of the immunological 
disorders it is an important question to ask why the causative or predisposing genes 
remain present in the human population despite their harmful effects. Insight into 
this question can be given by understanding the evolution of these genes. Tests like 
the relative extended haplotype homozygosity (REHH) and integrated haplotype 
score (iHS) have been developed to detect recent selection in the human 
genome16,17. Both tests look at the human genome to detect extended haplotypes 
without recombination, which are signatures of selective sweeps. Besides the finding 
of the genes and genotypes that show positive selection, it is also needed to 
understand the phenotypic consequences of these genetic variants. One of the 
genes that influence susceptibility to CD that has been under evolutionary pressure 
in recent history is SH2B3, a gene previously hypothesized to modulate the 
inflammatory response. In Chapter(9 I investigated the possible selection of CD risk 
alleles for the gene SH2B3 and the relation of SNP variants with phenotypic 
consequences for the immune response.
16
Finally, Chapter 10 provides a summary, a general discussion and future prospects 
for the evolution of this field of research.
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Abstract Review
Functional consequences of TLR4 polymorphisms
Toll-like receptor 4 (TLR4) is an important pathogen recognition receptor that 
recognizes mainly lipopolysaccharide (LPS) of Gram-negative bacteria, but also 
structures from fungal and mycobacterial pathogens, as well as endogenous ligands. 
Two nonsynonymous polymorphisms of TLR4, Asp299Gly and Thr399lle, have been 
suggested to alter the function of the receptor. Some, but not all, studies have 
proposed that these polymorphisms lead to reduced cytokine response and 
increased susceptibility to Gram-negative infections. In this review, we compare 
studies that assessed the effect of the Asp299Gly and Thr399lle polymorphisms on 
susceptibility to Gram-negative infections and examine the phenotypic 
consequences of these polymorphisms. In addition, we review the geographical 
distribution of TLR4 polymorphisms and present a model for evolutionary pressures 
on the TLR4 genetic make-up.
21
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Introduction
The innate immune system recognizes a broad range of pathogens and initiates 
protective responses. Recognition of pathogenic microorganisms by the innate 
immune system relies on pattern recognition receptors (PRRs) that detect preserved 
structures of bacteria, viruses, protozoa, and fungi, so-called pathogen-associated 
molecular patterns (PAMPs)1.
A major group of PPRs are the Toll-like receptors (TLRs). After PAMP recognition, 
TLRs activate cellular signaling pathways to induce immune-response genes, 
including inflammatory cytokines2. Ten different human TLRs have been identified3. 
TLR11, which binds and recognizes uropathogenic bacteria and profilin in mice, has 
been shown to be nonfunctional in humans owing to a premature stop codon4,5. 
Each TLR recognizes specific PAMPs, including recognition of lipoproteins, 
lipoteichoic acid, and zymosan by TLR2; dsRNA by TLR3; lipopolysaccharide (LPS) by 
TLR4; flagellin by TLR5; ssRNA by TLR7/8; and CpG DNA by TLR91,6. TLR4, considered 
one of the most important PRRs, recognizes LPS of Gram-negative bacteria; mannans 
from fungal pathogens, a soluble component of Mycobacterium tuberculosis; and 
endogenous ligands, such as fibronectin and several heat shock proteins.
22
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Role and signaling mechanism of TLR4
We owe the elucidation of the function and genetic structure of TLR4 to the 
discovery of Toll, a transmembrane protein, initially discovered for its role in the 
embryonic dorsal-ventral development of Drosophila7. Drosophila with a loss-of- 
function mutation for Toll exhibited a high susceptibility to fungal infection, 
demonstrating the importance of Toll in the antifungal response in the insect8,9. 
After this discovery, work by Rock et al.10 and Medzhitov et al.11 independently led 
to the discovery of several human homolog genes for Toll, the so-called Toll-like 
receptors (TLRs).
Structure analysis of TLR4 revealed that the receptor consists of 3 domains: an 
extracellular leucine-rich-repeat (LRR) domain, a transmembrane domain, and an 
intracellular Toll-interleukin-1 receptor (TIR) domain. The extracellular LRR part of 
the receptor is involved in the binding of LPS. The discovery that LPS is a ligand for 
TLR4 came from studies in mice. Mice challenged with high doses of LPS normally 
develop a shock-like state similar to Gram-negative septic shock. More than 30 years 
ago two mouse strains, C3H/HeJ and C57Bl/10ScCr, were discovered that were 
resistant to LPS18. The phenotype was thought to be caused by a mutation in a 
hypothetical lps gene, but the location and function of this gene remained elusive for
13 14 15a long period . The groundbreaking studies of Poltorak and colleagues , in 1998 
identified TLR4 as the lps gene and demonstrated that TLR4 is the LPS sensor in both 
mice and humans.
Overall, recognition of LPS and initiation of signaling by TLR4 is a complex process, 
which involves several accessory proteins. LPS is first bound by circulating 
lipopolysaccharide-binding protein (LBP), which functions as an opsonin for CD1416. 
CD14 then acts as a catalyst for the binding of LPS to MD-217"19. After the LPS is 
transferred to MD-2, the LPS/MD-2 complex interacts with TLR4. Recent MD-2/TLR4 
crystallography studies have elucidated the structures of this complex20. Formation 
of the LPS/MD-2/TLR4 complex eventually results in the dimerization of the TLR4 TIR 
domain, initiating downstream signaling transduction21.
Downstream signaling by the TLR4 receptor involves several intercellular TIR 
domain-containing adaptors mediating proinflammatory gene expression22,23. Two 
pathways that initiate downstream TLR4 signaling are known, namely the MyD88-
23
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and TRIF-dependent pathways (see Figure 1). One pathway is mediated by myeloid 
differentiation factor 88 (MyD88) and the TIR domain-containing adaptor protein, 
also called MyD88 adapter-like protein (TIRAP/MAL). Initiation of MyD88-dependent 
pathway activation leads to the activation of nuclear factor kB (NF-kB) and the 
transcription of proinflammatory genes24. A second pathway is mediated by the TIR- 
containing protein, also called TRIF-related adapter molecule (TIRP/TRAM), and TIR 
domain-containing adapter inducing interferon-ß (TRIF). Initiation of the TRIF- 
dependent pathway leads to the activation of interferon regulatory factor 3 (IRF3), 
and the expression of interferon (IFN)-ß and IFN-inducible genes21.
Much research has been performed to understand the signaling pathways and 
innate immune response against Gram-negative infections mediated by TLR4, which 
is therefore one of the best-understood Toll-like receptors. Because of this, TLR4 also 
provides an ideal model to study the consequences of genetic variation and their 
relation to the function of the receptor, and their susceptibility to diseases. Here we 
review several genetic polymorphisms of the TLR4 receptor. Also, we try to 
understand if there are any TLR4 genotypes that result in phenotypic consequences.
Genetic variation in human TLR4
Recognition of pathogens and downstream signaling through innate pathways 
involving the TIR domain show high conservation between organisms19. This is in line 
with the finding that the innate immune system shows a high degree of homology 
between mammals, insects, and plants, and apparently has been highly preserved 
during evolution25. Genetic variation between the TLR4s of different mammals is the 
highest in the extracellular LRR region26. The stronger variation in this region, which 
is involved in the recognition of PAMPs, is probably the result of the evolutionary 
pressure by pathogens on the host.
Sequencing of the human TLR4 revealed that most of the variation in non- 
synonymous polymorphisms is located in the third exon, coding for the LRR 
domain27. Despite this greater variation in the TLR4 LRR domain, the frequency of 
most nonsynonymous polymorphisms is low in human populations (<1%). Exceptions 
are 2 nonsynonymous polymorphisms (SNPs) that have been described with 
population frequencies >5%. These are an A/G transition causing an aspartic
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acid/glycine substitution at amino acid location Asp299Gly (rs4986790), and a C/T 
transition causing a threonine/isoleucine switch at amino acid location Thr399lle 
(rs4986791). Arbour et al.28 were the first to report that individuals with either the 
Asp299Gly and/or Thr399lle polymorphisms had a blunted response toward inhaled 
LPS.
Figure 1. Schematic overview of the LPS TLR4 signaling pathway. Recognition of 
LPS is established by the interplay between lipopolysaccharide-binding proteins 
(LBPs) and CD14 that transfer the LPS to the MD-2/TLR4 complex. Dimerization of 
TLR4 then initiates downstream intracellular signaling transduction through Toll- 
interleukin-1 receptor (TIR) domains and several adaptor molecules. Eventually, the 
intracellular signaling results in the activation of specific pro-inflammatory cytokine 
profiles by the MYD88-dependent or TRIF-dependent pathway.
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The finding that TLR4 polymorphisms Asp299Gly and Thr399lle had an effect on the 
responsiveness to bacterial endotoxin initiated many genetic association studies. The 
results of these studies led to contradictory conclusions about the role of the 
Asp299Gly polymorphism and its effect on susceptibility to Gram-negative bacterial 
infections29. This raises the question of the source of these discrepancies. One 
possible explanation may be that these studies looked at the Asp299Gly and 
Thr399lle polymorphisms separately. Most studies either deal with the Asp299Gly or 
the Thr399lle polymorphism, but neglect the fact that these polymorphisms also 
exist in a cosegregated (Asp299Gly/Thr399lle) way27. This cosegregated state of TLR4 
implies that 4 haplotypes, namely wt/wt, Asp299Gly/wt, Thr399lle/wt, and 
Asp299Gly/Thr399lle, are represented in the population. Our results on cytokine 
profiles in LPS-stimulated whole blood cultures demonstrated that only the 
Asp299Gly haplotype differs in phenotype, showing an increased, rather than a 
blunted, pro-inflammatory tumor necrosis factor (TNF)-a response30. lnterestingly, 
the LPS-induced cytokine response in the Asp299Gly/Thr399lle haplotype does not 
differ from the wild-type TLR4 cytokine response30. Because the single Thr399lle 
haplotype is rare, its phenotype is still unknown. Therefore, the TLR4 haplotype that 
alters the cytokine response to LPS (and thus could affect the susceptibility to Gram­
negative infection) contains the single TLR4 Asp299Gly mutation (Figure 2). 
Population studies also revealed a specific geographical distribution of the TLR4 
haplotypes27. All haplotypes trace their origin to before the out-of-Africa migration 
approximately 55,000 to 60,000 years ago. Nowadays, human populations from 
Africa have a 10- to 20-fold higher frequency of the Asp299Gly haplotype than those 
from the other continents. ln contrast, white populations show an almost complete 
absence of the Asp299Gly haplotype, but have a higher frequency of the 
Asp299Gly/Thr399lle haplotype. Asian populations lack all three of the Asp299Gly, 
Thr399lle, and Asp299Gly/Thr399lle haplotypes (Figure 2). This pattern of TLR4 
haplotypes has been the result of differences in environmental pathogenic pressure 
on the human population during the migration into Eurasia, Europe, Asia, and the 
New World30. As a consequence of this specific geographical distribution, most 
published studies performed in populations with a European genetic background
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Cytokine Phenotype
Figure 2. Distribution of TLR4 haplotypes and associated cytokine phenotypes 
across the 3 continents of the Old World. It shows that Africa, Asia, and Europe 
each have their own distinct haplotype, based on the alleles found, shown in 
white. The phenotypic end point is shown on the top of the figure, where the 
expected cytokine production following TLR4 stimulations is presented. When the 
geographic distribution of Asp299Gly and Thr399Ile polymorphisms is taken into 
account, it illustrates that research preformed in Europe has looked at the 
cosegregated Asp299Gly/Thr399Ile haplotype, whose cytokine phenotype does 
not differ from the wild-type TLR4 cytokine response. This also explains the large 
number of studies, performed in Europe, that did not find any association 
between TLR4 polymorphisms and susceptibility to disease. In contrast, the 
Asp299Gly/WT haplotype, that is found almost exclusively in Africa, has a 
stronger pro-inflammatory cytokine response compared with wild-type TLR4.
have analyzed the Asp299Gly/399 haplotype, with no distinct phenotype, instead of 
the Asp299Gly haplotype. To a certain extent, the genetic background of the studied 
populations could explain the lack of agreement between published TLR4 
polymorphism studies. We have therefore reanalyzed published data on the 
Asp299Gly/Thr399Ile and Asp299Gly haplotypes separately, and tested whether the 
presented Asp299Gly and Asp299Gly/Thr399Ile haplotypes correlate with the 
presented phenotypes.
27
Chapter 2
Terms used for a PubMed search were TLR4 polymorphisms, Asp299Gly, and Toll-like 
receptor 4 polymorphisms, which resulted in 164 articles after exclusion of all 
reviews. These articles studied the relationship between TLR4 polymorphisms and 
susceptibility to sepsis, atherosclerotic disease, asthma, Candida infections, chronic 
periodontitis, respiratory syncytial virus (RSV), transplantation, and Crohn's 
disease31"51. The pathogenic ligand in most of these studies is based on the Gram­
negative bacterial LPS, with the exception of the Candida and RSV studies. The 
strongest association to date between TLR4 polymorphisms and disease 
susceptibility has been reported in RVS infections52, but the functional relationship 
between TLR4 polymorphisms and RSV virus remains to be elucidated. Because 
specific parts of the LRR involved in the recognition of various ligands can differ, only 
the LPS studies were included. This resulted in 157 research articles about the effect 
of the TLR4 Asp299Gly and Asp299Gly/Thr399lle SNPs. Of these articles, 62% 
reported no association between the susceptibility to disease and TLR4 
polymorphisms (see Figure 3). The majority of articles included European 
populations (90%), and the rest screened Asian (6%) or African (4%) populations. The 
consequence of the studies involving European populations is in agreement with the 
suspicion that these studies did not look at the Asp299Gly haplotype, as they state, 
but reported de facto on the effect of the Asp299Gly/Thr399lle haplotype. Besides 
the population origin, study methodology can also influence results. For the TLR4 
studies, three types of methodology can be distinguished: genetic association 
studies, functional stimulation experiments, and cloning and transfections of the 
mutated TLR4. Figure 3 shows that the majority of published articles are studies of 
genetic associations. Most of the association studies on TLR4 polymorphisms are 
small and underpowered, whereas larger studies tend to be negative and find no 
correlation between the TLR4 Asp299Gly/Thr399lle haplotype and disease 
susceptibility53.
Although genetic association studies find no correlation between haplotypes and 
disease strictly, they do not give insight into the direct functional consequences of 
TLR4 mutation. Several studies have investigated the functional consequence of
Functional consequences of the cosegregated Asp299Gly/Thr399lle polymorphisms
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Figure 3. Circle diagrams with the frequency of the study results and outcomes 
(below) of TLR4 polymorphism from the PubMed search. This search revealed 
that more than half of the studies do not find any association between 
susceptibility to infection and TLR4 polymorphisms (n = 157). In the top diagrams, 
the frequencies of the methodologies used are presented in the studies that 
showed a positive effect or no association of the investigated TLR4 
polymorphisms. This figure shows that the majority of studies are based on 
genetic association studies, and a minority measured cytokine production 
following LPS stimulation of either whole blood or PBMCs. Overall, the contrast 
between study outcomes measuring the functional effects of TLR4 
polymorphisms and of those looking at the role these have in susceptibility is 
revealed.
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TLR4 SNPs, and the results are summarized in Table 1. The studies of Arbour et al.28 
and Schwartz54"56 show that transfected cells with any of the TLR4 haplotypes have a 
decreased NF-kB activity compared with normal TLR4. This suggest that the 
Asp299Gly/Thr399lle haplotype should have an effect on phenotype, leading to 
reduced cytokine production by the innate immune response. The question then is: 
why are the consequences of such a functional effect not observed in genetic 
association studies?
Table 1. TLR4 polymorphisms and their impact.
Association Stimulation Transfection
Effect of 
polymorphism
Coivano et al. (57) Systemic enaotoxemia Whole blood in vivo No
Kumpf et al. (65) Pre- and postoperative cytokines Whole blood No
Schippers et al. (59,ó0) In vivo and ex vivo response Whole blood No
Newport et al. (62) Pulmonary tuberculosis Whole blood No
Heesen et al. (66) Cytokine synthesis Whole blood No
Vton Aulock et al. (67) LPS-induced cytokine release Whole blood No
Chang et al. (68) TLR4 in peripheral neutrophils and 
monotypes
Whole blood No
Marsik et al. (58) Endotoxemia Whole blood in vivo Yes
Tiberio et al. (69) Innate response to candidate 
adjuvants RC529 and 
monophosphoryl lipid A
Whole blood No
Kroner et al. (70) Multiple sclerosis PBMCs No
Van der Graat et af. (71) Stimulations with different TLR4 ligands PBMCs No
Peeters et al. (51) Impact of polymorphisms on
monocytes in patients with Crohn's 
disease
PBMCs No
Fageràs et al. (72) Asthma PBMCs Yes
Erridge et al. (73) LPS-induced monocytes signaling 
(monocytes)
PBMCs Yes
Schmitt et al. (74) Response to LPS PBMCs Yes
Norata et al. (75) Intima-media thickness and LPS 
monocyte-derived m acrophage 
response
PBMCs No
Montes et al. (76) Hematogeneous osteomyelitis Neutrophils Yes
Kinane et al. (77) Porphyromonas gingivalis Epithelial Yes
Schwartz (54-56) Inhaled LPS Airway epithelia THP-1 Yes
Arbour et al. (28) Inhaled LPS Airway epithelia THP-Ì Yes
Railabhandi et al. (64) Insights in stoichiometry, structure, and 
signaling
HEK-239T Yes
One reason is that the use of transfection to investigate the phenotypic effect of 
certain mutations meets with several complications. Transfections represent a 
stripped-down model performed in altered cell lines. As a result, transfection 
measurements do not give the ideal end point of phenotypic difference representing 
the whole system. Transfections only represent the homozygous state. Most 
population studies of genetic association and function include TLR4 haplotypes in
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heterozygous state, whereas the homozygous state of these polymorphisms is rare. 
Disruptions of the receptor transport can influence results by overfeeding the 
system28. Therefore, determination of the association between the 
Asp299Gly/Thr399Ile haplotype and the phenotype, and its impact on the 
susceptibility to Gram-negative infection (based on transfection experiments), is 
difficult and prone to artifacts.
Besides transfection experiments, most functional studies are based on in vitro 
stimulation of either whole blood or peripheral blood mononuclear cells (PBMCs) 
stimulated with LPS. After stimulation, cytokine release by the cells is measured. The 
whole blood cultures and experiments using isolated PBMCs are in agreement with 
the association studies, as they find little difference between Asp299Gly/Thr399Ile 
and the wild-type haplotype (Table 1). Besides the in vitro experiments, three in vivo 
studies investigated the effects of LPS in human volunteers. Two of these in vivo 
experiments injected 2 ng/kg LPS57,58. Neither of them found a difference in the TNF- 
a serum concentration between individuals with different TLR4 haplotypes. 
However, one study found decreased IL-6 levels after 6 h in volunteers with TLR4 
polymorphisms, whereas the other did not find any differences57,58. The former 
study also reported strongly decreased IL-1[ production after 24-h stimulation, 
suggesting an effect on the late TRIF-dependent pathway58. A third paper measuring 
ex vivo and in vivo cytokine production of the different TLR4 haplotypes also did not 
find differences between Asp299Gly/Thr399Ile and the wild-type haplotypes57,59,60. 
Thus, most studies of stimulated whole blood and PBMCs do not find a distinct 
phenotype of the Asp299Gly/Thr399Ile haplotypes.
Functional consequences of the Asp299Gly polymorphism
As mentioned above, studies that include or define the Asp299Gly haplotype are 
scarce. The best studies of the Asp299Gly haplotype are those performed in Africa. 
Unfortunately, no association studies performed in Africa have focused specifically 
on the response to TLR4 ligands. The study by Mockenhaupt et al.61 focused on 
malaria, whereas that of Newport et al.62 looked at susceptibility to Mycobacterium 
tuberculosis. Neither study included stimulated cytokine production, and therefore it 
is impossible to say anything about the LPS responses in the Asp299Gly haplotypes.
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Although these studies indicate a role for the Asp299Gly haplotype in susceptibility 
to malaria and tuberculosis, they do not reveal the role of the haplotype in the 
recognition of Gram-negative bacteria and LPS.
In contrast, Lorenz et al.63 looked at sepsis patients versus healthy controls in France 
and specifically defined the Asp299Gly haplotype. The Asp299Gly haplotype was 
found only in the group of patients with septic shock, whereas the 
Asp299Gly/Thr399Ile haplotype was found equally in both patients and controls. This 
suggests that the Asp299Gly haplotype has an effect on phenotype, although 
cytokine measurements are lacking. Until now, only one study reported cytokine 
production by individuals with the Asp299Gly haplotype—it found a stronger, rather 
than a blunted, TNF-a cytokine response30. Although more research has to be 
performed to settle the functional consequences of the Asp299Gly haplotype, the 
evidence so far indicates that the TLR4 wild-type haplotype and the Asp299Gly 
haplotype have different phenotypes.
Effects of the Asp299Gly on the 3-dimansional structure of TLR4
Crystallography of the TLR4-LPS/MD-2 complex reveals that there are two highly 
preserved regions of TLR4 involved in the binding of the LPS/MD-2 complex20. These 
preserved domains are located at the N-terminal and central domain of the 
receptor20. The crystallography shows that the Asp299Gly is not directly involved in 
the binding of MD-2, but the mutation is located close to the TLR4-MD-2 binding 
area. Although there is no direct alteration of the binding location of the LPS/MD-2 
complex, it has been suggested using an ectodomain model of TLR4 that Asp299Gly 
polymorphism increases the rotational freedom of the peptide bond64. Interestingly, 
the same model also shows that the wild-type TLR4 has a negatively charged area at 
position 299, and this is lost in the Asp299Gly64. The modified response of cells of 
Asp299Gly polymorphism individuals could therefore be the result of the increased 
rotation and change of charge that may modulate the interaction of LPS with the 
TLR4 receptor.
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Conclusion
It is tempting to conclude that TLR4 polymorphisms have an effect on the 
susceptibility to infections, especially because of their location in the ligand 
recognition area of the receptor.
Despite the tempting theoretical considerations and a number of reports based on in 
vitro experiments, most if not all of the studies using primary cells isolated from 
individuals bearing the mutation reveal that the Asp299Gly/Thr399Ile haplotype has 
little or no effect on responsiveness to LPS, and the susceptibility to infections of the 
bearer is unchanged. Therefore, we tend to conclude that the Asp299Gly/Thr399Ile 
haplotype has no distinct phenotype. In contrast, the Asp299Gly haplotype exhibits a 
stronger pro-inflammatory TNF-a cytokine response after stimulation with LPS. In 
addition, this phenotype seems to predispose to septic shock. The effect of the rare 
Thr399Ile haplotype on function and susceptibility remains unclear due to its scarcity 
in the population.
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Abstract
Infectious diseases exert a constant evolutionary pressure on the genetic makeup of 
our innate immune system. Polymorphisms in Toll-like receptor 4 (TLR4) have been 
related to susceptibility to Gram-negative infections and septic shock. Here we show 
that two polymorphisms of TLR4, Asp299Gly and Thr399Ile, have unique 
distributions in populations from Africa, Asia, and Europe. Genetic and functional 
studies are compatible with a model in which the nonsynonymous polymorphism 
Asp299Gly has evolved as a protective allele against malaria, explaining its high 
prevalence in subSaharan Africa. However, the same allele could have been 
disadvantageous after migration of modern humans into Eurasia, putatively because 
of increased susceptibility to severe bacterial infections. In contrast, the Asp299Gly 
allele, when present in cosegregation with Thr399Ile to form the 
Asp299Gly/Thr399Ile haplotype, shows selective neutrality. Polymorphisms in TLR4 
exemplify how the interaction between our innate immune system and the 
infectious pressures in particular environments may have shaped the genetic 
variations and function of our immune system during the out-of-Africa migration of 
modern humans.
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Introduction
During evolution, our genetic makeup has been profoundly influenced, with 
important consequences for the predisposition to health and disease. In the past 
decades, the interest in the genetic and physiological mechanisms of predisposition 
to disease has led to the identification of several genetic polymorphisms that have 
evolved in response to specific evolutionary pressures. Among these, some of the 
best known are related to the susceptibility to infectious diseases: the selection of 
hemoglobin S, hemoglobin C, and thalassaemia a and ß as protective mechanisms 
against malaria1"3, the polymorphisms in CCR5 providing protection against plague 
or HIV infection*.
Toll-like receptors (TLR) have been discovered as the most important class of pattern 
recognition receptors, involved in the host defense against bacteria, viruses, fungi, 
and protozoa5. TLRs are evolutionarily conserved receptors for pathogenic 
microorganisms, initially described in Drosophila6 and with homologues in plants and 
lower vertebrates5. One of the best-studied TLRs is TLR4, the key receptor for the 
LPS component of Gram-negative bacteria and for structures of mycobacteria, fungi, 
and malaria parasites7"10.
Two nonsynonymous TLR4 polymorphisms have been described, an A/G transition at 
SNP rs4986790 that causes an Asp/Gly polymorphism at amino acid 299 and a C/T 
transition at SNP rs4986791 that causes a Thr/Ile polymorphism at amino acid 399. 
The derived states (G and T, or Gly and Ile, respectively) have been shown to change 
the ligand-binding site of the receptor11. Both these two derived states reach 
substantial frequencies and are found in cosegregation in Caucasian populations12"14. 
Some, but not all, studies have suggested a correlation between these 
polymorphisms and susceptibility to infectious diseases such as Gram-negative 
infections or disseminated candidiasis15"17. Despite a 98% cosegregation level of 
these two derived alleles in Caucasian populations, this aspect was not taken into 
account in susceptibility analyses: each polymorphism was treated as an 
independent variable in these studies (see review in ref. 13). In contrast to the 
situation in Caucasians, one study in West Africa identified a different TLR4
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haplotype composed only of the Asp299Gly-derived allele, with no individuals 
bearing the Thr399lle-derived allele18. These differences suggest that human 
populations around the world differ in the prevalence of TLR4 haplotypes, which in 
turn may reflect particular local infectious pressure and subsequent susceptibility to 
these infections.
In this study, we investigated whether the differences in the TLR4 polymorphism 
haplotypes in various populations of the three large continental masses, Africa, 
Eurasia, and America, could have been the result of local evolutionary pressures by 
infection during or after the out-of-Africa migration of modern humans. We analyzed 
the prevalence of the TLR4 haplotypes formed by these two SNPs in various 
populations from these continents and compared the phenotype of the two most 
prevalent TLR4 haplotypes with the wild-type (ancestral) TLR4. These results were 
used to get an insight into the evolutionary pressure of infections on the TLR4 
polymorphisms.
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Results and Discussion
Distribution and Origin of the TLR4 Haplotypes Among the Populations. DNA from 
2,491 individuals from 15 populations were included for TLR4 polymorphism 
analysis. The location and distribution of these populations were chosen to be 
representative of the original African populations before the migration and the 
different migration routes toward Europe, Asia, and the New World. As shown in 
Figure 1, significant differences were found between the existing prevalence of the 
two TLR4 polymorphisms between the major continents. African populations show a 
high prevalence of the Asp299Gly allele (rs4986790 G). Between 10% and 18% of the 
individuals tested have one copy of this allele, of which only 2% are present with 
Thr399lle (rs4986791 T). The Thr399lle allele was always found in individuals with 
Asp299Gly. Populations from Asia (Han Chinese, Indonesian, and Papuan) and 
America (Trio Indians in Surinam) were practically missing TLR4 polymorphisms, with 
single cases of the Asp299Gly allele alone or the Thr399lle allele alone in Indonesia. 
In contrast, 6-14% of Indo-European individuals were double heterozygotes for the 
Asp299Gly and Thr399Ile alleles (allele frequency 3-7%, respectively), a frequency 
that reaches 18% for Basques (allele frequency 9%) [allele frequencies, supporting 
information (SI) Table 3].
Because of the heterozygote state of most individuals bearing the Asp299Gly and 
Thr399Ile alleles in European populations, we analyzed whether these 
polymorphisms were in cosegregation on the same allele or whether the 
polymorphisms laid on different alleles. Several two-generation European families 
were investigated for the presence of these alleles to confirm that both 
polymorphisms were on the same haplotype and were therefore inherited in 
cosegregation. In all situations with a parent double heterozygote for Asp299Gly and 
Thr399Ile and a parent bearing wild-type TLR4 alleles, all heterozygous children had 
both Asp299Gly and Thr399Ile, confirming the cosegregated state of both alleles 
(Figure 2). Therefore, double-heterozygous Asp299Gly/Thr399Ile individuals were 
assumed to contain one haplotype with the two ancestral alleles and one haplotype 
with the two variant alleles in further analysis. This haplotypic composition is
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Figure 1. World distribution of the TLR4 haplotypes in human populations.
Circles indicate allele frequency (black, Asp299Gly; light grey, Thr399lle; and 
dark gray, Asp299Gly/Thr399lle). The Asp299Gly haplotype is concentrated in 
Africa, and the Asp299Gly/Thr399lle haplotype is concentrated in Europe. 
Arrows indicate the main out-of-Africa migration routes of modern Homo 
sapiens, based on refs. 19-21. Abbreviations used for the populations (and 
numbers): Ba, Basque, Spain (107); Nl, The Netherlands (209); Ge, Germany 
(632); Ro, Romania (102); Gr, Greece (162); Is, Israel (85); Ch, Han Chinese, 
China (100); Tr, Trio-lndians, Surinam (99); Do, Dogon tribe, Mali (241); Fu, 
Fulani tribe, Mali (243); Ca, Cameroon (142); Ta, Tanzania (121); Su, Sudan 
(101); In, Indonesia (98); and Pa, Papua New Guinea (49).
Figure 2. Inheritance of the Asp299Gly/Thr399lle heterozygote haplotype 
within two different families. Asp299Gly and Thr399lle polymorphisms 
cosegregate in the European populations.
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supported by the inferred phased haplotypes for the reference HapMap 
populations19.
Statistical analysis showed that all populations were in Hardy-Weinberg equilibrium. 
In addition, haplotype similarity analysis between the populations confirmed that 
the African, West-Eurasian (European), and East-Eurasian (including the American) 
populations segregate into three major groups according to their TLR4 haplotypes 
(Table 1). Interestingly, an Israeli population was the only one showing a mixed 
pattern of TLR4 haplotypes. This finding could have two possible explanations: either 
this is a testimony of the current mosaic of the population of Israel, encompassing 
emigration from many parts of the world, or alternatively, this may represent a 
particular distribution of the TLR4 haplotypes in the Middle East. More Middle 
Eastern populations should be studied for clarification of these aspects.
Table 1. TLR4 allele differentiations between populations.
Population (numbers) Tr Ch
Trio-lndians (99)
Papua (49) *
Han Chinese (100) *
Indonesia (98) 0.120
The Netherlands (209) <0.001 
Germany (632)
Basque (107)
Greece (162)
Romania (102)
Israel (85)
Sudan (101)
Cameroon (142)
Tanzania (121)
Dogon (241)
Fulani (243)
0.704 0.123
0.003 <0.001
<0.001 0.020 <0.001
<0.001 <0.001 <0.001
0.029 0.468 0.030
<0.001 0.002 <0.001
<0.001 0.006 <0.001
<0.001 <0.001 <0.001
<0.001 0.006 <0.001
<0.001 0.012 <0.001
<0.001 <0.001 <0.001
0.023 0.235 0.024
<0.001
<0.001 0.346
<0.001 0.361
0.083 <0.001
<0.001 0.403
<0.001 <0.001
<0.001 <0.001
<0.001 <0.001
0.095
0.002  <0.001
0.111 0.547
<0.001 0.002
<0.001 <0.001
<0.001 <0.001
<0.001 <0.001 <0.001 <0.001 
<0.001 <0.001 <0.001 <0.001 
0.021 <0.001 <0.001 <0.001
0.012
0.002 0.004
<0.001 <0.001
<0.001 <0.001
<0.001 <0.001
<0.001 <0.001
<0.001 <0.001
0.004
0.004
0.156
<0.001
<0.001
0.394
0.211 0.337
0.897 0.479 0.081
<0.001 0.008 0.001 <0.001
Allele distribution differences between each population were tested according to the Fisher exact test. These data show a clustering of the populations into 
an African, West-Eurasian, and East-Eurasian group. Each asterisk indicates populations that could not be analyzed because only the wild-type allele was present. 
Abbreviations are as in Fig. 1.
The clustering pattern of the TLR4 haplotypes in the various populations according to 
their geographical location suggests, on the one hand, that the present pattern of 
TLR4 haplotypes may be explained by the out-of-Africa migration routes of modern 
humans (Figure 1) and, on the other hand, that these differences may have been 
shaped by local environmental conditions (e.g., infectious pressure). Archaeological 
and genetic evidence suggests that anatomically modern humans originated 
=195,000 years ago in subSaharan Africa16,20,21. Approximately 55,000-60,000 years
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ago, a first wave of migration traversed the Bab-el-Mandab strait from the Horn of 
Africa to the Arabic peninsula. From this West Asian source, humans migrated 
toward Southeast Asia, reaching Australia by 50,000 years ago22, and toward 
Northern Eurasia (and subsequently to America from a Northeast Asian source) 
=40,000 years ago (ref. 23; Figure 1).
The presence of Asp299Gly and Thr399lle in the African populations, as well as in the 
Basque and Indo-European populations, suggests these are mutations that arose in 
Africa >60,000 years ago and migrated toward Europe through the Middle Eastern 
route. In addition, the much higher prevalence of the Asp299Gly haplotype 
compared with the Asp299Gly/Thr399Ile haplotype in Africa (whereas Thr399lle is in 
linkage with Asp299Gly allele; Figure 1 and SI Table 3), suggests the Asp299Gly 
mutation arose first, whereas the Thr399lle mutation must have appeared later a 
chromosome bearing the Asp299Gly mutation.
Phenotypes of the Different TLR4 Haplotypes.
The difference in the frequency of the TLR4 haplotypes demonstrates there must 
have been a shift in the population frequencies of the polymorphisms during or after 
the migration. To answer which evolutionary or genetic force could have caused the 
shift responsible for the current distribution of TLR4 haplotypes in Europe and Asia, 
which differ from that found in Africa, we assessed whether TLR4 haplotypes result 
in a different functional activity of the receptor. Therefore, we studied the 
functionality of the two most common haplotypes, namely the ancestral 299- 
ancestral 399/Asp299Gly-ancestral 399 haplotypes in one African (Dogon) 
population and the ancestral 299-ancestral 399/Asp299Gly-Thr399Ile haplotypes in 
one European (Dutch) population, which both have a high prevalence of these 
haplotypes (Figure 1 and SI Table 3). Whole-blood samples from Dogon individuals 
were exposed to increasing concentrations of bacterial LPS. Cells from Asp299Gly 
heterozygous individuals (homozygous for the ancestral state at 399) released 
significantly higher amounts of the proinflammatory cytokine TNF-a than those from 
donors with a double-homozygous wild-type (ancestral state) genotype TLR4 (Figure 
3A). No differences were observed in the production of the antiinflammatory 
cytokine IL-10 (Figure 3B). In contrast, the presence of the double-heterozygous
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Asp299Gly/Thr399lle in cosegregation in the Dutch population did not modulate 
cytokine production induced by LPS: no differences in TNF-a or lL-10 production 
were observed between individuals bearing the double-heterozygous wild-type 
genotype and those heterozygous for the Asp299Gly/Thr399lle alleles (Figure 3C and 
D). Cells harvested from one individual homozygous for the Asp299Gly/Thr399lle 
allele also displayed a normal production of pro- and antiinflammatory cytokines. 
These data demonstrate that the Asp299Gly allele is accompanied by a 
proinflammatory phenotype, whereas the Asp299Gly/Thr399lle haplotype does not 
functionally differ from wild-type TLR4. ln addition, our data represent an important 
argument suggesting caution in the interpretation of overexpression studies of the 
different forms or TLR4, which are known to be prone to artifacts due to unequal 
efficiency of receptor expression. ln this respect, overexpression studies in cell lines 
have suggested that Asp299Gly and Asp299Gly/Thr399lle TLR4 expression may lead 
to a defective function of TLR411, 12. However, this assertion has been refuted in case 
of the Asp299Gly/Thr399lle TLR4 haplotypes by many experimental and clinical 
studies24"26, and our results also do not confirm a decreased function of the 
Asp299Gly haplotype.
Functional studies of the TLR4 gene neglected the TLR4 Asp299Gly allele in human 
primary cells; other studies to date were performed in Caucasians bearing the 
cosegregated Asp299Gly/Thr399lle haplotype or used cell lines transfected with the 
mutated TLR4. The proinflammatory phenotype of the TLR4 Asp299Gly allele may 
represent the explanation of why this haplotype disappeared from Eurasia: the 
strongly enhanced TNF production may predispose for an increased mortality in 
septic shock by contributing to the systemic inflammatory response syndrome27. ln 
the only study that investigated the role of all TLR4 haplotypes on the susceptibility 
to septic shock, Lorenz et al.16 showed that the presence of the Asp299Gly alone, but 
not that of the Asp299Gly/Thr399lle haplotype, is associated with an increased 
mortality to septic shock. A strong body of medical literature demonstrates the 
deleterious effects of high cytokinemia during septic shock28, and this most likely 
explains the evolutionary disadvantage of a strong proinflammatory bias in 
individuals with a Asp299Gly allele (and homozygous for the wild-type allele of the 
399 polymorphism) who migrated into Eurasia toward northern latitudes. Pandemic
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infections of the past millennia such as plague (Yersinia pestis infection), typhoid 
fever, and influenza (with its important secondary bacterial infections) may also have 
been contributors to this particular geographical distribution29. A similar scenario 
may have been behind the loss of the Asp299Gly allele in Asia.
Figure 3. Production of cytokines induced by LPS in individuals bearing the 
Asp299Gly or Asp299Gly/Thr399lle haplotypes. Mean TNF-a (A and B) and IL­
IO (C and D) concentrations are given as mean and SEM (nanograms per 
milliliter) from Asp299Gly heterozygotes (n = 4) and wild-type individuals (n = 
32) with Dogon ethnicity (A and C) and Asp299Gly/Thr399Ile heterozygotes (n = 
4) and wild-type individuals (n = 8) from The Netherlands (B and D). Significant 
difference: *, P = O.O4; **, P = O.O3 (Mann-Whitney U test).
Evolutionary Neutral Phenotype of Asp299Gly/Thr399lle Haplotype.
Although these data could explain the difference in frequency of the Asp299Gly 
between Africa and Eurasia, they are not the reason for the variable prevalence of 
the cosegregated Asp299Gly/Thr399Ile haplotype in the different populations, 
ranging from O% in Asian populations, 1-2% in African populations, and 5% in Dutch 
Indo-Europeans, to 9% in Basques. One clue may come from the observation that 
cells from individuals with the Asp299Gly/Thr399Ile haplotype have a response to
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LPS stimulation that is indistinguishable from that of cells with wild-type TLR4 alleles
17 25 26 24(Figure 3). This is supported by data from other in vitro ' ' and ex vivo studies . 
Thus, although the presence of Asp299Gly alone is accompanied by an increased 
function of the receptor, the Asp299Gly/Thr-399/lle haplotype results in an LPS/TLR4 
interaction similar to that present in wild-type individuals. To strengthen these 
experimental data, we investigated the effect of the Asp229Gly/Thr399lle haplotype 
on the severity of sepsis. First, no significant differences were observed in the 
prevalence of the Asp299Gly/Thr399lle haplotype between a healthy control 
population (6%) and a cohort of patients with Gram-negative sepsis (7%). Second, 
the severity and clinical parameters of sepsis were similar in patients bearing two 
wild-type haplotypes or one wild-type haplotype and one Asp299Gly/Thr399lle 
haplotype (Table 2), suggesting that the later TLR4 haplotype does not increase 
susceptibility and mortality because of severe Gram-negative infections. Thus, these 
clinical data also point to a neutral effect of the Asp299Gly/Thr399lle phenotype and 
suggest that the spread of this cosegregated haplotype is the consequence not of 
infectious pressure but more likely of functional neutrality and chance (genetic drift 
and/or bottlenecks).
Table 2. Epidemiological and clinical data in 159 Indo-European patients with 
sepsis bearing the wild-type or heterozygote Asp299Gly/Thr399Ile
Wild type
Asp299Gly/
Thr3999lle P value
Number of patients 150 9 —
Age (mean ±  SD, years) 59.4 ±  18.8 57.4 ±  19.3 0.76
Male/female 112/38 8/1 0.58
APACHE II (mean ± SD) 15.9 ±  5.5 14.3 ±  5.1 0.17
SOFA score (mean ±  SD) 7.87 ± 3.32 7.33 ± 3.00 0.65
Lymphocytes count (mean ±  SD/ml) 13.3 ±  6.7 13.1 ±  3.8 0.93
CRP (mg/liter, median IQR) 145.0 (669) 221.5 (260) 0.49
Septic shock, % 67 (44.7%) 4 (44.4%) 0.51
Mortality, % 45 (30.0%) 1 (11.1%) 0.51
To assess possible differences in the clinical outcome between the TLR4 wild-type and Asp299Gly/Thr399lle 
haplotypes, the Acute Physiology and Chronic Health Evaluation II (APACHE II) disease score, the Sepsis-Related 
Organ Failure Assessment (SOFA) disease severity score, C-reactive protein (CRP), and the percentage of patients 
with septic shock were measured. Mann-Whitney U test statistics showed no differences in the epidemiological 
and clinical parameters between the two groups of patients.
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Another aspect concerning the phenotypic consequences of the 
Asp299Gly/Thr399lle TLR4 variant refers to noninfectious diseases such as 
atherosclerosis30 and nonallergic asthma31, in which some studies (albeit not all) 
proposed a beneficial effect of the TLR4 polymorphisms. However, although these 
diseases are important for the long-term quality of life of an individual, they are very 
unlikely to have played any role in selection processes, because of the age at which 
they affect the individual and which is after the reproductive period. 
ln addition, to test whether the increased frequency of Asp299Gly/Thr399lle was 
due to some kind of positive selection acting on this haplotype, we evaluated 
whether the extent of haplotype homozygosity (EHH) (EHH test; see Materials and 
Methods) was longer than expected under neutrality. After extensive simulations 
using a neutral coalescent model with recombination (see Materials and Methods), 
we observed that, although the EHH at the 3' end seems to be longer than expected 
under neutrality (observed length until EHH < 1 = 257,122 bp; 95% expected upper 
limit, 242,319 bp), however, the 5' end shows a drop in EHH already at 41,895 bp 
from the core, whereas the expected 95% is at least 350,000 bp. This reinforces the 
idea that neutrality is a compatible hypothesis to explain the evolution of this 
haplotype in Europeans.
Two Faces of Asp299Gly.
Why is the Asp299Gly haplotype still found in Africa? The increased mortality due to 
severe sepsis (i.e., severe bacterial infection) could represent an important 
evolutionary disadvantage in individuals bearing the Asp299Gly allele (wild-type 
allele homozygotes for 399) who migrated into Eurasia toward northern latitudes, 
whereas demography and genetic drift can be sufficient to explain the frequencies of 
Asp299Gly/Thr399lle. This leaves the question why there is a high prevalence of 
Asp299Gly allele (associated with a wild-type allele at "399") in subSaharan Africa. 
As a putative evolutionary pressure in subSaharan Africa, malaria immediately 
comes to mind. Indeed, it has been demonstrated that, although the Asp299Gly 
allele increases susceptibility to malaria in a Ghanese population, mortality was 
lower in individuals with Asp299Gly allele compared with "299" wild-type TLR4 
patients9. We have been able to confirm and extend this observation in a pilot study
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in a malaria hyperendemic region of Cameroon. In children with malaria, the 
presence of the Asp299Gly haplotype was associated with higher parasitemia (80% 
higher compared with the TLR4"299" wild type) yet lower prevalence of cerebral 
malaria (12% compared with 24% in the TLR4"299" wild-type group) (B.F., 
unpublished results). These findings strongly suggest that the higher prevalence of 
haplotype Asp299Gly/wild-type "399" in subSaharan Africa is due to protection 
against mortality from malaria. Thus, the TLR4 amino acid site 299 (more precisely, 
SNP rs4986790) should be added to the list of gene polymorphisms selected by 
malaria, next to sickle cell disease, thalassaemias, and TNF polymorphisms1,2,32.
In summary, we present evidence that the TLR4"299"-"399" (rs4986790-rs4986791) 
haplotypes are geographically clustered. Functional data in individuals bearing the 
haplotype composed of the Asp299Gly allele associated to the wild-type "399" allele 
demonstrate a proinflammatory profile in line with an increased susceptibility to 
septic shock in patients bearing this haplotype16. In contrast, this allele seems to 
protect against mortality in severe malaria9, although the mechanism of protection is 
not yet understood. In Africa, where malaria exercises a strongly selective pressure, 
the beneficial effect of Asp299Gly in malaria seems to override the negative effect in 
sepsis. During the migration of humans into Eurasia, where malaria is less prevalent, 
the Asp299Gly allele was eliminated because of increased mortality in severe Gram­
negative bacterial infections. The absence of the TLR4 polymorphisms in the Trio 
Indians from South America is a testimony that these evolutionary pressures have 
already eliminated the Asp299Gly/wild-type "399" haplotype in the population that 
migrated over the Behring strait to the New World 15,000 years ago. In contrast, the 
variable prevalence of the Asp299Gly/Thr399Ile haplotype in the Eurasian 
populations is most likely the result of genetic drift.
This study explains the geographic distribution of the TLR4 haplotypes in populations 
according to susceptibility to infection and provides an understanding of how our 
innate immune system has been molded by infectious pressures.
52
TLR4 polymorphisms, infectious diseases, and evolutionary pressure
Materials and Methods
DNA Samples and Asp299Gly and Thr399lle Screening.
DNA samples from the Han people came from Corriell (Camden, NY) (catalog no. 
HD1000CHI). All other DNA was extracted from whole blood by using the isolation kit 
Puregene (Gentra Sytems, Minneapolis, MN). PCR conditions, concentrations, and 
determinations of the Asp299Gly and Thr399Ile polymorphisms were preformed as 
described by Van Der Graaf et al.17.
Cytokine Stimulation Assays.
Venous whole blood was collected into 2-ml heparin tubes (BD, Plymouth, U.K.). 
Blood from healthy individuals of Dogon ethnicity was diluted to a final 
concentration of 1:5 in RPMI medium 1640 (containing 1% glutamine, 1% pyruvate, 
and 1% gentamicin) and stimulated with control medium or highly purified LPS at 
various concentrations (0.1, 1, and 10 [g /[l). After 24 h at 37°C, supernatants were 
collected and stored at -80°C until cytokine measurements were done.
In the Dutch population, venous blood was collected in EDTA tubes, and peripheral 
blood mononuclear cells were isolated by density centrifugation on FicollbHypaque 
(Amersham Biosciences, Diegem, Belgium). Peripheral blood mononuclear cells 
resuspended in RPMI medium 1640 were plated into 96-well cell culture plates at a 
final density of 5 x 106 cells/ml and stimulated for 24 h at 37°C with RPMI medium 
1640 or LPS (0.1, 1, and 10 [g / [l) . After 24 h, supernatants were collected and 
stored at -80°C until cytokine measurements were done.
Cytokine Measurements.
IL-10 cytokine concentrations were measured by sandwich ELISA (Sanquin, 
Amsterdam, The Netherlands). TNF-a production was measured by a specific ELISA, 
as described33.
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Sepsis Patients.
Blood was sampled from 162 patients with ventilator-associated pneumonia and 
sepsis. Diagnosis was made by published criteria34. Patients were followed up for 28 
days. Disease severity was assessed by Acute Physiology and Chronic Health 
Evaluation II (APACHE II) and Sepsis-Related Organ Failure Assessment (SOFA) scores 
on the first day of diagnosis, and mortality was given at the end of the observation 
period. C-reactive protein was estimated in serum by a nephelometric assay 
(Behring, Berlin, Germany).
Statistics.
The distributions between the TLR4 alleles in the different populations and the 
Hardy-Weinberg equilibrium were preformed with the GENEPOP program35. The 
differentiation analysis is based on the unbiased estimation of the P value of a log- 
likelihood- (G) based exact test, which is based on the same principles as Fisher's 
exact test.
Cytokine and sepsis statistics were performed by using the SPSS program (Rel. 
14.0.2, 2006; SPSS, Chicago, IL), and differences were tested by the Mann-Whitney 
U test. P < 0.05 was considered to represent a statistically significant difference.
As a neutrality test, we applied the EHH test36 to the phased genotypic information 
available from HapMap Data Rel. 21a/phaseII Jan 07, on National Center for 
Biotechnology Information NB35 assembly, dbSNP b125. We used as the core 
haplotype that formed by allele G of rs4986790 and allele T of rs4986791 within 
TLR4 (which corresponds to haplotype Asp299Gly/Thr399Ile). We analyzed the 
extent to which the EHH for this core haplotype was 1 in the HapMap Caucasian 
population in a genomic region that extended 350 kb in both directions from the 
core. To test whether the distance observed was longer than expected under 
neutrality, we ran coalescent simulations that took into account the heterogeneity in 
recombination rates across these regions (obtained from the HapMap link) by means 
of msHOT37. We used demographic parameters reflecting the out-of-Africa model of 
human evolution by slightly modifying Schaffner et al.'s model38. Simulations were 
run for both the 350 kb downstream from the core and the 350 kb upstream from 
the core. The number of SNPs was adjusted to that observed in the HapMap sample
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for that region. We added three filters to the neutral simulations: (i) We considered 
only those simulations that resulted in a number of different haplotypes equal to 
that observed in the HapMap sample (as determined by the core SNPs rs4986790 
and rs4986791); in the simulations, the first two SNPs were considered the core set.
(ii) In addition, one of the simulated core haplotypes had to show a similar frequency 
to that core haplotype under examination [obtained from the HapMap Caucasian 
SNP information and defined by core SNPs (allele G of rs4986790 and allele T of 
rs4986791)]. (iii) The ancestral/derived states of the core SNPs in this preselected 
simulated haplotype also had to be identical to the ancestral/derived states of the 
core SNPs at the core haplotype under examination. By comparison with the 
orthologous genome regions of the chimpanzee and Rhesus macaque, both G and T 
were defined as "derived." Simulations satisfying these conditions were kept, but 
only the information on the core haplotype was used for the EHH analysis. Finally, 
the extent from the core SNPs for which EHH was 1 was recorded for the observed 
HapMap data, and this was tested against the distribution obtained from the filtered 
simulations.
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Supporting Information
Table 3. Number of studied individuals from each population and allele 
frequencies.
Population (number) WT/WT Asp299Gly/W T W T/Tlir399Ile Asp299Gly/Thr399Ile
Trio-Indiaus (n = 99) 1.00 - - -
Papua (ii = 49) 1.00 - - -
Han Chinese (?) = 100) 1.00 - - -
Indonesia (n =  98) 0.985 0.005 0.01 -
Netherlands (n= 209) 0.928 - - 0.072
Germany (« = 632) 0.943 0.002 - 0.055
Basque (n = 107) 0.907 - - 0.093
Greece (w = 162) 0.963 0.003 0.006 0.028
Romania ( n = 102) 0.917 - 0.005 0.078
Israel in = 85) 0.912 0.041 0.047
Sudan (n = 101) 0.901 0.094 0.005
Cameroon (n = 142) 0.933 0.063 - 0.004
Tanzania (n = 121) 0.926 |0.058 - 0.017
Dogon ( n = 241) 0.911 0.083 - 0.004
Fulani ( n = 243) 0.975 0.025 - -
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Abstract
Adequate responses by our innate immune system toward invading pathogens were 
of vital importance for surviving infections, especially before the antibiotic era. 
Recently, a polymorphism in Mal (Ser180Leu, TIRAP rs8177374), an important 
adaptor protein downstream of the Toll-like receptor (TLR) 2 and 4 pathways, has 
been described to provide protection against a broad range of infectious pathogens. 
We assessed the functional effects of this polymorphism in human experimental 
endotoxemia, and we demonstrate that individuals bearing the TIRAP 180L allele 
display an increased, innate immune response to TLR4 and TLR2 ligands, but not to 
TLR9 stimulation. This phenotype has been related to an increased resistance to 
infection. However, an overshoot in the release of proinflammatory cytokines by 
TIRAP 180L homozygous individuals suggests a scenario of balanced evolution. We 
have also investigated the worldwide distribution of the Ser180Leu polymorphism in 
14 populations around the globe to correlate the genetic makeup of TIRAP with the 
local infectious pressures. Based on the immunological, clinical, and genetic data, we 
propose that this mutation might have been selected in West Eurasia during the 
early settlement of this region after the out-of-Africa migration of modern Homo 
sapiens. This combination of functional and genetic data provides unique insights to 
our understanding of the pathogenesis of sepsis.
The Mal/TIRAP allele variant 180L
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Introduction
The nonsynonymous single nucleotide polymorphism Serl80Leu (S180L) of the TIR 
domain-coding adaptor protein (TIRAP) gene, also known as adaptor protein Mal1, 
was found to be protective in heterozygous individuals for a broad range of 
infectious diseases such as malaria, tuberculosis, bacteremia, and pneumococcal 
disease1. Mal is involved in the signaling pathways of Toll-like receptors (TLR) 2 and 
4, which are important innate immune receptors for the recognition of a broad 
range of pathogenic Gram-negative and Gram-positive bacteria2. Recognition by 
TLRs eventually leads to activation of NF-kB and the transcription of 
proinflammatory genes that activate the mechanisms of host defense and the 
clearance of the pathogens. However, little is known about the in vivo functional 
consequences of the S180L polymorphism or the possible differences in the 
geographic distribution of the S180L polymorphism in relation to infectious pressure. 
In this study we hypothesized that the difference in the frequency of TIRAP 180L 
between the different geographical regions was due to the effects of the mutation 
on the function of TLR signaling, and was shaped by the pressure exerted by 
different infections, either during the out-of-Africa migration of early modern 
humans during the early Upper Paleolithic period (60v40kya)3 or the Neolithic demic 
expansion from the Near East into Europe (Y10,000kya)4,5. This pressure may have 
resulted in an increase of the frequency of TIRAP S180L heterozygous individuals and 
thereby a strong rise of the frequency of the TIRAP 180L allele in West-Eurasia 
populations.
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Results and Discussion
In Vivo Models of Sepsis That Determine the Phenotypic Effect of the S180L 
Genotype.
Because of the high prevalence of the TIRAP S180L polymorphism in the European 
population, we tested the hypothesis that under severe bacterial pressure there is a 
pathophysiological advantage that could favor selection of the TIRAP 180L allele 
variant. Therefore, we evaluated the functional consequences of the heterozygous 
TIRAP S180L genotype during sepsis, a life-threatening infection accompanied by a 
systemic inflammatory response6. TLR4 is mainly involved in the recognition of the 
lipopolysaccharide (LPS) of Gram-negative bacteria7, inducing intracellular signals 
through the adaptor protein TIRAP/Mal8. To avoid limitations of artifacts between in 
vitro and in vivo results, we determined the inflammatory phenotype in the most 
relevant in vivo model of sepsis: that of experimental endotoxemia of human 
volunteers by i.v. challenge with LPS.
Before and after exposure to LPS, blood was drawn at several time points for 
proinflammatory (TNF, IFN-y, IL-6) and anti-inflammatory cytokine (IL-10) 
measurements. We found that, compared with the normal homozygous TIRAP S180 
individuals, the heterozygous TIRAP S180L volunteers had a produced significantly 
more proinflammatory cytokines after challenge with LPS (Figure 1 A-D). The higher 
in vivo production rate of proinflammatory cytokines in individuals bearing the 180L 
allele was accompanied by increased cytokine production when cells isolated from 
these individuals were stimulated with the TLR2 ligand Pam3Cys, but not when they 
were stimulated with the TLR9 ligand 3'5'-cytidylylguanosine (CpG) DNA (Figure 1E). 
Although the cells isolated from the individuals bearing the 180L did not release 
significantly more cytokines in vitro after LPS stimulation, it is interesting to observe 
that the TIRAP 180L homozygous individuals produced the highest amount of IL-6 
after both Pam3Cys and LPS stimulation, but not after CpG DNA. Both TLR2 and TLR4 
signal through the TIRAP adaptor molecule and therefore it is expected that the 
effect of the 180L polymorphism should be observed in both. In contrast, TLR9 does 
not need the TIRAP adaptor molecule pathway and therefore showed no difference
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Figure 1. Cytokine production capacity in individuals screened for the TIRAP 
S180L polymorphism. (A-D)Serum concentrations of proinflammatory cytokines 
TNF, IFN-y, IL-6 (A-C) and the anti-inflammatory cytokine IL-10 (D) after 2 ng/kg 
LPS injection. Concentrations are given as mean (pg/mL) and SD for TIRAP S180 
homozygous (SS, n = 14) and S180L heterozygous (SL, n = 6) individuals. (E) To 
study the effect of the TIRAP 180L polymorphism on other TLRs, PBMCs were 
stimulated with TLR2 (10 vg/mL Pam3Cys), TLR4 (10 ng/mL LPS), and TLR9 (25 
Vg/mL CpG) ligands. (F) IFN-a release by PBMC of patients with or without 
polymorphisms was also assessed. Concentrations are given as mean (pg/mL) and 
SEM for TIRAP S180 homozygous (SS, n = 4), S180L heterozygous (SL, n = 5) 
individuals, and one 180L homozygous individual. *, P = 0.05; **, P = 0.01; ***, P = 
0.001 (Mann-Whitney U test).
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between the various TIRAP genotypes. TIRAP-mediated signals are involved in LPS- 
induced NF-kB activation, but not for the IFN regulatory factor 3 (IRF3)-induced, type 
I IFN release. In line with the hypothesis that type I IFN release would not be 
effected by the 180L TIRAP allele, we found its production after cell stimulation with 
CpG DNA was not increased in individuals bearing this polymorphism (Figure IF). LPS 
alone was not able to induce production of type I IFN. These data, clearly 
demonstrating an increased cytokine production in primary cells of individuals 
bearing the S180L polymorphism, are in contrast to the functional in vitro analyses 
of Khor et al.1, based on transfection studies of the mutated TIRAP allele, who 
reported diminished proinflammatory cytokine induction in cells transfected with 
the mutated allele. It is possible that endogenously expressed 180L modulates 180S 
in a positive way, and that the transfection-based experiments do not provide an 
accurate reflection of the in vivo data.
The increased cytokine production in individuals bearing the TIRAP S180L genotype 
may have important consequences for the susceptibility and severity of infections. It 
has been proposed that individuals with relatively low cytokine production would be 
protected against the effects of systemic inflammation. This idea is based on the 
assumption that the high cytokine release during sepsis is the cause of systemic 
inflammatory response syndrome (SIRS), which ultimately leads to septic shock and 
death. Although this may be the case for individuals already in a septic state, it is 
unlikely to be true for the initial susceptibility to infections. During the first stage of 
infections, the proinflammatory response of the host has to be strong and adequate 
for a good clearance of the pathogenic microorganism9,10. Therefore, a moderately 
increased cytokine release during the primary stage of infection, as would be 
expected in heterozygous S180L individuals, is likely beneficial for the outcome of 
the infection, and the early clearance of bacteria prevents those individuals from 
developing sepsis that could lead to SIRS. However, if the cytokine release is 
reaching a certain threshold leading to systemic inflammatory effects, which is 
suggested to take place in homozygous 180L individuals, then this could ultimately 
prove deleterious to the host and preclude the fixation of the mutation in the 
population. This hypothesis is supported by a study performed on 166 patients with 
Gram-negative bacterial sepsis and ventilator-associated pneumonia (VAP).
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Individuals homozygous for the 180L polymorphism had a significantly more severe 
infection compared with the other TIRAP genotypes (P = 0.038 concerning clinical 
pulmonary infection score) and a tendency toward a decreased oxygenation of the 
tissues (Table 1).
Table 1. Clinical characteristics of 160 patients with VAP and sepsis enrolled 
in the study.
Characteristics SS SL LL
n (Male/female) 121 (91/30) 43 (31/12) 2(2/0)
A ge  in years, mean ±  SD 61.4 ±  18.1 55.9 ±  12.2 48.5 ±  27.6
CPIS, mean ±  SD* 7.76 ± 1 .1 1 7.74 ±  1.31 9.50 ±  0.70
SAPS II score, mean ±  SD 38.8 ±  13.8 37.4 ±  13.5 39.0 ±  0
W hite blood cells per mL, mean ±  SD 13,312.1 ±  7,013.4 12,809.8 ±  4,921.8 10,030.1 ±  5,600.3
Septic shock: no (% )T 65 (53.7) 25 (58.1) 1 (50?)
Septic shock: yes (% )f 56 (46.3) 18(41.9) 1 (50)
p02/Fi02, mean ±  SD 226.1 ±  117.1 222.3 ±  100.2 190.5 ±  13.4
Polymorphism between genotypes are in Hardy-Weinberg equilibrium. SS, wild type, i.e. patients without Mai 
mutations; SL, mutant Mai, i.e. patients carrying the Ser180Leu SNP; LL, homozygous mutants, i.e., patines only 
carrying the 180Leu SNP; CPIS, clinical pulmonary infection score. p02/Fi02 ratios are given as an index of the 
oxygentation.
*P =  0.038 between W T and homozygotes; P =  0.039 between heterozygotes and homozygotes (P values after 
Bonferroni correction).
Total numbers of patients in the subgroups comparing patients with and without septic shock. There were no 
differences between groups.
Distribution of the TIRAP Polymorphism in Different Populations.
We determined the distribution of the TIRAP polymorphism frequencies in 14 
populations originating from Africa, West-Eurasia, East-Eurasia, and the Americas 
(Figure 2 and Table 2). Distribution of the TIRAP S180 and 180L allele showed a high 
frequency of 180L in West-Eurasian compared with African and East-Asian 
populations (Figure 1). To gain insight in the allelic distribution of the TIRAP 180 
polymorphism, all populations were compared pairwise by using both an exact test 
for population differentiation11 and the Fst12 statistics (Table 3). Combining the 
population differentiation results with the Fst test reveals that the populations are 
broadly divided according to these 3 main geographic regions (Africa, East Eurasia, 
and West Eurasia; see Table 2). The apparent difference in TIRAP allelic frequencies 
within populations in Africa is most likely caused by the low frequencies of the TIRAP 
180L allele among these populations (Table 2). Our data also revealed that the
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Figure 2. World distribution frequency of TIRAP S180 (gray) and 180L (black) 
alleles among 14 populations. Populations of the African continent are Mali (MA)@ 
Gambia (GA)@ Ghana (GH)@ and Kenya (KE). Eurasia populations are the Bedouins 
(BE). European populations are Romania (RO)@ Basque (SP)@ the Netherlands (NL)@ 
and United Kingdom (UK). Asian and New World populations are India (IN)@ Han 
Chinese (CH)@ Vietnam (VI)@ Papua New Guinea (PA)@ and Trio Indians from 
Surinam (SU). The number of individuals of each population is given in Table 1.
Table 2. Frequencies of the TIRAP S180L polymorphism (SL) in all screened 
populations.
OBS EXP
Genotype Allele frequency Hardy-W einberg
SS SL LL N S L Horn Het
Mali 64 2 0 66 0.985 0.015 64.02 1.98 0.992
Gambia 1237 15 0 1252 0.994 0.006 1237.08 14.92 0.978
Ghana 1094 1 0 1095 1.000 0.000 1094.00 1.00 1
Kenya 1877 68 0 1945 0.983 0.017 1887.85 57.15 0.735
Bedouins 35 48 14 97 0.608 0.392 50.53 46.47 0.931
Romania 75 20 3 98 0.867 0.133 74.60 23.40 0.534
Basque 68 39 3 110 0.795 0.205 74.04 35.96 0.64352
Netherlands 458 171 14 643 0.845 0.155 474.66 168.34 0.915
United Kingdom 944 350 35 1329 0.842 0.158 975.23 353.77 0.932
India 152 50 5 207 0.855 0.145 155.57 51.43 0.935
Han Chinese 87 1 0 88 0.994 0.006 87.00 1.00 0.999
Vietnamese 438 8 0 446 0.991 0.009 438.06 7.94 0.981
Papua 23 0 0 23 1.000 0.000 - - -
Surinam 97 0 0 97 1.000 0.000 - -
OBS, observed frequencies; EXP, expected frequency if populations would be in Hardy-Weinberg equilibrium (HW); Horn, homozygotes (SS and LL); Het, 
heterozygotes (SL). P values for the HW represent values for the HW probability test. P <  0.0035, corrected with the Bonferroni method, was considered 
significant.
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highest frequencies of the TIRAP 180L allele is found in the Middle-Eastern Bedouins 
from the Negev desert, which results in the highest differentiation and dissimilarity 
with all other studied populations. Two scenarios may explain this distribution of the 
mutation. In one of the scenarios, the mutation arose in Africa, where it persisted in 
low prevalence after spreading due to human migration in the Middle-East and 
Europe; and in the other scenario, the mutation arose in West-Eurasia and was 
brought back later in Africa through the gene transfer by the European colonists. 
However, the high prevalence of the mutation in the Middle-East and Europe 
suggests that if any selection has influenced TIRAP 180L prevalence, it most likely 
took place in the West-Eurasian region.
Table 3. Population differentiation test outcomes.
Dating the Selection on the 180L TIRAP Allele.
The S180L TIRAP polymorphism is conspicuously low in the African population and 
absent in the Asian population. This similarity between the African and East-Asian 
populations could indicate that the selection on TIRAP 180L did not take place during 
the first human Paleolithic migration out of Africa, because higher frequencies of the 
TIRAP 180L allele would then also be expected in Asia. Therefore, we tested the 
hypothesis that selection on TIRAP 180L occurred during the more recent Neolithic 
period when farming settlement of Europe took place1,4,5,13. To test this, we
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performed an extended haplotype homozygosity (EHH) test on the European panel 
from HapMap14. The EHH test, which can discern recent selection until a maximum 
of k 30,000 years15'16, revealed no statistically significant difference (3' end borders, 
significance P = 0.053; 5' end, P = 0.438), indicating no strong recent selection on the 
TIRAP 180L allele in the West-Eurasian population sample (individuals with Northern 
and Western European ancestry). Although this could indicate that the observed 
differences between the populations of West-Eurasia and other continents was the 
result of genetic drift, an alternative explanation is that selection could also have 
taken place during the period between the out-of-Africa migration [60-40 kya3] and 
the first successful colonization of Europe [40-45 kya3]. This time scale allows for 
recombination to have had enough time to make it difficult to discover an 
evolutionary pressure by using the EHH test16. The hypothesis of an old ancestry of 
the mutation in West-Eurasia is also supported by the presence of the mutation in 
India, most likely due to the Indo-European origin of the population tested. India 
clusters with other West-Eurasian populations, rather than East-Asian neighbors.
With the use of HapMap14, we investigated the distribution pattern of the haplotype 
allele network of the TIRAP gene between African, West-Eurasian, and East-Eurasian 
populations. Within these 3 HapMap populations, we detected 17 different 
haplotypes based on 12 polymorphisms (see Figure 3 and Table S1). Modeling 
established that Haplotype 3 is the ancient haplotype of TIRAP, also to be found in 
the chimpanzee. Most haplotypes form a star-like pattern around Haplotype 1, 
which is a direct descendant of Haplotype 3. The exception is Haplotype 17, which is 
the only haplotype containing the TIRAP 180L mutation. Haplotype 17 is closely 
linked to the ancient Haplotype 3, representing a different branching than the 
Haplotype 1 cluster (Figure 3). In the HapMap database, no African individuals with 
Haplotype 17 were found, although our own screening revealed the presence of this 
haplotype in a small proportion of the African individuals tested (Figure 2 and Table
2). It is likely that this is a result of recent genetic flow between the modern human 
populations. This modeling shows that all haplotypes, with the exception of 
Haplotype 17, are equally spread among the different populations. The lack of the 
TIRAP 180L mutation within the African HapMap database supports the scenario of 
the origin of the mutation in a population already located outside of Africa.
The Mal/TIRAP allele variant 180L
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Figure 3. TIRAP gene allele haplotype network of the HapMap. Numbers stand 
for the different alleles, and letters between each circle are the different 
polymorphisms included (see Table S I). Area of each circle correlates with the 
amount of alleles.
72
Conclusion
These combined genotypic and phenotypic studies have shown that a potent 
cytokine response, as a marker of an adequate innate immune response, is 
associated with a lower susceptibility to infections. Our findings form a link between 
this hypothesis and support of the protective effects of heterozygosity for TIRAP 
S180L reported by Khor and colleagues1. Moreover, in an evolutionary context this 
suggests that before the dispersal of modern humans into Western Eurasia [40-45 
kya3], those individuals bearing the TIRAP S180L heterozygous phenotype would 
have had greater resistance to infections in a harsh environment. Furthermore, they 
would have been more likely to survive should an infection become established. 
However, the deleterious effects during severe sepsis in homozygous individuals, 
due to even-higher proinflammatory cytokine production, prevented fixation of this 
haplotype in the entire population.
In summary, our study confirms the finding that TIRAP S180L heterozygous 
individuals have a distinctive phenotype compared with the TIRAP S180 homozygous 
bearers, with the 180L allele associated with a more pronounced inflammatory 
response and a lower risk of developing septic shock. The frequency of the TIRAP 
180L allele is highly elevated in West-Eurasia, with selection due to infectious 
pressure in this region being a likely explanation. We could not confirm that this 
selection has taken place recently during the Neolithic period from the Near East 
into Europe. More likely, the selection of the advantageous TIRAP variants that has 
shaped the West-Eurasian populations has taken place during the early phase of the 
dispersal of modern humans into West-Eurasia. Finally, the present study 
demonstrates that, by determining the evolutionary path of genes involved in the 
innate immune system, and complementing genotype analysis with the functional 
phenotype, one can provide new insights in our understanding of the pathogenesis 
of severe infections such as sepsis.
The Mal/TIRAP allele variant 180L
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Materials and Methods 
Human Endotoxemia Model.
Twenty healthy volunteers were infused with highly purified LPS at a dose of 2 
mg/kg, as previously described18. Before and after 30, 60, 90, 120, 240, and 360 min, 
blood was collected and plasma separated by centrifugation. Circulating 
concentrations of TNF, IL-6, IFN-y, and IL-10 were measured by specific LUMINEX kit 
(BioRad). Among the volunteers, 14 were homozygote for the wild-type TIRAP allele, 
whereas 6 individuals were heterozygous for the TIRAP 180L allele.
Peripheral Blood Mononuclear Cell (PBMC) Stimulation.
PBMCs were isolated by density gradient centrifugation on Ficoll, washed 3 times in 
cold RPMI medium 1640, counted, and resuspended in complete culture medium. 
PBMCs (final concentration 2.5 x 106/mL) were stimulated with Pam3Cys (10 zg/mL), 
LPS (10 ng/mL), or CpG DNA (25 zg/mL) in 96-well, round-bottom plates for 24 h at 
37 °C. After stimulation, supernatants were collected and directly used for cytokine 
measurement.
Sepsis Patients.
One-hundred-sixty-six patients were enrolled in a prospective study conducted over 
the period of June 2004 to September 2005 at the Department of Critical Care of the 
Evangelismos General Hospital and in the 2nd Department of Critical Care of the 
Attikon University Hospital of Athens, Greece. The study was approved by the Ethics 
Committee of both hospitals. All enrolled patients were intubated for at least 48 h 
before diagnosis of sepsis and they were all aged above 18 years. Exclusion criteria 
were the presence of (i) neutropenia (<500 neutrophils per mm3), (ii) HIV infection, 
and (iii) oral intake of corticoids at a dose >1 mg/kg of equivalent prednisone for a 
period greater than 1 month. Enrolled patients were followed-up for 28 days. 
Inclusion criteria were the concomitant presence of (i) VAP and (ii) sepsis, severe 
sepsis, or septic shock. The patients were selected based on infection with a Gram­
negative microorganism. The most commonly cultured microorganisms were
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Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and 
Enterobacter spp. Septic shock was defined as sepsis with sepsis-induced 
hypotension requiring vasopressor therapy despite adequate fluid challenge, along 
with the presence of hypoperfusion and organ dysfunction.
DNA Samples and TIRAP 180 Screening.
DNA samples from the Han people came from Corriell (Cat No. HD1000CHI). Other 
included populations are described elsewhere1,19. Informed consent and written 
approval from the relevant ethical review boards has been granted from all sample 
collections. From most populations, blood was drawn and the DNA was extracted by 
using the isolation kit Puregene (Gentra Sytems). Genotyping of the Mal/TIRAP 
S180L polymorphism was performed by using TaqMan, SNP Genotyping Assay 
(Applied Biosystems). PCRs were set up according to the manufacturer's instructions. 
Thermal cycling was performed on a fast optical 96-well reaction plate on the 7500 
Fast Real-Time PCR system (Applied Biosystems) as follows: Initial denaturation and 
enzyme activation at 95 °C for 10 min, followed by 40 cycles of denaturation at 95 °C 
for 15 s, and annealing/extension at 60 °C for 1 min. Mal SNP polymorphism was 
determined by performing an Allelic Discrimination Assay run on the 7500 Fast Real­
Time PCR system (Applied Biosystems). SNP polymorphism results were verified by 
using positive controls20.
Statistics.
The distributions between the TIRAP alleles in the different populations, the Hardy 
Weinberg equilibrium, and Fst were preformed by means of GENEPOP21. The 
differentiation analysis is based on the unbiased estimation of the P value of a log- 
likelihood-based (G) exact test, which is based on the same principles as the Fisher 
exact test.
Cytokine and sepsis statistics were preformed by using the Statistical Package for the 
Social Sciences package, and differences were tested by the Mann-Whitney U test. P 
< 0.05 was considered to represent a statistically significant difference.
The Mal/TIRAP allele variant 180L
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As a neutrality test, we applied the EHH test36 to the phased genotypic information 
available from HapMap Data Rel. 21a/phasell Jan 07, on NCBI NB35 assembly, dbSNP 
bl25. We used as the core haplotype that haplotype formed by allele G at rs3802813 
and allele A at rs3802814 as proxies for rs8177374, which is absent in the phased 
haplotype display of this HapMap release. As a summary statistic we used the extent 
for with the EHH for this core haplotype was 1 in the HapMap Caucasian population 
within a genomic region that extended 100 kb in each of the directions from the 
core. To test whether the distance observed was longer than expected under 
neutrality, we ran coalescent simulations that took into account the heterogeneity in 
recombination rates across these regions (obtained from the HapMap link) by means 
of msHOT22. We used demographic parameters reflecting the Out-of-Africa model of 
human evolution by slightly modifying the model by Schaffner et al.23. Simulations 
were run for both 100kb downstream from the core and for 100kb upstream from 
the core. The number of SNPs was adjusted to that observed in the HapMap sample 
for that region. We added 3 filters to the neutral simulations: (i) We only considered 
those simulations that resulted in a number of different haplotypes equal to that 
observed in the HapMap sample (as determined by the core SNPs rs3802813 and 
rs3802814), in the simulations the first 2 SNPs were considered the core set; (ii) in 
addition, one of the simulated core haplotypes had to show a similar frequency to 
that core haplotype under examination (obtained from the HapMap Caucasian SNP 
information and defined by core SNPS, (allele G at rs3802813 and allele A at 
rs3802814); (iii) the ancestral/derived states of the core SNPs in this preselected, 
simulated haplotype had to also be identical to the ancestral/derived states of the 
core SNPs at the core haplotype under examination. By comparison with the 
orthologous genome regions of the Chimp and Rhesus Macaca, rs3802813 "G" and 
rs3802814 "A" were defined as "ancestral" and "derived", respectively. Simulations 
satisfying these conditions were kept, but only the information on the core 
haplotype was used for the EHH analysis. Finally, the extent from the core SNPs for 
which EHH was 1 was recorded for the observed HapMap data and this was tested 
against the distribution obtained from the filtered simulations.
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Network analysis was preformed by using the program Network 4.5.0.0 from Fluxus­
engineering (http://www.fluxus-engineering.com) using the median joining 
methodology24. For information regarding the composing of the allele haplotypes 
and weighting of the different SNPs, see Table S1.
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Supporting Information
Table S I. Summary information of all included allele genotypes and polymorphic 
sites of the network analyzed.
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ancient nucleotide of that position. Each polymorphic site was given a letter and all 
different allele genotypes numbers. Before preforming the network analysis, all 
polymorphic sites were checked on their nucleotide surroundings if they were part 
of a CpG, because of the influence the higher mutation rate could have on the 
homoplasy. Two included SNPs, namely rs8177352 and rs817739, were therefore left 
out of the network analysis. Also, networks were analyzed that weighed the 
mutation rate of transversion and transition sites differently. With these weightings, 
no difference was seen in the network outcome.
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TLR4 Asp299Gly and TB susceptibility in African HIV patients
Abstract
Toll-like receptor 4 (TLR4) plays an important role in the pattern recognition of 
Mycobacterium tuberculosis, and polymorphisms in the TLR4 gene influence the 
function of the receptor. We therefore investigated in a cohort of HIV-infected 
Tanzanian patients whether the Asp299Gly TLR4 polymorphism is associated with 
the development of active tuberculosis. We found a greater risk of developing active 
tuberculosis as well as a reduction in CD4 T-cell counts in patients with the 
Asp299Gly TLR4 polymorphism.
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Results and Discussion
As a result of the growing number of HIV infections in sub-Saharan Africa, the 
number of co-infections of HIV and Mycobacterium tuberculosis is also increasing 
fast, with a significant contribution to morbidity and mortality1,2. It is well known 
that the incidence of infection with M. tuberculosis is much higher than that of 
active tuberculosis, even in the case of co-infection with HIV. Toll-like receptors (TLR) 
are a class of receptors that is important for the recognition of pathogens by the 
innate immune system and for bridging the innate and acquired immune response3. 
Research revealed that TLR4 mediates cytokine production stimulated by M. 
tuberculosis, and that TLR4 knockout mice are more susceptible to infection with M. 
tuberculosis4,5. Therefore, we wanted to assess whether the TLR4 polymorphism, 
Asp299Gly, which is common in Africa, is involved in the development of active 
tuberculosis in HIV-infected patients.
At Kilimanjaro Christian Medical Center in Tanzania, we enrolled 120 HIV-infected 
patients who presented with symptoms of chest infection or chest radiographic 
abnormalities. These patients underwent bronchoscopy with a collection of 
bronchoalveolar lavage fluid for tuberculosis culture and real time polymerase chain 
reaction (qPCR) DNA amplification for M. tuberculosis6. Combined results of the 
tuberculosis diagnostics were used to form group 1 with active tuberculosis disease 
(culture and qPCR positive) and group 2 with no active tuberculosis (culture negative 
and qPCR negative or positive). Patients with a negative culture and positive qPCR 
were followed for 18 months, in which time none developed active tuberculosis. 
Patients on antituberculosis treatment were regarded as active tuberculosis cases if 
qPCR was positive despite a negative culture. Sixteen patients were excluded 
because of incomplete data, thus a total of 104 patients remained for analysis. From 
all these patients, the TLR4 Asp299Gly polymorphism was determined, as described 
before7.
Twenty-four patients had active tuberculosis and 80 had no active tuberculosis. Sex 
and age did not differ between the two groups. The percentage of the Asp299Gly 
polymorphism in patients with no active tuberculosis was 7.5% (N = 6/80) compared 
with a 2.8-fold higher prevalence within the active tuberculosis group (20.8%, N =
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5/24). This difference almost reached significance (%2 P = 0.06), suggesting that HIV- 
infected patients carrying the Asp299Gly allele have an increased susceptibility to 
develop active tuberculosis. These findings are in line with the in-vivo reports that 
TLR4 is a receptor involved in the recognition of the soluble factor of M. tuberculosis 
and for whole mycobacterium ligands8,9. The difference between our results and 
those of Newport et al.10, who were not able to find a role for the TLR4 Asp299Gly 
polymorphism in non-HIV-infected individuals, indicates that the role of TLR4 
recognition and activation of the innate immune system is likely to be more 
pronounced in HIV-infected individuals4,11. Another cause of the differences 
between the studies may be the different genetic background (west Africa/Gambia 
and east Africa/Tanzania), because ethnicity is known to interact with susceptibility
to tuberculosis10,12.
Because all patients were HIV infected, we also looked at the difference between 
CD4 T-cell counts. As expected, patients with active tuberculosis had a lower median 
CD4 T-cell count compared with the no active tuberculosis group (Mann-Whitney U- 
test, P = 0.01; Fig. 1a). Interestingly, within the group of patients without the 
Asp299Gly polymorphism, median CD4 T-cell counts were significantly lower in 
individuals with active tuberculosis, compared with individuals in the no active 
tuberculosis group (Mann-Whitney U-test, P = 0.01; Fig. 1a). This difference was no 
longer present in patients with the Asp299Gly polymorphism who all except one had 
CD4 T-cell counts below 100 cells/]l (Mann-Whitney U-test, P = 0.79; Fig. 1a). 
Further investigation revealed that the distribution of the Asp299Gly polymorphism 
in subgroups of patients according to the clinically important categories of CD4 T-cell 
counts (350, 200, 100 cells/]l; Fig. 1b) showed an increased prevalence of the 
Asp299Gly polymorphism in all subgroups of patients having CD4 T-cell counts below 
350, 200 and 100 ce lls/]l. Only in patients with CD4 T-cell counts below 100 cells/]l 
was the prevalence of the Asp299Gly polymorphism (15.6%) significantly higher than 
in patients with CD4 T-cell counts of more than 100 cells/]l (2.5%; % P = 0.03). It 
should be noted that only one individual with the Asp299Gly polymorphism had a 
CD4 T-cell count above 100 cells/]l (Fig. 1b). On the one hand, this striking 
observation is probably caused by the mechanisms through which Asp299Gly 
increases susceptibility to tuberculosis. On the other hand, this phenomenon is likely
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(a)
Figure 1. Details of the study patients, (a) Median CD4 T-cell counts of 
the 104 patients studied, grouped by their tuberculosis and TLR4 status. 
*P=0.01, **P=0.79;
Dark gray square is TLR4; white square is TLR Asp299Gly. (b) Distribution 
of the 299 alleles of the patients when they were grouped by CD4 T-cell 
counts equal to or above, and below 350, 200 and 100 cells/[mu]l, 
respectively. Numbers in the bars represent the numbers of patients in 
each. [black square] TLR4; [white square] TLR4 Asp299Gly.
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to be important for the pathology and clinical presentation of HIV infection, because 
both therapeutic and antibiotic prophylaxis decisions are based on CD4 T-cell counts. 
So the surprising difference between CD4 T-cell counts within TLR4 polymorphisms 
indicates that the HIV-infected status is important for the impact of TLR4 Asp299Gly. 
CD4 T-cell counts are the most important prognostic factor in HIV infection for the 
development of opportunistic infections, including tuberculosis.
Different factors may explain the observed low number of CD4 T cells in HIV-infected 
patients bearing the TLR4 Asp299Gly polymorphism. TLR4 is known to activate the 
interferon response, thus inhibiting HIV replication. Therefore, individuals bearing 
the TLR4 Asp299Gly polymorphism may have a more pronounced viral replication, 
with an enhanced loss of CD4 T cells and increased susceptibility to tuberculosis. 
Another explanation could be that the absence of potent inflammation in TLR4 
Asp299Gly HIV-infected individuals leads to fewer symptoms caused by infection 
with M. tuberculosis, therefore patients will present to the hospital at a later stage 
of the disease. Additional studies with a prospective follow-up of newly diagnosed 
HIV-infected patients bearing either wild-type or the Asp299Gly allele is needed to 
answer these questions.
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Conclusion
In conclusion, the Asp299Gly polymorphism at the level of TLR4 is associated with an 
increased chance of developing active tuberculosis in HIV-infected patients, and this 
seems to involve an effect of this polymorphism on the CD4 T-cell counts in these 
patients.
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Abstract
Background: Caspase-12 functions as an antiinflammatory enzyme inhibiting 
caspase-1 and the NOD2/RIP2 pathways. Due to increased susceptibility to sepsis in 
individuals with functional caspase-12, an early-stop mutation leading to the loss of 
caspase-12 has replaced the ancient genotype in Eurasia and a significant proportion 
of individuals from African populations. In African-Americans, it has been shown that 
caspase-12 inhibits the pro-inflammatory cytokine production.
Methodology/Principal Findings: We assessed whether similar mechanisms are 
present in African individuals, and whether evolutionary pressures due to plague 
may have led to the present caspase-12 genotype population frequencies. No 
difference in cytokine induction through the caspase-1 and/or NOD2/RIP2 pathways 
was observed in two independent African populations, among individuals with either 
an intact or absent caspase-12. In addition, stimulations with Yersinia pestis and two 
other species of Yersinia were preformed to investigate whether caspase-12 
modulates the inflammatory reaction induced by Yersinia. We found that caspase-12 
did not modulate cytokine production induced by Yersinia spp.
Conclusions: Our experiments demonstrate for the first time the involvement of the 
NOD2/RIP2 pathway for recognition of Yersinia. However, caspase-12 does not 
modulate innate host defense against Y. pestis and alternative explanations for the 
geographical distribution of caspase-12 should be sought. Toll-like receptor 4 (TLR4) 
plays an important role in the pattern recognition of Mycobacterium tuberculosis, 
and polymorphisms in the TLR4 gene influence the function of the receptor. We 
therefore investigated in a cohort of HIV-infected Tanzanian patients whether the 
Asp299Gly TLR4 polymorphism is associated with the development of active 
tuberculosis. We found a greater risk of developing active tuberculosis as well as a 
reduction in CD4 T-cell counts in patients with the Asp299Gly TLR4 polymorphism.
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Introduction
Caspases are cysteine proteases that are involved in apoptosis and inflammation 1-3. 
Three human caspases involved in the inflammation path<ay are =no<n> namely 
caspase-1> 4> and 52,3. In other mammals s;ch  as mice and chimpanzees> another 
caspase <ith m od;latory effects on inflammation is caspase-12. In h;mans> a 
tr;ncated non-f;nctional form of caspase-12 d ;e  to a m;tation res;lting in an early 
stop codon has largely replaced the ancient genotype4. Genetic and pop;lation 
analysis revealed that the f;nctional form of caspase-12 is present in 20 to 30% of 
the African pop;lations> <hile completely absent in E;rope and Asia5'6. D ;e to this 
partic;lar <orld<ide distrib;tion and its involvement in inflammation> caspase-12 
has been proposed as an exq;isite example of an imm;ne gene changed ;nder 
evol;tionary press;re.
F;nctionally> caspase-12 has been reported to be involved both in the apoptotic and 
inflammatory path<ays7. Whole blood stim;lation < ith  lipopolysaccharide (LPS) 
sho<ed that individ;als bearing the f;nctional caspase-12 <ere hypo-responsive. 
LPS' an o ;ter cellular membrane str;ct;re  fo;nd on Gram-negative bacteria is 
recognized by our innate immune system8. The innate immune system recognizes 
specific pathogen structures> such as LPS through pattern recognition receptors 
(PRR) like toll-li=e receptors (TLRs)9. TLR4 is the most important PRR involved in the 
recognition of LPS> TLR2 recognizes bacterial lipopeptides> and the NOD2 receptor 
recognizes peptidoglycans. PRR engagement induces production of proinflammatory 
cytokines such as TNF-a and IL-1[. The IL-1[ activation requires cleavage by another 
inflammatory caspase termed IL-1[ converting enzyme or caspase-110.
After LPS stimulation> individuals <ith  a functional caspase-12 produced lo<er TNF-a 
and IL-1[ levels compared to individuals bearing only the truncated form of caspase- 
1211. It has been therefore proposed that caspase-12 has anti-inflammatory effects 
by inhibiting both the NFkB and caspase-1 path<ays12. As a consequence of the 
altered NFkB and caspase-1 path<ay stimulation in individuals bearing functional 
caspase-12' the clearance of Gram-negative bacteria may be defective and 
eventually this could result in a life threatening bacterial infection13'14. A small
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clinical study among African Americans showed that the pressure of a functional 
caspase-12 was accompanied by an increased susceptibility to sepsis15. These 
findings were supported by a sepsis mouse model showing that caspase-12 mice had
a higher bacterial count and lower pro-inflammatory cytokine production during
11sepsis .
Evolutionary studies6'16 determined that the loss of functional caspase-12 in 
Caucasian and Asian populations was caused by recent positive selection. The loss of 
function of caspase-12 is due to truncation of the protein' rather then modulation of 
mRNA transcription. These data combined with the correlation of caspase-12 with 
susceptibility to sepsis' lead to the hypothesis that the loss of functional caspase-12 
was due to the increasing pressure of sepsis during the human migration towards 
Europe and Asia6. After blood stimulation of individuals bearing the functional and 
non-functional caspase-12 with LPS it was shown that the non-functional caspase-12 
protein was not transcriped11. This indicates that early stop codon results in a loss of 
function of the caspase-12. However' the assumption that the loss of function of 
capase-12 involved in the innate immune response are based on a single study in a 
small number of African Americans' but no data on the function of caspase-12 in 
African populations are available16.
This is essential for the understanding of how the selection has driven selection of 
caspase-12 genotypes during human history. In the present study we assessed the 
impact of caspase-12 genotypes on inflammation in two African populations' and the 
potential effect of caspase-12 on a microorganism known to have exerted intense 
evolutionary pressure on European and Asian populations: Yersinia pestis' the agent 
of bubonic plague.
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Results
Functional and non-functional caspase-12 frequencies in Mali volunteers
To evaluate the effect of non-functional and functional caspase-12 genotypes on 
proinflammatory cytokines, blood was initially collected from 50 healthy Mali 
volunteers. Thirthy-three of the volunteers were homozygous (66%) for the non­
functional caspase-12 allele, 16 volunteers were heterozygous (32%), and one (2%) 
was homozygous for the functional caspase-12 allele (Table 1). These frequencies of 
the caspase-12 genotypes were in line with previous reports5.
Table 1. Caspase-12 genotypes and allele frequency in two cohorts of Mali 
volunteers, one collected in 2006 and one in 2007.
Non-functional Functional Functional Genotype frequency (%) Allele frequency
TG A  S/S (T/Q GA S/L CG A L/L Total T/T C/T C/C T  C
2006 a 33 16 1 50 66.00 32.00 2.00 0.82 0.18
2007 a 24 22 1 47 51.06 46.81 2.13 0.74 0.26 
Total a b 57 38 2 97 58.76 39.18 2.06 0.78 0.22
Population do not violate Hardy-Weinberg equilibrium.
distribution of Caspase-12 genotypes between 2006 and 2007 populations did not differ (x2-test). 
doi:10.1371/journal.pone.0006870.t001
Pro-inflammatory cytokine production of the caspase-12 genotypes
Stimulation of whole blood was performed with either the TLR4 ligand LPS 
(concentrations 1, 10 and 100 ng/ml) or Pam3Cys (10 Qg/ml), a TLR2 specific ligand. 
Similar levels of TNF-a between caspase-12 genotypes were observed between the 
groups (Figure 1A). Surprisingly, the IL-1ß production was even increased in 
individuals heterozygous for the functional caspase-12 allele, for all LPS 
concentrations tested (Mann-Whitney, P<0.05, figure 1B). In addition, the individual 
homozygous for the functional caspase-12 allele showed no evidence of inhibition of 
the production of pro-inflammatory cytokines (Figure 1). The release of the anti­
inflammatory cytokine IL-10 was independent of the caspase-12 genotype (Figure 
1C).
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Figure 1. In-vitro cytokine measurements after whole blood LPS and Pam3Cys 
stimulation between the caspase-12 genotypes from the volunteers enrolled in 
2006. Stimulation was performed with 1, 10 and 100 ng/ml LPS (E. coli) and 10 
mg/ml Pam3Cys. TNF (A), IL-1b (B) and IL-10 (C) were measured by ELISA in the 
supernatant after 24 hour stimulation. Volunteers were grouped as homozygous 
bearing the nonfunctional caspase-12 genotype (S/S), heterozygous bearing the 
nonfunctional and functional caspase-12 (S/L), and homozygous bearing the 
functional caspase-12 (L/L). Numbers of volunteers included for each cytokine are 
S/S = 33, S/L = 16 and L/L = 1. Values represent mean + SD for each group of 
volunteers. P-values for differences between caspase-12 genotype were calculated 
with the Mann-Whitney test. *P,0.05.
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Replication within second field study of previous findings
Because the result of our initial study clearly contradicted one earlier report of 
inhibition of the pro-inflammatory response by caspase-12, we initiated a second 
field study to assess the function of caspase-1211. During this second study we 
collected blood from 47 Mali volunteers and determined their caspase-12 genotype 
(volunteers 2007, Table 1). Twenty-four individuals were homozygous (51%) for the 
non-functional caspase-12 allele, 22 heterozygous (47%), and one volunteer was 
homozygous (2%) for the functional caspase-12 allele (Table 1). No difference was 
found between cells isolated from individuals homozygous for the non-functional 
caspase-12 allele and from the heterozygous volunteers, when production of TNF-a, 
IL-1ß or IL-10 was measured (Figure 2). No differences for the production of IL-1ß 
were found between the groups in this second study. The cytokine production of 
cells isolated from the volunteer homozygous for the functional caspase-12 was 
comparable with the other genotypes (Figure 2 B and C).
Yersinia spp stimulations
Stimulation with pure TLR4 (LPS) and TLR2 (Pam3Cys) ligands showed no anti­
inflammatory role of the functional caspase-12. The lack of inhibition could have 
been caused by the specific TLR stimuli used in these experiments. Therefore, whole 
blood from the second volunteer cohort was also stimulated with three pathogenic 
Yersinia species, namely Y. enterocolitica, Y. pseudotuberculosis and Y. pestis (Figure
3). These three Yersinia spp were chosen due to their important role as human 
pathogens. With all three Yersinia species no different pro-inflammatory cytokine 
production was observed between the functional and non-functional caspase-12 
individuals (Figure 3). This indicates that the caspase-1 pathway was not affected by 
the functional caspase-12.
NOD2/RIP2 pathway
Beside the caspase-1 pathway it has been shown that caspase-12 inhibition of the 
NOD2/RIP2 pathway is important for the lower pro-inflammatory cytokine release17. 
To test if the NOD2/RIP2 pathway was involved in the innate immune response 
against Yersinia spp. we preformed stimulations with the same three Yersinia spp. in
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Figure 2. In-vitro cytokine measurements after whole blood LPS and Pam3Cys 
stimulation between the caspase-12 genotypes from the volunteers enrolled in 
2007. Stimulation with LPS was performed with 10 ng/ml. TNF (A), IL-1ß (B) and IL- 
10 (C) were measured by ELISA after 24-hour stimulation. Volunteers were grouped 
as homozygous bearing the nonfunctional caspase-12 genotype (S/S), heterozygous 
bearing the nonfunctional and functional caspase-12 (S/L) and homozygous that 
bear the functional caspase-12 (L/L). Numbers of volunteers included for each 
cytokine are S/S = 24, S/L = 22 and L/L = 1. Values represent mean + SD for each 
group of volunteers. P-values for differences between caspase-12 genotype were 
calculated with the Mann-Whitney test.
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Figure 3. In-vitro cytokine measurements after whole blood stimulation with 
Yersinia enterocolitica, Yersinia pseudotuberculosis and Yersinia pestis. TNF (A), 
IL-lß  (B) and IL-10 (C) were measured by ELISA after 24-hour stimulation. 
Volunteers were grouped as homozygous bearing the nonfunctional caspase-12 
genotype (S/S), heterozygous bearing the functional caspase-12 and nonfunctional 
(S/L) and homozygous that bear the functional caspase-12 (L/L). The numbers of 
volunteers included for each cytokine are S/S = 24, S/L = 22 and L/L = 1. Values 
represent mean + SD for each group of volunteers. P-values for differences 
between caspase-12 genotype were calculated with the Mann-Whitney test.
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cells isolated from individuals homozygous for the 3020insC NOD2 mutation (Figure
4). It was observed that the individuals homozygous for the 3020insC NOD2 
mutation display a tendency towards reduced TNF-a production (Figure 4A) and a 
significant lower IL1-ß production after stimulation with all three Yersinia spp (Figure 
4B). This demonstrates that the NOD2 receptor does play an important role in 
Yersinia recognition by the innate immune system. Secondly, involvement of the 
NOD2/RIP2 pathway during Yersinia spp recognition also indicates that if functional 
caspase-12 would have inhibited the pro-inflammatory response through the 
NOD2/RIP2 pathway, a reduction in IL-1ß production induced by Yersinia would have 
been expected, and that was not the case (Figure 3B).
Figure 4. In-vitro cytokine measurements after PBMC stimulation with Yersinia 
enterocolitíca, Yersinia pseudotuberculosis and Yersinia pestis. Caucasian 
individuals bearing a normal (NOD2 wt, N = 10) or homozygous for the 3020insC 
NOD2 mutation (NOD2 del, N = 5) were stimulated with the various Yersinia spp. 
TNF (A) and IL-1ß (B) were measured by ELISA after 24-hour stimulation. Values 
represent mean + SD for each group of volunteers. P-values for differences 
between caspase-12 genotype were calculated with the Mann-Whitney test. 
*P<0.05, **P<0.01
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Discussion
Caspase-12 is a member of the caspase family of cysteine proteases that has been 
suggested to exert inhibitory effects on proinflammatory cytokines. The only 
populations that retain a sizeable proportion of individuals with active caspase-12 
are those in Sub-Saharan Africa. The aim of the present study was to assess the 
effect of caspase-12 on the cytokine response of cells isolated from volunteers of 
African origin, after stimulation with bacterial stimuli. These experiments revealed 
that functional caspase-12 had no inhibitory effect on the pro-inflammatory 
response (Figure 1). In a small previous study performed in cells isolated from 18 
African Americans (eight homozygous for the non-functional allele, eight 
heterozygous, two homozygous for the functional caspase-12), Saleh et al suggested 
that a functional caspase-12 decreased cytokine production11,15.
Because our data from the first field study clearly differed from this previous 
investigations we repeated our experiments in cells isolated from volunteers from a 
second independent African population from the same region (Table 1, Figure 2). 
The results from the second study support the conclusion that caspase-12 had no 
modulatory effect on the TLR-stimulated production of cytokines.
In the first cohort of volunteers, we did observed an elevated IL-1ß production in 
individuals with an active caspase-12. Interestingly, in a colonic inflammation mouse 
model Leblanc et al also found that mice with a functional caspase-12 had a higher 
production of pro-inflammatory cytokine on day 14, although no differences in the 
production of the pro-inflammatory cytokines were observed early in the process17. 
However, this effect on IL-1ß production could not be reproduced in the second field 
study. Therefore, the overall conclusion of these two studies must be that caspase- 
12 is unlikely playing a major role in the modulation of the inflammatory reaction 
induced by LPS or bacterial lipopeptides.
Our first set of experiments used specific TLR4 and TLR2 ligands to elicit 
inflammation. However, bacterial pathogens are much more complex structures, 
and an effect of caspase-12 during stimulation with intact microorganisms could still 
be envisaged. In support of this hypothesis, it has been reported that individuals
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with a functional caspase-12 are more susceptible to sepsis11. Therefore, we wanted 
to assess whether stimulation of cells with various caspase-12 genotypes with 
complex Gram-negative microorganisms resulted in differences in pro-inflammatory 
cytokines. We performed stimulations with the Gram-negative bacteria Y. pestis, the 
agent of bubonic plague, an infection that is well-known to have induced an 
important evolutionary pressure on Europe and Asian populations (Figure 3)18. In 
addition, we also stimulated cells with Y. enterocolitica, an important pathogene of 
the digestive tract, and with Y. pseudotuberculosis the recent ancestor of Y. pestis18. 
Previous studies have shown the role of TLR2 and TLR4 for Y. pestis recognition19. In 
our stimulation of individuals with the homozygote 3020insC NOD2 mutation we 
demonstrate the involvement of the NOD2 pathway during Yersinia spp recognition 
(Figure 4). The fact that both TLR and NOD2 pathways have been proposed to be 
modulated by caspase-12, makes Yersinia therefore the ideal bacterial model for the 
assessment of caspase-12 effects.
Important in the recognition of Yersinia strains is the recognition through TLR4. 
Montminy et al. showed that Y. pestis actively changes its LPS structure after the 
transmission to humans20. By doing this, Y. pestis actively avoids TLR4 recognition 
and the innate immune response necessary for the clearance. Yersinia also 
manipulates the innate immune system of hosts with a mechanism known as the 
type III secretion system21. Hereby Yop proteins are secreted and interfere with the 
inflammation response. These proteins take control of host cells by inhibiting the 
caspase-1-mediated maturation and IL-1ß release22. This indicates that both NFkB 
and caspase-1 signaling pathways are involved in the recognition of Yersinia. 
However, our experiments performed in a large number of volunteers bearing a 
functional caspase-12 do not show any modulation of Yersinia-induced cytokines, 
and thus of the TLR/NOD2 pathways.
Earlier studies on the distribution of caspase-12 genotypes have shown important 
differences between populations5'6, but it is unclear how environmental pressure 
caused selection of certain alleles, and lead to loss of caspase-12 function in the 
majority of individuals23. Our study in two African populations does not support a 
role for caspase-12 in the modulation of the pro-inflammatory response after TLR 
challenge. Similarly, no effect of caspase-12 on Yersinia stimulation of cytokines was
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observed. Phylogenetic analyses show that structurally, caspase-12 is grouped with 
the other inflammatory caspases, but the potential mechanisms through which 
caspase-12 potentially modulate the inflammation are still not well understood24,25. 
Most data available to date have been obtained in mice defective in caspase-12, that 
showed a higher cytokine response and increased resistance in bacterial models15,17. 
These data seem to be supported by a small study in humans, suggesting high 
cytokine responses in humans with inactive caspase-1211. Unfortunately, this study 
has not been independently confirmed and seem to be contradicted by our data. The 
cause of the differences between the study of Saleh and colleagues and the present 
study are unclear. In our study we have performed a dose-response curve of LPS 
concentrations (Figure 1), and therefore it is unlikely that differences in LPS 
concentrations could explain the discrepancy. We have also preformed the 
experiments in a larger numbers of individuals than the original study of Saleh et al, 
and the results were verified in a second cohort. Ethnic differences between the 
African American volunteers in the study of Saleh et al and the Mali population 
investigated in our study could account for some differences, although the theoretic 
basis for this is unclear. The only additional study investigating the role of caspase-12 
in infections found no correlation between caspase-12 and hepatitis C virus 
infection26. It is possible that caspase-12 may interact also with other PRRs than TLR4 
and NOD2. However, by using whole microorganisms as Yersinia spp., that very likely 
stimulates also TLR2, TLR5, TLR9 (etc), we practically exclude an influence of 
caspase-12 on other important PRR pathways as well.
In summary, the data of the present study show no regulatory role of human 
caspase-12 on the inflammation induced by TLR ligands or Yersinia spp. Although a 
role of caspase-12 for the susceptibility to sepsis can still be envisaged (which has to 
be confirmed in larger studies), this is highly unlikely to be mediated through 
modulation of cytokine response. Alternatively, the selection found in European and 
Asian populations on the non-functional caspase-12 may have not been caused by 
sepsis at all, and other biological explanations should be sought.
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Materials and methods 
Volunteers
Blood samples were collected in the Koro district of Mali, West Africa during two 
fieldtrips in September 2006 and April 2007. These studies are part of the 
investigational into interethnic differences in susceptibility to malaria, as described 
in detail elsewhere27. From these volunteers we only included the healthy individuals 
without any suspicion or diagnosis for malaria. Approval for the study was provided 
by the institutional review board of the University of Bamako (N°0527/FMPOS).
A total of 10 Dutch Caucasian controls and 5 Dutch Caucasian volunteers 
homozygous for the loss-of-function 3020insC NOD2 mutation were used for the 
stimulation experiments investigating the role of NOD2 in the recognition of 
Yersinia. The characteristics of the NOD2-defective individuals are described 
elsewhere28.
Cytokine stimulation assays
Venous whole blood was collected into 10 ml heparin tubes (BD, Plymouth, UK) 
Blood from healthy individuals was diluted to a final concentration of 1:5 in RPMI 
1640 medium (containing 1% glutamine, 1% pyruvate and 1% gentamicin). 
Stimulation was performed with control medium, highly purified lipopolysaccharide 
(Escherichia colli 055:B5, sigma, extra purified according to Hirshfeld et al.29) at 
various concentrations (1, 10 and 100 ng/ml), and the lipopeptide Pam3Cys (10 
ag/ml, EMC Microcollections, Erlaugen). Heat-Killed Yersinia enterocolitica (clinical 
isolated), Yersinia pseudotuberculosis, serotype O1 (strain YERS0068) and Yersinia 
pestis antiqua, biovar Antiqua (strain BD94-oo544), were used for the stimulation 
experiments at a final concentration of 1x104/ml. Yersinia strains were cultured in 
BHI-broth (Tritium, Eindhoven, The Netherlands) for 48 hours at 37°C. The cells were 
resuspended in milliQ and heat treated at 95°C for 30 minutes. Colony forming units 
(CFU) and loss of viability of the cells after heat treatment were determined by 
plating appropriate dilutions on blood agar (Biotrading, Mijndrecht, The 
Netherlands) followed by incubation at 37°C for 48 hours. After 24 hours of
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stimulation at 37°C, supernatants were collected and stored at -80°C until cytokines 
measurements were preformed.
For the stimulations of cells isolated from the NOD2-defective individuals, peripheral 
blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation 
on Ficoll, washed three times in cold RPMI, counted and resuspended in complete 
culture medium. PBMCs (final concentration 2.5x106/ml) were stimulated with three 
Yersinia strains in 96-well round-bottom plates for 24 hours at 37°C. After 
stimulation, supernatants were collected and directly used for cytokine 
measurement.
Cytokine measurements
IL-10 and ILl-ß  cytokine concentrations were measured by sandwich ELISA (Sanquin, 
Amsterdam, The Netherlands). TNF-a production was measured by a specific ELISA, 
as previously described30.
Caspase-12 genotypic determination
DNA for all volunteers was extracted from whole blood using the Puregene (Gentra 
Systems, Minneapolis, MN) isolation kit. Flanking primers of the surrounding T125C 
polymorphism region and methodology was adopted as described by Saleh et al11. 
Sequencing was performed at the sequence faculty at the department of human 
genetics Nijmegen on the 48-capillary 3730 sequencer (Applied Biosystems). 
Genotypes of the volunteers were analyzed and determined using the software 
4Peaks by A. Griekspoor and T. Groothuis (mekentosj.com).
Statistical analysis
Data were analysed in SPSS (Rel.16; SPSS, Chicago, IL). Genotypic distribution 
between 2006 and 2007 was assessed by x2-test. Differences in cytokine response to 
the stimuli between groups were analysed by Mann-Whitney. P-values<0.05 were 
considered statistically significant in all analysis.
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Abstract
Background
The full-length (L-)variant of caspase-12 may predispose to sepsis and has been 
eliminated from most human gene pools by the untranslated (S-)variant. Strikingly, 
the L-allele is still widely prevalent in African populations, presumably due to a 
counterbalancing selective force specific to this continent, for which malaria is a 
prime candidate.(
Methods
We investigated associations between caspase-12 genotype and malarial parameters 
in three West-African populations, in studies encompassing immunological, clinical 
and obstetric data.(
Results
The caspase-12 L-allele was found at frequencies of 11-34%. Plasmodium 
falciparum-stimulated mononuclear cells from L-allele carriers produced stronger 
interferon- y and interleukin-10 responses than S/S homozygotes. Nevertheless, we 
found no association between caspase-12 genotype and either the presentation of 
severe malaria or individual clinical parameters in sick children. Amongst pregnant 
women, caspase-12 genotype influenced neither peripheral or placental malaria 
infection, nor basic obstetric parameters. Interestingly, perinatal mortality was 
more frequent in children of both S/S and L/L than S/L mothers, independent of 
placental Pf- infection.
Conclusions
We find little clinical or epidemiological evidence that malaria has contributed to the 
persistence of functional caspase-12 in Africa, suggesting either that alternative 
selective forces are at work or that genetic drift underlies its current global 
distribution.
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Introduction
Caspase-12 is a member of the large family of cysteine proteases involved in 
apoptotic and inflammatory pathways1, although it has limited proteolytic activity of 
its own2. Recently, caspase-12 has been implicated in the regulation of the pro- 
inflammatory cytokine IL-1ß, through the inhibition of caspase-1 mediated cleavage 
of pro-IL-1ß to IL-1ß3 and through the inhibition of NOD/RIP signalling4. Mice lacking 
the caspase-12 gene generated a stronger pro-inflammatory response than wild type 
animals5. In man, two allelic forms of the caspase-12 locus exist, the long (L-) and 
short (S-) variant. The former encodes for a full-length protein, whereas the latter 
encodes for a prematurely terminated, untranslated form. The emergence of the S- 
variant forms a relatively recent event in human evolution, since this variant is not 
found in chimpanzee populations6. Clinical studies associated the L-variant of 
caspase-12 with an increased risk of sepsis7. Whereas in Caucasian populations 
exclusively the S-variant of caspase-12 is found, in African populations the L-variant 
is still common8.
The distinct global distribution of caspase-12 alleles on the one hand suggests 
selection of the inactive S-variant outside of Africa, presumably due to its protective 
role in sepsis9. On the other hand, maintenance of the functional L-variant in sub- 
Saharan Africa implies a comparative advantage of this allele against some major 
selective force specific to this continent.
Malaria remains to this day responsible for a high burden of morbidity and mortality 
in large parts of the developing world, but nowhere more so than in sub-Saharan 
Africa, that suffers by far the highest transmission intensities. This virulence, 
combined with its target of particularly young, pre-pubescent children, means that 
the disease has exerted a strong selective pressure on human populations for at 
least the last 10.000 years. Such selective pressure is visible today in the genetic 
make-up of humans from malaria-endemic areas, more specifically in the presence 
of allelic variants or other genetic polymorphisms that confer some measure of 
protection against malaria10. Indeed some of the oldest and best-studied human 
genetic variations, those of the haemoglobin genes, including the HbS and HbC
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variants and a-and ß-thalassaemias are found in African populations as a result of 
selection by malaria11. In addition to red blood cell phenotypes, malaria has also 
exerted strong selective pressure on genes involved in both the adaptive12,13 and
14-18innate immune response .
The strong selective pressure malaria is known to have exerted on other genes, 
particularly in African populations, suggests it may also have played a role in the 
maintenance of full-length caspase-12 on this continent. In the present manuscript 
we have combined caspase-12 genotype data from three separate studies 
investigating susceptibility to malaria in different African populations, and we 
assessed associations with immunological, clinical and obstetric data.
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Results
Distribution of caspase-12 alleles in African populations
Table 1 presents the varying frequencies of caspase-12 alleles amongst the African 
populations studied. Frequencies of the L-allele as high as 34% were observed. 
None of the populations studied showed evidence for violation of Hardy-Weinberg 
equilibrium.
Table 1. Distribution of caspase-12 alleles in the populations studied.
Population N Genotypea allele freq.
S/S# S/L L/L S L
Cameroon 138 81 (58.7%) 53 (38.4%) 4 (2.9%) 0.78 0.22
Ghana 885 699 (79.0%) 172 (19.4%) 14 (1.6%) 0.89 0.11
Mali Dogon 81 56 (69.1%) 25 (30.9%) 0 (0%) 0.85 0.15
Mali Fulani 91 42 (46.2%) 37 (40.7%) 12 (13.2%) 0.66 0.34
a All populations are in Hardy-Weinberg equilibrium
# L: full-length variant (ancient); S: prematurely truncated, non-translated variant (derived) 
Mali study -  cytokine profile
During the malaria transmission season, parasite prevalence differed between 
caspase-12 genotypes within the Fulani ethnic group (S/S, 13/31; S/L, 11/26; L/L, 
1O/11; x 2=8.8, p=O.O12) but not within the sympatric Dogon (S/S, 2O/42; S/L, 9/15; 
x2=O.7, p=O.41). Irrespective of ethnicity, no effect of caspase-12 genotype was 
found on clinical parameters, including parasite density or Hb levels (data not 
shown).
Ex vivo stimulation assays were performed with PBMCs of 33 uninfected and 31 P. 
falciparum-infected donors in September 2OO6 and a further 38 uninfected 
volunteers in April 2OO7. Cytokine production by volunteers' PBMCs stimulated ex 
vivo with P. falciparum-infected erythrocytes (PfRBC) is presented in figure 1. 
Interferon-y (IFNy) and interleukin-1O (IL-1O) responses to uninfected-erythrocytes 
(uRBC) or to medium alone were generally below the detection limit of the assay 
(IFNy, 3.1 pg/mL; IL-1O, 4.7 pg/mL). IFNy, but not IL-1O, responses to PfRBC were
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Figure 1. Ex vivo cytokine responses to 
PfRBC by caspase-12 genotype in Malian 
donors. PBMCs from uninfected (left) 
and P. falciparum-infected donors (right) 
were stimulated for 21 hours with 5x106 
PfRBC/mL and cytokine production in the 
supernatant was measured by ELISA (A -  
IFNy; B - IL-10; C - IFNy/IL-10 ratio). 
Donors were stratified by caspase-12 
genotype and data represent mean+SEM 
for each group of volunteers (number for 
whom cytokine data was available is 
indicated under each bar). Dashed lines 
indicate mean responses to uRBC. P- 
values for differences between caspase- 
12 genotypes by Mann-Whitney.
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significantly stronger in uninfected than in infected volunteers (p<0.001 and p=0.29, 
respectively), and therefore cytokine responses were analysed separately by 
infection status; cytokine responses did not differ between uninfected volunteers in 
the rainy and dry season. IFNy responses to PfRBC were stronger in caspase-12 S/L 
carriers than in S/S carriers for the infected group (p=0.011) but not for the 
uninfected group, although the pattern remained similar (Figure 1). IL-10 responses 
were higher in S/L than in S/S carriers among uninfected donors (p=0.023) but not 
among infected donors, although again the pattern remained similar. These 
patterns were furthermore observed individually in both Fulani and Dogon 
populations and during both the transmission- and non-transmission seasons (data 
not shown). Cytokine data was only available for 3 infected L/L carriers; both IFNy 
and IL-10 appeared slightly lower than in S/L carriers. We also analysed the IFNy /IL-
10 ratio as an estimate of the overall pro/anti-inflammatory balance. This ratio was 
lower in S/L than in S/S carriers for both uninfected and infected donors, although 
not significantly so. Interleukin-1ß (IL-1ß) production was also assessed, but 
responses to PfRBC were barely measurable above the detection limit of the assay 
(40 pg/mL IL-1ß) (data not shown).
Cameroon study-clin ical presentation
Table 2 presents the distribution of caspase-12 genotypes amongst Cameroonian 
children with uncomplicated or severe malaria. Amongst the 38 patients with severe 
malaria, most had symptoms of cerebral malaria (31 were in coma [Blantyre score 
<3] and 10 suffered repeated convulsions), nine were in severe respiratory distress 
and one had severe anaemia (Hb <5g/dL). However, no association was found 
between caspase-12 genotype and disease severity overall (x2=0.31, p=0.86), nor 
between caspase-12 genotype and individual manifestations of severe malaria (Table 
2). Furthermore, there was no evident effect of caspase-12 genotype on individual 
clinical parameters among either uncomplicated or severe cases (Table 2).
Ghana study -  obstetric outcome
Table 3 shows the distribution of caspase-12 genotypes amongst 885 women 
attending antenatal clinics at Agogo District Hospital, Ghana for whom genetic data
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Table 2. Cameroon study (clinical presentation).
Clinical presentation
N
Genotype
S/S S/L
p-valuea 
L/L overall
All 138 81 (58.7%) 53 (38.4%) 4 (2.9%)
Uncomplicated malaria 100 6 o 6 0 \o ) 37 (37.0%) 3 (3.0%)
Severe malaria (all presentations) 38 21 (55.3%) 16 (42.1%) 1 (2.6%) 0.86
coma (Blantyre score <3) 31 16 (51.6%) 14 (45.2%) 1 (3.2%) 0.66
repeated convulsions 10 6 (60.0%) 4 (40.0%) 0 (0.0%) 0.80
respiratory distress 9 6 (66.7%) 3 (33.3%) 0 (0.0%) 0.80
severe anaemia (Hb<5) 1 1 (100%) 0 ( 0.0%) 0 (0.0%) 0.70
Clinical parameters uncomplicated cases
Gender % male 60% 53% 0% 0.11
Age years (SD) 4.8 (3.5) 5.2 (3.8) 6.3 (5.0) 0.79
Temp.oC (SD) 39.2 (1.1) 38.3 (6.7) 39.2 (0.6) 0.89
Parasitaemia log/mL (SD) 4.4 (0.9) 4.5 (1.1) 4.7 (1.8) 0.61
Hb g/dL (SD) 8.9 (2.0) 9.0 (1.7) 7.3 (3.4) 0.45
WBC x106/mL (SD) 8.7 (3.9) 9.8 (5.2) 8.4 (1.2) 0.60
Heart rate /min (SD) 126 (22) 127 (23) 127 (11) 0.92
Respiratory rate /min (SD) 37 ( 9) 39 (14) 36 (7) 0.99
Clinical parameters severe cases
Gender % male 55% 47% 100% 0.56
Age years (SD) 3.3 (2.2) 3.3 (2.2) 7.8 (-) 0.31
Temp.oC (SD) 39.1 (1.2) 38.7 (1.2) 39.0 (-) 0.57
Parasitaemia log/mL (SD) 4.4 (1.3) 4.6 (1.0) 5.1 (-) 0.89
Hb g/dL (SD) 8.7 (1.9) 9.3 (1.5) 9.4 (-) 0.52
WBC x106/mL (SD) 11.2 (5.2) 14.3 (7.7) 11.9 (-) 0.37
Heart rate /min (SD) 137 (27) 130 (44) 160 (-) 0.57
Respiratory rate/min (SD) 43 (13) 45 (18) 32 (-) 0.69
a x2-test or Kruskal-Wallis test
was available. Overall, neither prevalence of P. falciparum by PCR nor parasite 
density was found to vary significantly between caspase-12 genotypes (Table 3). In a 
sub-group analysis of primiparae (n=315), the prevalence of peripheral (but not 
placental) parasitaemia by PCR was slightly higher in S/L than S/S mothers (7O.8 vs 
56.9%, p=O.O4), although this significance was lost after adjusting for confounders. 
Peripheral parasite densities in these S/L mothers were, if anything, lower (2.6 vs 3.1 
log1O/uL, p=O.O9).
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The mother's caspase-12 genotype was not associated with fever, preterm delivery, 
or LBW (Table 3). In L/L mothers, anaemia appeared to occur at a reduced rate but 
this marginal association (p=0.04) was lost after stratification for malaria. Also, 
stratification into infected and non-infected women did not change the observed 
absence of effect of caspase-12 genotypes on maternal and foetal morbidity (data 
not shown).
Interestingly, however, the incidence of perinatal mortality was lower in infants of 
S/L mothers (0/172) than of either S/S mothers (19/699, p=0.02) or L/L mothers 
(2/14, p=0.005). This effect could not be ascribed to malaria, however, since the 
majority of all such cases occurred in mothers without placental parasitaemia by PCR 
(Table 3). Although the precise cause of death could not always be defined, LBW 
appeared to contribute in a majority (58%) of recorded cases. Furthermore, 
perinatal mortality was associated with a history of complicated labour (47% of 
cases), often requiring caesarean section (47% of cases). Finally, 52% of cases 
involved either still birth or poor delivery outcome (10' Apgar score <7).
Table 3. Ghana study (obstetric outcome).
G e n o typ e p -va lu e
S S S L LL O v e ra l la S S  v s  S L b S S  v s  L L b S L  v s  L L b
D ata  o f a ll 8 8 5  w o m e n
Genotype %  (N) 79.0%  (699) 19.4% (172) 1.6% (14)
Age of mother in years (mean) 26.3 26.4 27.8 ns
Primiparae % 35.5%  (246) 38.2%  (65) 28.6% (4) ns
Maternal fever % 3.2%  ( 22) 3.5%  ( 6) 0.0%  (0) ns
Maternal anaemia % 37.5% (262) 33.7% (58) 7.1%  (1) 0.048 0.36 0.02 0.04
Perinatal mortalityc % 2.7%  (19) 0.0%  ( 0) 14.3% (2) 0.001 0.02 0.06 0.005
- infectedd %  (n = 516) 2.2%  ( 9) 0.0% ( 0) 0.0% (0) 0.28 0.22 1 -
- not-infected %  (n=368) 3.1%  ( 9) 0.0% ( 0) 33.3% (2) <0.001 0.22 0.017 0.006
P a ra s ite  p re v a le n c e  (b y  P C R ) :
- peripheral venous blood 51.9% (363) 53.5% ( 92) 42.9%  (6) ns
- placental intervillous blood 57.9% (405) 60.5%  (104) 57.1% (8) ns
Geometiric mean parasite density:
- peripheral blood (log10/!L) 2.79 2.69 2.24 ns
- placental blood (log10/100 fields) 1.91 1.81 2.43 ns
D ata  o f l iv e  s in g le to n  d e liv e r ie s
Preterm delivery %  (n=827) 18.4% (119) 18.5% (31) 33.3% (4) ns
Low birth weight %  (n=834) 16.1% (105) 16.0% (27) 8.3%  (1) ns
a x2-test or Kruskal Wallis test, ns -  not significant (p>0.1) 
b x2-test or Fisher's exact test 
c child born dead or died within 24 hours 
d placental P. falciparum  infection detected by PCR
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Discussion
The striking global distribution of caspase-12 alleles brings the question of what 
evolutionary pressures have shaped this pattern. Humans are the only mammals, 
apart from rabbits and cows, to have lost a functional caspase-12 gene, indicating 
relatively recent and species-specific selective pressure6. The proposed evolutionary 
benefit of an untranslated caspase-12 gene is in protection against sepsis7, although 
to our knowledge no further studies have yet confirmed this. Presumably, sepsis 
(e.g. plague) has become a major selective force on human populations only during 
the recent past, as agriculture allowed permanent settlement and consequently 
higher population densities.
In line with previous reports9, we confirm the presence of L-variant caspase-12 in 
African populations, at allele frequencies of up to 34%. Whatever the selective force 
which has eliminated the functional L-variant outside of Africa, within Africa it must 
have been counter-balanced by a factor acting with an opposite effect, in order to 
explain the continued high frequencies of this functional allele in populations on this 
continent. Malaria, given its strong selective effect, specifically in Africa, would 
appear to be a prime candidate for this role.
However, in none of the three studies did we find any convincing evidence for an 
effect of the functional caspase-12 L allele on either the prevalence or density of 
parasitaemia or the clinical severity of malaria. Furthermore, caspase-12 genotypes 
did not directly affect most individual obstetric parameters, including prevalence or 
density of placental parasitaemia, fever, preterm delivery or LBW. Nor was there 
any robust effect on Hb levels or anaemia in delivering women (or either of the 
other two study populations).
One limitation that must be borne in mind when considering these findings, is the 
low number of data on L/L homozygotes, limiting the characterisation of their 
phenotype. However, although L/L homozygotes may arguably show a more 
pronounced phenotype than heterozygous individuals, this difference would not be 
expected to be greater than between heterozygotes and S/S homozygotes, since
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both L/L homozygotes and heterozygotes will express the full-length caspase-12 
protein and S/S homozygotes do not.
The full-length caspase-12 protein has been proposed to reduce pro-inflammatory 
cytokine production through inhibition of caspase-1 mediated activation of IL-1ß3. 
To test this hypothesis, we measured cytokine responses to P. falciparum-infected 
erythrocytes by PBMCs from healthy and parasitaemic African volunteers. Although 
IL-1ß production was too weak to draw meaningful conclusions, we were able to 
measure robust IFNy responses. IFNy is induced downstream of IL-18, which itself 
requires activation by caspase-1 in a manner similar to IL-1ß25,26. Remarkably, IFNy 
production in caspase-12 S/L-heterozygotes tended to be stronger than in S/S 
individuals. However, S/L donors also elicited stronger anti-inflammatory IL-10 
responses than S/S homozygotes and, overall, the IFNy/IL-10 ratio was lower in 
heterozygotes. For diseases in which inflammation contributes significantly to 
pathology, such as is the case for various presentations of severe malaria27, a 
relatively stronger anti-inflammatory balance may actually provide a survival 
advantage. IL-10 production has been shown to reduce susceptibility to severe 
malaria in animal models28,29, but in humans the role of IL-10 is less well established. 
Clinical and post-mortem studies have shown elevated levels of both pro- 
inflammatory cytokines and IL-10 in most forms of severe malaria30-32. However, the 
ratios of pro-inflammatory cytokines (IFNy, TNFa, IL-6) to IL-10 are usually increased 
in severe malaria patients30-34, suggesting that enhanced anti-inflammatory 
responses protect against severe manifestations of malaria. In particular, high IL-10 
levels appear to attenuate severe anaemia33,35. It remains unclear, however, by 
what pathway a full-length caspase-12 might lead to stronger IL-10 production. 
Finally, the observed association between maternal caspase-12 genotype and infant 
perinatal mortality risk, although potentially coincidental, remains intriguing. This 
effect could not be ascribed to malaria, or specifically to other infections. Rather, 
perinatal death was associated with LBW and complicated labour requiring 
caesarean section, possibly implying a role of caspase-12 in the physiology of 
pregnancy. Nevertheless, this finding may represent a balanced evolutionary force 
acting on caspase-12 alleles. Bearing in mind sampling error, the observed relative 
selection against both homozygote states predict an equilibrium frequency of the L-
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allele of 2.7/(2.7+14.3)=0.16 by standard population genetics theory, remarkably 
similar to the observed frequency in this population of 0.11. This alone, of course, 
could not explain the disappearance of the L-allele in Europe and Asia, which would 
then presumably be due to the superimposed effects of other infections on those 
continents (e.g. plague, influenza).
In summary, we aimed to investigate the evolutionary pressures that maintain a full- 
length caspase-12 allele on the African continent, with an emphasis on malaria 
infection. No major effects of caspase-12 genotype on clinical or parasitological 
parameters were apparent, although functional studies assessing cytokine 
stimulation by P. falciparum-infected erythrocytes showed a slightly more anti­
inflammatory profile in the presence of functional caspase-12. These data obtained 
in cross-sectional settings should be followed by larger prospective studies, in order 
to fully understand the impact of caspase-12 polymorphisms on malaria. 
Coincidentally, we found indications of an effect of caspase-12 genotype on 
perinatal mortality, which could itself represent an important selective pressure. 
Alternatively, genetic drift or other (parasitic) infections that could have led to the 
balanced evolution of caspase-12 in Africa should be considered.
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Materials and methods 
Mali study
Blood samples for functional assays were collected in the Koro district of Mali as part 
of investigational studies into interethnic differences in susceptibility to malaria. 
This study site has been described in detail elsewhere19. Briefly, it is a rural Sahelian 
area with intense malaria transmission exclusively during the rainy season (June­
September). Samples for this study were collected both during the 2006 rainy 
season (September) and the 2007 dry season (April). The study included healthy 
Dogon or Fulani adult male volunteers and patients with symptoms of 
uncomplicated malaria. A thick blood film was made from each participant; slide- 
negative patients were excluded from the study. No positive blood films were 
recorded during the April 2007 inclusion. Approval for the study was provided by the 
institutional review boards of the University of Stockholm (National Ethical 
Committee no. 03 536) and the University of Bamako (N°0527/FMP0S).
Cameroon study
This was a hospital-based study, set up to investigate inflammatory parameters in 
relation to clinical severity of malaria, details of which are published elsewhere [20]. 
Briefly, the samples for this study were collected from children aged between 8 
months and 14 years (mean age 5.8) presenting to the outpatient clinic or admitted 
to the Central Hospital of Yaounde, Cameroon, with symptoms of malaria. Based on 
a positive thick blood smear for Plasmodium falciparum and a complete physical 
examination, patients were classified by clinical presentation according to the 2000 
World Health Organization (WHO) standard21 as uncomplicated or 
complicated/severe malaria. The number of patients categorised as suffering from 
mild and complicated/severe disease was 100 and 38, respectively. Clinical 
parameters at admission, including temperature, heart rate and respiratory rate 
were recorded and venous whole blood was collected for a complete blood count. 
Informed consent was provided in all cases by a parent or guardian.
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Ghana study
This study on diagnosis and manifestation of placental malaria in pregnancy has 
been described in detail22. The study area is characterized by perennial and hyper- to 
holoendemic malaria transmission. Briefly, 889 women attending the Presbyterian 
Mission Hospital in Agogo, Ghana, for delivery were recruited after informed written 
consent was obtained. Peripheral venous blood and, following delivery, placental 
intervillous blood were collected and examined for P. falciparum by microscopy, 
immuno-chromatographic test (ICT Malaria P.f/P.v, Becton Dickinson, Germany ) and 
nested PCR assays23. Haemoglobin (Hb) was measured by a HemoCue photometer 
(Ángelholm, Sweden) and anaemia defined as Hb <11 g/dL. Crude birth weight and 
gestational age were assessed within 24 hours after delivery. Low birth weight (LBW) 
was defined as <2500 g and preterm delivery (PD) as gestational age <37 weeks 
applying the Finnström score24. The study protocol was reviewed and approved by 
the Committee on Human Research Publications and Ethics, School of Medical 
Sciences, University of Science and Technology, Kumasi.
Cytokine stimulation assay
In the Mali study, venous blood was collected from healthy volunteers and patients 
into lithium heparin vacutainers. Further manipulations took place in Bandiagara, 
approximately three hours from the study sites; all samples were worked-up on the 
day of collection. Peripheral blood mononuclear cells (PBMCs) were isolated by 
density gradient centrifugation on Ficoll, washed 3x in cold RPMI, enumerated and 
resuspended in complete culture medium (RPMI 1640 containing 2mM glutamine, 
1mM pyruvate, 50'g/m L gentamicine and 10% pooled human AB+ serum (Sanquin, 
Nijmegen, NL)) for a final concentration of 2.5x106/mL. PBMCs were transferred into 
96-well round-bottom plates and were immediately stimulated in duplo wells with 
either cryopreserved NF54 strain P. falciparum-infected erythrocytes (PfRBC) or 
uninfected erythrocytes (uRBC) at 5x106/mL final, or RPMI only. Cells were incubated 
for 21 hours at 37°C, following which cell supernatants were collected and stored at 
-80°C for subsequent cytokine measurement by ELISA. Cell supernatants were 
analysed for cytokine production by commercially available ELISA kits
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according to the manufacturers' instructions: IFNy, IL-10 (Sanquin, Nijmegen, NL) 
and IL-1ß (R&D, Abingdon, UK).
Caspase-12 genotyping
DNA was extracted from whole blood using either the Puregene isolation kit (Gentra 
Systems, Minneapolis, MN) or the QIAmp blood mini kit (Qiagen, Hilden, Germany). 
Primers flanking the T125C polymorphism region and methodology was adopted as 
described by Saleh et al.7. Sequencing was performed on either a 48-capillary 3730 
sequencer (Applied Biosystems) or a Lightcycler 480 (Roche). Genotypes were 
analysed using the software 4Peaks by A. Griekspoor and Tom Groothuis, 
(mekentosj.com).
Statistics
Data were analysed in SPSS; differences in genotype distributions between 
populations were assessed by x2-test or Fisher's exact test. Differences in clinical 
parameters between groups were analysed by Kruskal-Wallis test. Differences in 
cytokine responses to PfRBC between groups were analysed by Mann-Whitney after 
subtracting the response to uRBC; negative values were set to zero. P-values <0.05 
were considered statistically significant in all analyses.
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Abstract
Mucocutaneous fungal infections are typically found in patients who have no known 
immune defects. We describe a family in which four women who were affected by 
either recurrent vulvovaginal candidiasis or onychomycosis had the early-stop-codon 
mutation Tyr238X in the ß-glucan receptor dectin-1. The mutated form of dectin-1 
was poorly expressed, did not mediate ß-glucan binding, and led to defective 
production of cytokines (interleukin-17, tumor necrosis factor, and interleukin-6) 
after stimulation with ß-glucan or Candida albicans. In contrast, fungal phagocytosis 
and fungal killing were normal in the patients, explaining why dectin-1 deficiency 
was not associated with invasive fungal infections and highlighting the specific role 
of dectin-1 in human mucosal antifungal defense.
Human dectin-1 deficiency
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Introduction
Recurrent vulvovaginal candidiasis is a relatively common pathological condition, 
afflicting women of all ages, with more than 90% of cases caused by C. albicans1. 
Although the role of diabetes as a predisposing condition has been recognized, most 
cases occur in healthy women. Recurrent oral, esophageal, or mucocutaneous 
candidiasis is also diagnosed in some patients without clear predisposing factors. 
Onychomycosis is a common infection of the nail beds, most often caused by 
dermatophytes but sometimes caused by C. albicans, that also affects 
immunocompetent persons2. In contrast, disseminated forms of candida infections 
are mostly found in patients in whom a defect in neutrophil function is easily 
recognized or candida species have been introduced in the bloodstream through 
invasive procedures3. Very little is known about the genetic factors predisposing 
patients to mucosal or disseminated candida infections.
Recognition of C. albicans by the innate host defense system is mediated by pattern- 
recognition receptors from the toll-like-receptor (TLR) and lectinlike-receptor 
families4. Mannans from the candida cell wall are recognized by the mannose 
receptor and TLR45, and TLR2 recognizes phospholipomannan6 and collaborates with 
the ß-glucan receptor dectin-1 in the stimulation of cytokine production7,8. 
Recognition of 1,3-linked ß-glucans by dectin-1 has been shown to be one of the 
main fungal-recognition pathways, and mice deficient in dectin-1 have an increased 
susceptibility to C. albicans9 and Pneumocystis carinii10. Dectin-1 amplifies TLR2- and 
TLR4-induced cytokine production in both murine and human cells, resulting in the 
production of cytokines such as tumor necrosis factor11, but also induces signals, 
independently of the TLRs, for the production of interleukin-17, interleukin-6, and 
interleukin-10 through a pathway dependent on spleen tyrosine kinase12.
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Results
Patients and Pedigree
During the first phase of the screening, we identified a patient (the index patient) 
who had recurrent vulvovaginal candidiasis and had cells that were hyporesponsive 
to C. albicans stimulation, defined as cytokine production that was 15% or less of 
that stimulated by C. albicans in cells from healthy volunteers. The lack of cytokine 
production was pinpointed to an impaired response to ß-glucan, indicating a 
potential defect in dectin-1 recognition.
To test this hypothesis, we sequenced the dectin-1 gene in the patient. All six exons 
of dectin-1 gene, and the nearby intronic regions, were sequenced (see Table 1 in 
the Supplementary Appendix). We identified a homozygous SNP in exon 6 that 
caused a change of amino acid 238 from tyrosine to a stop codon (Tyr238X), leading 
to the loss of the last nine amino acids of the carbohydrate-recognition domain 
(Figure 1A). Additional clinical questioning revealed that one of the patient's two 
sisters also had recurrent vulvovaginal candidiasis and both sisters had 
onychomycosis. The mother of the patient also had chronic onychomycosis, whereas 
the father had had only transient onychomycosis, with a relatively late age at onset 
and a complete recovery. The nucleotide sequence of wild-type dectin-1 in one 
healthy volunteer and the nucleotide change (AC) in exon 6 in two persons who 
were heterozygous or homozygous for the stop mutation are shown in Figure S3A in 
the Supplementary Appendix.
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Figure 1. Dectin-1 Mutation in a Family with Mucocutaneous Fungal Infections.
Panel A shows the structure of the dectin-1 gene and the location of an early- 
stop-codon mutation consisting of a homozygous single-nucleotide polymorphism 
(rs16910526, exon 6, chromosome 12; location, 10162354 bp). The mutation (AC) 
causes a change of amino acid 238 from tyrosine to a stop codon (Tyr238X), 
leading to the loss of the last nine amino acids of the carbohydrate-recognition 
domain (CRD). Cyto denotes the cytoplasmic tail and TM the transmembrane 
region. Panel B shows the genetic pedigree of the index family with dectin-1 
deficiency. Circles indicate female patients; the square indicates the father. Solid 
symbols denote homozygosity for the mutation (X/X, seen in all three daughters), 
and half-solid symbols denote heterozygosity (X/Tyr, seen in the parents).
The clinical characteristics of the patients are presented in Table 1. Microbiologic 
assessment of the nails of the three patients who were homozygous for the dectin-1 
mutation revealed growth of Trichophyton rubrum. The patients had no known 
predisposing factors, such as diabetes mellitus or infection with the human 
immunodeficiency virus. Genetic analysis revealed that both sisters of the patient 
were homozygous for the Tyr238X mutation, whereas the parents were 
heterozygous (Figure 1B). The family members were white persons of Dutch 
ancestry, according to self-report, and the parents were not known to be related. 
Investigation of the human dectin-1 protein structure containing the early stop 
codon (Figure S3B in the Supplementary Appendix) revealed that a cysteine disulfide
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bridge between the helix and the deleted strand was absent, a finding likely to have 
important functional consequences.
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Table 1. Clinical Characteristics of a Family of Patients with the Tyr238X Dectin-1 
mutation and with Mucocutaneous Fungal Infection, Onychomycosis, or Both.
Table 1. Clinical Characteristics of a Family of Patients with theTyr238X Dectin-1 Mutation and with Mucocutaneous Fungal Infection, 
Onychomycosis, or Both.
Characteristic
Index Patient 
(Female) Sister Sister Mother Father
Dectin-1 nucleotide genotype* X/X X/X X/X X/Tyr X/Tyr
Age (yr) 25 27 23 53 58
Age at onset of symptoms (yr) 10 10 12 40 55
Fingers and toes affected All fingers and 4 
toes, chronically
All fingers and toes, 
chronically
3 Fingers and 5 
toes, transiently
All fingers and toes, 
chronically
4 Toes partially affect­
ed, with complete 
recovery
Recurrent vulvovaginal 
candidiasis
Yes No Yes No Not applicable
* X denotes the presence of a stop codon, rather than tyrosine (Tyr), at amino acid 238.
Immunologic Defects
In the patients who had the early-stop-codon mutation, both monocytes (Figure 2A) 
and macrophages (not shown) had significant defects in the production of 
interleukin-6 after stimulation with ß-glucan for 4 hours (P=0.04 for monocytes). 
Similar defects were apparent after stimulation of cells with either heat-killed or live 
C. albicans yeast (Figure S1A in the Supplementary Appendix). The cytokine response 
was also defective after 24 hours of stimulation with heat-killed C. albicans hyphae 
(with a 25% reduction of tumor-necrosis-factor production and a 34% reduction of 
interleukin-6 release). In addition, cells from dectin-1-deficient patients had a 
marked reduction in interleukin-17 production as compared with cells from persons 
with the dectin-1 wild-type allele (Figure S4A in the Supplementary Appendix). 
Heterozygotes had intermediate production of proinflammatory cytokines on 
stimulation with C. albicans or ß-glucan. In contrast, the response of the patients' 
cells to TLR stimuli, such as lipopolysaccharide or lipopeptides, was normal (Figure 
S1B in the Supplementary Appendix). In addition, the amplification effect of the 
interaction between ß-glucan and dectin-1 on TLR2 stimulation of cytokines7 was 
absent in persons who were homozygous for the mutation (Figure S1C in the 
Supplementary Appendix).
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Figure 2. Functional Defects Resulting from Dectin-1 Mutation. Panel A shows 
interleukin-6 production in monocytes isolated after stimulation for 4 hours with 
ß-glucan; for five healthy subjects with wild-type dectin-1 (with data pooled), the 
two patients who were heterozygous for the dectin-1 mutation, and the three 
patients who were homozygous for the mutation. Panel B shows the mean 
binding of nonopsonized fluorescent heat-killed Candida albicans to monocytes 
isolated from healthy subjects with wild-type dectin-1 and from the patients who 
were homozygous for the mutation. In both panels, T bars indicate standard 
deviations.
To demonstrate that the defect in ß-glucan recognition in the patients was indeed 
due to the truncated dectin-1 variant, we constructed vectors for both wild-type and 
mutated isoforms A and B of dectin-1 and transfected them into NIH3T3 cells. These 
experiments revealed that neither mutated isoform A nor mutated isoform B could 
mediate ß-glucan binding, in contrast to the wild-type receptors (Figure S4B in the 
Supplementary Appendix). Moreover, although the wild-type dectin-1 isoforms A 
and B were normally expressed, the mutated isoforms were associated with 
significantly lower expression on the cell surface of the transfected cells (Figure S4C 
in the Supplementary Appendix).
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The in vitro data were corroborated in freshly isolated cells from the patients 
bearing the stop-codon mutation. Messenger RNA production by cells with the 
dectin-1 isoforms was similar in persons who were homozygous for the wild-type 
allele and the patients who were homozygous for the stop mutation (Figure S4D in 
the Supplementary Appendix). In contrast, monocytes and neutrophils from the 
patients who were homozygous for the stop-codon polymorphism lacked cell- 
membrane expression of dectin-1 (Figure S4E in the Supplementary Appendix). 
Heterozygotes had intermediate expression of dectin-1. The binding of heat-killed 
fluorescence-labeled C. albicans, which has high levels of ß-glucan13, to monocytes 
was significantly lower in the patients who were homozygous for the mutation than 
in healthy controls (Figure 2B). However, phagocytosis of live C. albicans was normal 
in both monocytes and neutrophils from the patients who were homozygous for the 
stop codon (Figure S2 in the Supplementary Appendix), showing the importance of 
alternative receptors for phagocytosis of live yeasts (other lectinlike receptors and 
TLRs)4. Monocytes and neutrophils from the patients who were homozygous for the 
mutation were as effective at killing C. albicans as were cells from normal persons 
(Figure S2 in the Supplementary Appendix).
Frequency of the Mutation in Populations
To determine whether the dectin-1 stop mutation was occurring in a 
phylogenetically conserved site, we compared the amino acid sequence of dectin-1 
among several mammals (Figure S5A in the Supplementary Appendix). This 
investigation revealed that the mutation lies in an evolutionarily conserved region 
within the mammalian lineage. We then investigated the prevalence of the mutation 
in various human populations, and we genotyped persons from four cohorts of 
healthy persons of various ethnic groups, each representing populations from the 
major continents: 138 whites of Dutch ancestry (Europe), 99 people from Tanzania 
(Africa), 100 Han Chinese (Asia), and 105 Trio Indians (Native Americans) from 
Surinam (South America). Dectin-1 was sequenced completely in the Dutch 
population, with Tyr238X being the only nonsynonymous mutation identified. The 
Dutch population had an allele frequency of 0.069, and the Tanzanian population,
Human dectin-1 deficiency
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0.035; all persons with the mutation were heterozygotes. The mutation was absent 
in the populations from China and Surinam. This variant has been recorded in the 
dbSNP database, as rsl6910526.
A Human Genome Diversity Project selection browser was used to obtain further 
information about the frequency and world distribution of the SNP; this analysis 
confirmed our findings (Figure 3). We analyzed haplotype diversity within a white 
population and a black population by studying genomewide SNP data sets for 
samples obtained from 1422 whites from the U.K. 1958 birth cohort14 and 171 
African Maasai from Kinyawa, Kenya (from HapMap Phase III)15. Allele frequencies of 
the polymorphism within both populations did not differ significantly from those 
reported previously (whites, 0.078, and blacks, 0.023, as measured in our 
populations)14. Minimal mutation-network analysis revealed that, among the 23 
haplotypes found in both populations, only 2 contain the stop mutation (Figure SB in 
the Supplementary Appendix). Both haplotypes are present in both the European 
and African populations, and therefore are not population specific. In addition, the 
haplotypes are located near the ancient haplotype in the network, indicating that 
they are closely related to the ancient haplotype (Figure S5C in the Supplementary 
Appendix).
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SNP rsl6910526
0° 30° 60° 90° 120° 150°
Longitude
Figure 3. Polymorphisms and Haplotypes of the Dectin-1 Stop Mutation 
Worldwide. The frequency of the dectin-1 polymorphism rs16910526 is shown 
for various populations of the world. The ancestral allele A leads to a functional 
dectin-1 receptor, whereas the derived allele C leads to an early-stop-codon 
mutation and nonfunctional dectin-1 receptor. The derived allele is observed only 
in populations from Africa and western Eurasia. The highest prevalence of the 
mutation (nearly 40%) is found in the San population in South Africa.
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Discussion
Defective surface expression of dectin-1 due to the Tyr238X polymorphism results in 
lack of ß-glucan recognition and an impaired cytokine response by monocytes and 
macrophages but normal killing of C. albicans by neutrophils. These data show the 
important role of ß-glucan-dectin-1 pathways for normal activation of the cytokine 
response16, but also show the redundant nature of dectin-1 in the phagocytosis and 
killing of Candida albicans. The normal function of neutrophils in persons in whom 
dectin-1 function is absent provides protection against invasive fungal infection. In 
contrast, the defective function of monocytes and macrophages with regard to 
cytokine release in the patients who were homozygous for the Tyr238X dectin-1 
mutation is the most likely cause of the clinical phenotype characterized by 
mucocutaneous fungal infections.
Dysregulation of cytokine profiles is typically seen in patients with mucocutaneous 
fungal infections such as recurrent vulvovaginal candidiasis17. Dectin-1 is expressed 
on epithelial cells, and proinflammatory cytokines have been reported to be 
secreted by vaginal epithelial cells18 and to increase the natural antifungal activity of 
these cells19. It is therefore conceivable that dectin-1 function on epithelial cells 
would also be defective in our patients. Our data showing that a complete deficiency 
of dectin-1 is accompanied by mucosal fungal infections are in line with a recent 
study showing the susceptibility of dectin-1-knockout mice to mucosal candidiasis20. 
Dectin-1 is also important for the development of the responses of type 17 helper T 
cells21, and interleukin-17 production in our patients with defective dectin-1, as 
compared with healthy subjects, was reduced by 50% to 80% (Figure S4A in the 
Supplementary Appendix). A clinical syndrome that closely resembles the syndrome 
in our family, with regard to fungal complications, is the hyper-IgE syndrome. 
Patients with the hyper-IgE syndrome have a defect in interleukin-17 production in 
response to infections with Staphylococcus aureus (cutaneous and pulmonary 
infection) and C. albicans (onychomycosis and mucosal infection)22,23. Our family had 
an isolated interleukin-17 defect in response to C. albicans stimulation, and it is 
tempting to speculate that this is the cause of the clinical picture of fungal infections
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in the patients. Our findings are strengthened by the description in this issue of the 
Journal of a family with a mutation of CARD9, the adaptor molecule for dectin-1, 
who presented with a phenotype practically identical to that of our family24.
Finally, the finding of this dectin-1 mutation in persons from both Europe and Africa 
leads to additional hypotheses. First, the identification of this polymorphism in all 
African populations assessed (including the San population) suggests that this is an 
ancient mutation that most likely emerged more than 60,000 years ago, before the 
split of the modern human populations in the late Paleolithic25. This hypothesis is 
supported by the finding that the location of the haplotypes containing the Tyr238X 
mutation was close to the ancient haplotype. Second, the relatively high prevalence 
of the polymorphism in these populations may represent an important genetic 
susceptibility factor for mucosal fungal infection.
Human dectin-1 deficiency
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Materials and methods 
Index Family and Other Subjects
To identify functional defects in the immune response to C. albicans, we designed a 
functional screening assay of mononuclear cells isolated from patients with 
recurrent vulvovaginal candidiasis or oral or esophageal candidiasis. Cells were 
stimulated with heat-killed C. albicans, and cytokine production after 24 hours was 
assessed during screening. An immunologic and genetic analysis was performed on 
mononuclear cells obtained from a patient who had defective cytokine production, 
on stimulation with C. albicans or ß-glucan, and from four family members. The 
study protocol was approved by the ethics committee of Nijmegen-Arnhem, the 
Netherlands. Written informed consent was obtained from all family members 
studied.
In addition, we studied DNA samples, previously collected to assess the prevalence 
of the Tyr238X mutations, from several populations in various geographic locations. 
These samples were obtained from the country of origin, with the exception of the 
Chinese Han cohort, for which samples were from the Corriell Institute (catalog 
number, HD1000CHI). For all populations, subjects had provided written informed 
consent, and study approval was obtained from local ethics committees.
For haplotype analyses, we used genomewide data on single-nucleotide 
polymorphisms (SNPs) from 1422 whites from the 1958 United Kingdom birth 
cohort14 and from 171 Maasai from Kinyawa, Kenya15. Genotype data for the Maasai 
population were downloaded from the International HapMap Project Web site 
(www.hapmap.org) and for the white population were obtained with the use of 
HumanHap300 BeadChips (Illumina). A region of 20 kb around the SNP rs16910526 
was extracted from all samples in both genomewide SNP data sets. We used the 
Beagle software program to determine the haplotypes from genotypes of all
subjects26.
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A detailed description of the methods used to sequence the dectin-1 gene is 
presented in the Supplementary Appendix (available with the full text of this article 
at NEJM.org). Network analysis was performed with the Network program, version 
4.5.0.0 (www.fluxus-engineering.com), which uses the median-joining method27. The 
ancient haplotype was determined with the use of the dbSNP database 
(www.ncbi.nlm.nih.gov/projects/SNP/). Various analyses were conducted, with 
weighting applied separately for synonymous changes, nonsynonymous changes, 
transitions, and transversions.
Modeling of Dectin-1 Structure
The crystal structure of mouse dectin (Protein Data Bank code 2clS [PDB] ) was used 
as a template to build a homology model of the extracellular domain of human 
dectin-1. Modeling of the extracellular domain was performed on the "WHAT IF" 
server (http.//swift.cmbi.ru.nl). Energy minimization and analysis were performed, 
to obtain the most reliable model of protein folding, with the YASARA program 
(www.yasara.org/)2S.
Fluorescence-Activated Cell Sorting
Human peripheral-blood mononuclear cells (PBMCs) were obtained from the three 
family members who were homozygous for a dectin-1 mutation, the two family 
members who were heterozygous for a dectin-1 mutation, and five persons who 
were homozygous for the wild-type dectin-1 allele. The cells were incubated with 
murine anti-dectin-1 monoclonal antibody GE2 (5 'g  per milliliter)29 or isotype­
control antibody, followed by allophycocyanin-conjugated goat antimouse antibody 
(Pharmingen). Dectin-1 expression was determined by means of flow cytometry with 
the use of a fluorescence-activated cell sorter (FACSCalibur, BD Biosciences). Dectin- 
1 expression was assessed in cells from a mouse embryonic fibroblast cell line 
(NIH3T3) after transfection, with the use of an antihemagglutinin antibody 
(Covance), an IgG1 isotype-control antibody, and an antimouse antibody covalently 
labeled with R-phycoerythrin (Jackson ImmunoResearch).
Human dectin-1 deficiency
Genetic Analysis
145
Chapter 8
Candida Binding, Phagocytosis, and Fungal-Killing Assays
Binding of PBMCs to C. albicans yeast cells was measured by means of flow 
cytometry30. The phagocytosis and fungal-killing assays for C. albicans were 
performed as previously described 31.
Cytokine Measurements
PBMCs12 (5x105) were incubated with 100 j l  of ß-glucan (10 jg  per milliliter) and C. 
albicans that was live or had been heat-killed (through heating for 30 minutes at 
56°C) at a concentration of 1x106 yeast cells per milliliter. For interleukin-17 
stimulation assays, PBMCs were stimulated for 5 days in RPMI medium 
supplemented with 10% pooled human serum. After 4 hours, 24 hours, or 5 days of 
incubation at 37°C, supernatants were collected and stored at -70°C until enzyme- 
linked immunosorbent assay with the PeliKine-Tool set of reagents (Sanquin).
Cloning and Transfection Studies
The human dectin-1 isoforms were amplified, by means of a polymerase-chain- 
reaction (PCR) assay, from complementary DNA isolated from samples of peripheral- 
blood leukocytes obtained from the patients. The two primers used were 5'- 
AAAGGATCCAGGGGCTCTCAAGAACAATG-3' and 5'-
AAACTCGAGTCTTCCACCCTTCCCCTTAC-3'. The PCR products were purified with the 
use of the QIAquick PCR purification kit (Qiagen), cloned into the pCR4-T0P03.1 
vector (Invitrogen), and sequenced. The wild-type and mutant dectin-1 were cloned 
with the use of reverse primers — 5'-CCCTTCCTCGAGCATTGAAAACTTC-3' and 5'- 
AAATCTCGAGTGAGGGCAGACTAC-3', respectively — allowing for the in-frame 
cloning of a hemagglutinin tag, which does not affect ß-glucan binding7. The 
products were subcloned into the retroviral vector pFB-Neo (Stratagene) and 
transfected into ecotropic packaging cells (Phoenix) with the use of FuGENE 
transfection reagent (Roche Molecular Biochemicals). After 48 hours, retroviral 
supernatants were harvested and used to transduce NIH3T3 cells in the presence of 
Polybrene (Sigma), at a concentration of 5 jg  per milliliter. A binding assay for 
zymosan was also performed, as previously described32.
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Supplemental methods and figures
Isolation of cDNA, DNA and development of primers.
RNA was isolated from whole blood using the PAXgene blood RNA kit (Qiagen) 
according to the protocol. Isolated RNA was thereafter treated with DNase (Ambion) 
and reverse transcribed to cDNA using oligo(dT) primers and MMLV reverse 
transcriptase (Invitrogen). PCR on the cDNA to investigate transcription of the 
different Dectin-1 isoforms was performed with primer pairs adapted from Meyer­
Wentrup et al (2007). DNA isolation was performed on whole blood using the 
isolation kit Puregenetm (Gentra system). DNA template of the Dectin-1 (also named 
CLEC-7A) sequence was taken from Genebank, chromosome position 12q13, 
NC_000012.10 (10160643..10174135, complement). Primer3 software was used to 
develop all primers shown in Table 1. After amplification PCR products were cleaned 
using the kit High Pure PCR product purification kit (Roche) according to the 
manufacture protocol. Sequencing was performed at the Sequence Faculty at the 
department of human genetics Nijmegen. Sequence for four out of six exons was 
obtained using both forward and reverse primers (Table S1). However, equences for 
exon 3 and 4 were based on more than one forward sequences due to the lack of 
reverse primer specificity. No variations were detected in any exons other than exon 
6.
Supplementary table S I
Exon Primer Sequence (50 to 30) [MgClJ(mM) Annealingtemperature
1
Dectin-1 205 FW TTT-CAC-CAC-GTT-AGC-CAA-GCT
2.5 52 “CDectin-1 205 RV CTG-AAA-TAG-TTT-GCA-TCG-GTT
2
Dectin-1 203 FW CCC-TTT-ATA-AGT-GAA-ATG-GGC
1.75 60 “CDectin-1 203 RV ACC-GTG-CAA-GGC-CAG-ATT-TT
3
Dectin-1 127 FW GCC-AGT-GAT-AAA-TCA-GTT-ACT
3.5 56°CDectin-1 127 RV TTC-TTC-TTC-TCC-ACC-TTC-TT
3
Dectin-1 202 FW TGG-CAA-CAT-TTT-CCC-TTC-TT
3.5 56 °CDectin-1 202 RV GCC-AAG-GGC-ATA-GTT-AAA-GG
4
Dectin-1 301 FW TCA-TTA-CCT-GGA-ATC-TCC-CTC-T
2.5 56 °CDectin-1 301 RV TGG-C AA-CTA-ATT-GGT-TAT-TTC -A
5
Dectin-1 119 FW GCT-GCT-CGA-CAG-AGG-TTT-TC
1.75 62 °CDectin-1 119 RV GGA-TGG-TCT-CGA-TCT-CCT-GA
6
Dectin-1 106 FW AAT-CAC-AGC-CTC-TCC-CTT-CA
2.5 60 °CDectin-1_106_RV GAT-TTA-AGC-CTC-CTT-TTC-CAA
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Supplementary figure S I. Dectin-1 mutation leads to functional defects. Panel 
A: IL-6 production capacity of monocytes isolated from healthy volunteers 
(dectin-1 wt), patients heterozygous (dectin-1 het), or patients homozygous for 
the mutation (dectin-1 hom), and stimulated for 4h with heat-killed or live C. 
albicans. Each patient represents a white or a black bar. Variation in the control 
group is presented as SD (n=5). Panel B: IL-6 production capacity of monocytes 
isolated from healthy volunteers (dectin-1 wt), patients heterozygous (dectin-1 
het), or patients homozygous for the mutation (dectin-1 hom), and stimulated for 
4h with the TLR4 antagonist LPS, or the TLR2 anatagonist Pam3Cys. Panel C: 
Synergism between dectin-1 and TLR2 stimulation of proinflammatory cytokines 
in cells isolated from control volunteers (dectin-1 wt) or patients homozygous 
(dectin-1 hom) for the stop codon mutation, after 24h stimulation at 37°C. 
(means ± SD of three experiments, n=5 healthy volunteers, n=3 homozygous 
patients; p<0.05).
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Supplementary figure S2. Dectin-1 deficiency does not impair Candida 
phagocytosis and killing. Phagocytosis (A) and killing (B) of opsonized C. albicans 
by monocytes and neutrophils from healthy volunteers (five healthy volunteers 
without clinical signs of fungal infections, dectin-1 con) or patients homozygous 
for the mutation (dectin-1 hom). Using this methodology in medium enriched 
with 10% human serum, phagocytosis receptors such as Fc-receptors or 
complement-mediated binding are apparently sufficient to compensate for the 
absence of dectin-1. Results are presented as means ± SD of four experiments.
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Supplementary figure S3. Dectin-1 mutation in a family with mucocutaneous 
fungal infections. Panel A: The nucleotide change (A > C) in exon 6 is shown in a 
person with the functional dectin-1 receptor (wild type) and two individuals having 
the stop mutation in heterozygote or homozygote state. Panel B: Modeling of the 
mutated dectin-1 receptor. The missing nine aminoacids are depicted in red, the 
diagram showing the loss of a disulfide bridge and a Ca2+-binding site.
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Supplementary figure S4. Dectin-1 mutation leads to functional defects. Panel 
A: IL-17 production capacity of PBMC from healthy volunteers (dectin-1 wt), 
patients heterozygous (dectin-1 het), or patients homozygous for the mutation 
(dectin-1 hom) stimulated for 5 days with heat-killed C. albicans. Panel B: Only 
wild-type, but not mutated, isoforms A or B of dectin-1 were able to mediate 
binding of zymosan to the transfected NIH3T3 cells. The specificity of the binding 
was demonstrated by its inhibition with the dectin-1 antagonist laminarin. 
Representative results of five independent experiments are presented. Panel C: 
The variant dectin-1 isoforms A (dectin-1Amut) and isoform B (dectin1-Bmut) 
were poorly expressed on the surface of transfected NIHT3T cells, when 
compared to wild-type dectin-1 isoforms. Panel D: The pattern of transcription of 
the dectin-1 isoforms is similar between healthy individuals with wild-type dectin-
1 gene and patients homozygous for the early stop codon mutation. Panel E: 
Extracellular FACS staining of monocytes (Mo) and neutrophils (PMN) isolated 
from healthy volunteers (dectin-1 con) or patients homozygous for the mutation 
(dectin-1 hom).
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Supplementary Figure S5. Dectin-1 stop mutation/polymorphism and haplotypes in 
different populations. Panel A: Phylogenetic representation of the dectin-1 receptor 
aminoacid area surrounding the Tyr238Stop, shown in green, in the mammalian 
lineage showing that the location of the mutation is conserved. Panel B: Dectin-1
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allele haplotype network of 1422 Caucasian (2844 haplotypes) and 171 African (342 
haplotypes) individuals. Each circle represents a unique haplotype node and colours 
represent the different populations. Green is used for Caucasian haplotypes, Blue for 
African, and black for the ancient haplotype according to the dpSNP information. 
Circles with red outline contain the two haplotypes containing the stop 
polymorphism. The red circle following the ancient haplotype represents a vector 
node and does not represent an observed haplotype. Area of all circles indicates the 
amount of alleles with that haplotype. At the lower part, which includes the two 
haplotypes containing the stop polymorphism, SNP rs numbers that change between 
the nods are presented. Panel C:The two haplotypes containing the 238Stop 
mutations. Only the first three SNPs differ between these haplotypes, which are 
located after exon 6.
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Abstract
Celiac disease (CD) is a food intolerance to dietary proteins of wheat, barley and rye. 
CD may have substantial morbidity, yet it is quite common with a prevalence of 1-2% 
in the Western world. It is interesting to ask why the CD phenotype is so prevalent 
despite its negative effects on human health, especially because appropriate 
treatment in the form of a gluten-free diet has only been available since the 1950s 
when dietary gluten was discovered to be the triggering factor. Evolutionary 
processes have shaped Homo sapiens and the high prevalence of CD suggests that 
genes underlying this disease may have been favored by the process of natural 
selection.
We assessed signatures of selection for 10 confirmed CD-associated loci in several 
genome-wide datasets, comprising 3,796 cases and 8,154 controls from four 
Caucasian populations and 195 individuals from a North African population, by 
studying haplotype lengths using the Integrated Haplotype Score (iHS) method. 
Consistent signs of positive selection for CD-associated derived alleles were 
observed in three loci: IL12A, IL18RAP and SH2B3. The significant difference in allele 
frequency distribution (Fst) of the SH2B3 risk allele in HapMap phase II data further 
confirms a differential selection pressures between populations.
Functional investigation of the effect of the SH2B3 genotype in response to 
lipopolysaccharide and muramyl dipeptide revealed that carriers of the SH2B3 
rs3184504*A risk allele showed stronger activation of the NOD2 recognition 
pathway, suggesting a role for SH2B3 as a master regulator of immune responses to 
infections. This suggests a role for SH2B3 in protection against bacteria infection and 
provides a possible explanation for the selective sweep on SH2B3, which occurred 
sometime between 1,200 and 1,700 years ago.
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Introduction
Celiac disease (CD) is a common intestinal inflammatory disorder, resulting from 
intolerance to gluten, a major dietary protein of wheat, and related proteins from 
barley and rye. CD is the most common food intolerance in the Western world, 
where it affects 1-2% of the population*. It is also common in North Africa, India and 
the Middle East1,2. The highest prevalence of CD has been observed in the Saharawi 
from North Africa, where it affects 5.6% of the population. The clinical presentation 
of CD can vary from a severe form, characterized by diarrhea, anemia and weight 
loss, to a mild form, presenting with osteoporosis, autoimmune disease, and low 
fertility. Mortality in CD patients is significantly increased, especially in undiagnosed 
and untreated individuals3,4.
Susceptibility to CD has a strong genetic basis. The recurrence risk for siblings of CD 
patients to develop the disease is about 20 times higher than in the general 
population, and concordance between monozygotic twins is more than 80%5. The 
strongest genetic risk factors are the HLA-DQ2 or HLA-DQ8 haplotypes6. Genome- 
wide association studies (GWAS) and their replications recently led to the discovery 
of 10 novel non-HLA loci7-9. To date, CD is one of the best elucidated complex 
diseases, as approximately 50% of its genetic susceptibility can now be explained by 
association to common HLA and non-HLA genetic variants.
It is interesting to ask why the CD phenotype is so common despite its negative 
effects on human health (appropriate treatment in the form of a gluten-free diet has 
only been available since the 1950s when dietary gluten was discovered to be a 
triggering factor). Evolutionary processes have shaped Homo sapiens and the high 
prevalence of CD suggests that genes underlying this disease may have been favored 
by the process of natural selection. When a genetic variant is under positive 
selection, it increases in prevalence in a population and this leaves a 'signature' or 
pattern in the human genome. These signatures can be identified by comparing 
them with the background distribution of genetic variation in humans, which is 
generally argued to have evolved largely under neutrality10-12.
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The recently identified CD susceptibility variants, in combination with the available 
genome-wide single nucleotide polymorphism (SNP) data, provides the opportunity 
to study whether genetic variants underlying this disease have indeed been favored 
by positive natural selection7,8. We used existing GWAS data and unpublished data 
from a second ongoing genome-wide association study (GWAS) in five different CD 
populations, comprising 3,796 cases and 8,154 controls from four Caucasian 
populations and 195 individuals from a North African population, to examine 
whether CD susceptibility loci had been under recent positive selection by studying 
haplotype lengths using the Integrated Haplotype Score (iHS) method12 and the 
Fixation index (Fst)13.
Furthermore, to test if the loci have been selected because they provide protection 
against pathogen infection, we investigated genotype differences in cytokine 
response of IL-6, IL-8 and IL1-ß to LPS and MDP stimulation in 56 Caucasians.
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Results and discussion
For our analysis, we selected the SNPs that were most strongly associated with the 
disease from each of the 10 non-HLA loci that had been shown to be associated with 
CD in a recent GWAS7,9. We included a single SNP for nine of the loci (table 1) and 
two independently associated SNPs for the IL12A locus. For the analysis we used 
3,796 CD cases and 8,154 controls from four European populations (UK, Dutch, 
Italian, Finnish) and 195 founder individuals from Saharawi (N. Africa) CD families. 
We used the iHS statistic to detect evidence of recent positive selection (< 30,000 
years ago) at a locus, based on the differential levels of linkage disequilibrium 
surrounding a positively selected allele compared to the background allele at the 
same position12. The iHS calculations for the 11 SNPs were performed separately for 
the groups of cases and controls from each of these populations (described in 
materials and methods). We also investigated the iHS values for these 11 SNPs in the 
three publically available HapMap populations (using Haplotter, http://hg- 
wen.uchicago.edu/selection/haplotter.htm12). The haplotype structures (iHS values) 
were similar for the four European populations. Table 1 presents the iHS values for 
the UK controls (which contains the most extended European population) and for 
the Saharawi. The results of each separate group are presented in Supplementary 
Table 1. Since the Illumina chip used for genotyping contains a limited number of
Table 1. Characteristics of the alleles associated with celiac disease.
Chro
mos
ome SNP ID Gene
Associated
allele
Associated
allele
Derived
allele
frq
_iHScorr
(UK)
p  value iHS 
in
European
populations
Average age Derived 
o f the sweep allele frq 
(Europeans) Saharawi
_iHScorr
Saharawi
p  value 
iHS
Saharawi
3 rs6441961 CCR2_3 A derived 0.297 -0.728 0.467 n/a 0.249 -0.422 0.673
3 rs9811792 IL12A
IL12A,
G derived 0.46 -1.157 0.247 n/a 0.344 -1.174 0.240
3 rs17810546 SCHIP G derived 0.128 -3.321 0.0009 ~2500 yr 0.06 n/a n/a
2 rs917997 IL18RAP A derived 0.238 -2.036 0.042 ~6500 yr 0.154 -1.703 0.089
4 rs13151961 IL2, IL21 A ancestral 0.167 -0.521 0.603 n/a 0.02 n/a n/a
3 rs1464510 LPP A derived 0.435 0.668 0.504 n/a 0.313 1.104 0.270
2 rs842647 REL A ancestral 0.348 -1.022 0.307 n/a 0.136 -0.512 0.608
1 rs2816316 RGS1 A derived 0.822 0.042 0.966 n/a 0.756 0.106 0.915
12 rs3184504 SH2B3 A derived 0.468 -2.214 0.027 ~1500 yr 0.151 -1.224 0.221
6 rs1738074 TAGAP A ancestral 0.577 -1.499 0.134 n/a 0.531 -1.425 0.154
6 rs2327832 TNFAIP3 G derived 0.23 -1.531 0.126 n/a 0.249 -0.616 0.538
p  values calculated from iHS scores in four European (UK controls) populations and the 
Saharawi population, and average age o f the selective sweep for selected alleles in European 
populations.
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SNPs selected by a tagging approach, we additionally tested whether our results 
depended on the density of the genotyped markers. After imputing all 10 loci in the 
Dutch cases and controls, we observed similar results to the iHS analysis (table 2).
In the four European populations we observed consistent and significant signs of 
positive selection for three of the CD-associated alleles: rs17810546*G (IL12A locus), 
rs917997*A (IL18RAP locus), and rs3184504*A (SH2B3 locus). For all three loci the 
derived allele was under positive selection and this allele was also the CD susceptible 
allele (i.e. risk allele) (Table 1, Supplementary Table 1). In the Saharawi population 
we observed similar signs of positive selection for rs3184504*A (SH2B3 locus) and 
rs917997*A (IL18RAP locus).
The strongest results were observed for rs17810546*G from the IL12A locus (iHS 
between -2.923 and -3.434; p values between 0.0035 and 0.0006). We estimated the 
age of selective sweep to be in the range of 2,000-2,500 years ago for all four 
European populations (Supplementary Table 2a, Supplementary Fig. 1a). The 
associated variant from the IL18RAP locus, rs917997*A, was borderline significant in 
the European populations (iHS between -1.834 and -2.03; p values between 0.04 and 
0.06), and showed a similar selection trend in the Saharawi (iHSSaharawi = -1.703; p 
= 0.089) (Table 1, Supplementary Table 1). The frequency of the rs917997*A risk
Table 2 Comparison of iHS results observed in genotyped and imputed 
datasets in Dutch cases (n=803) and controls (n=846).
genotyped SNPs genotyped and imputed SNPs
gene population RS ID allele frq N SNPs IHS p-value N SNPs IHS p-value
NL cases 0.379 -0.381 0.704 0.647 0.52
CCR3 NL controls rs6441961 0.31 488 -0.534 0.594 1057 0.391 0.7
NL cases 0.498 -1.401 0.161 -1.514 0.13
IL12A NL controls rs9811792 0.444 612 -1.424 0.154 1174 -1.553 0.12
NL cases 0.169 -3.004 0.0027 -3.379 0.00073
IL12A NL controls rs17810546 0.118 608 -3.434 0.0006 1174 -3.909 0.00009
NL cases 0.287 -2.013 0.044 -1.903 0.06
IL18RAP NL controls rs917997 0.216 787 -1.911 0.056 1615 -1.725 0.08
NLcases 0.127 -0.617 0.537 -0.849 0.4
IL2 NL controls rs13151961 0.194 618 -0.516 0.606 1242 -0.705 0.48
NL cases 0.531 0.228 0.819 0.058 0.95
LPP NL controls rs1464510 0.493 1059 0.56 0.576 1469 0.806 0.42
NL cases 0.294 -0.719 0.472 -1.128 0.26
REL NL controls rs842647 0.346 660 -1.1 0.271 1184 -1.556 0.12
NL cases 0.752 -0.951 0.342 0.124 0.9
RGS1 NL controls rs2816316 0.711 543 -0.756 0.45 1221 0.323 0.75
NL cases 0.524 -2.597 0.009 -3.062 0.0022
SH2B3* NL controls rs3184504 0.465 1300 -2.114 0.035 1355 -2.491 0.0127
NL cases 0.555 -1.761 0.078 -2.023 0.04
TAGAP NL controls rs1738074 0.605 800 -2.059 0.039 1744 -1.852 0.06
NL cases 0.233 -1.387 0.166 -1.565 0.12
TNFAIP3 NL controls rs2327832 0.205 766 -1.43 0.153 1454 -1.6 0.11
N  SNPs - num ber o f  genotyped or genotyped+im puted SN Ps in selected region o f  2 M b
(*for SH2B3 a w indow  o f  4 M b w as used in genotyped dataset and a w indow  o f  2 M b in im puted dataset).
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allele varied from 15% in the Saharawi population to 20-28% in the four European 
populations. Signs of selection for rs917997*A were also observed in Asian HapMap 
samples (iHSAZN_HapMap = -2.115)12 (Supplementary Table 1)). The age of selective 
sweep of rs917997*A in the European populations was estimated to be around 
6,000 years ago (Supplementary Note, Supplementary Table 2b, Supplementary Fig. 
1b). Genome-wide studies of gene expression have identified a strong correlation 
between the rs917997 genotype and IL18RAP expression, with the lowest level of 
expression for carriers homozygous for the risk allele. Such a cis-regulatory variant 
may lead to individuals having different IL18-mediated innate immune responses to 
infection. Interestingly, IL18RAP also confers a susceptibility for Crohn's disease14.
The haplotype containing the SH2B3 rs3184504*A allele was consistently selected in 
all the populations (maximum IHSITcases = -2.754 (p = 0.006)) (Table 1, 
Supplementary Table 1, Figure 1, Supplementary Fig. 1c). The age of the selective 
sweep in SH2B3 was estimated to be in the range of 1,200-1,700 years ago in the 
European populations (Supplementary Table 2c). The haplotype containing the 
SH2B3*A allele is associated with many diseases, including several immune-related 
diseases (CD, type 1 diabetes, rheumatoid arthritis) and metabolic disorders 
(hypertension, myocardial infarction)15.
We studied whether the Fst values of the susceptibility alleles between the HapMap
II population were outliers in contrast to an empirical genome-wide distribution of 
Fst(16). An Fst value of 0 means that different populations are identical in allele 
frequency, whereas an Fst value of 1 means that different populations have different 
alleles. The SH2B3 risk allele had an Fst value of 0.61, which was a significant outlier 
compared to a genome-wide distribution (p value < 0.05) and indicates a sign of 
differential selection in HapMap II populations (table 3). The worldwide allele 
frequency distribution of rs3184504 in SH2B3 in the Human Diversity Project Data is 
shown in figure 2.
An important question concerns the mechanism that underlies the selection of these 
gene variants. It is interesting to note that two of the genes identified here (IL12A 
and IL18RAP) are involved in the activation of pro-inflammatory cytokine pathways, 
and the phenotypic effect of the selected variants most likely involves modulation of 
cytokine responses. Even more interesting is that the third gene identified to have
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A
Figure 1 Example of EHH plot of SH2B3 rs3184504 SNP in a. European 
(UK controls) and b. Saharawi population. Long -  derived haplotype, 
short -  ancestral haplotype. 1.4 Mb left and right from rs3184504 are 
included. EHH plots for all selected SNPs and for all studied 
populations are presented in supplementary figure 1a-c.
Table 3, Fst measure of population differentiation.
Chromosome SNP ID Gene
Associated
allele
Associated
allele
Fst
HapMapII
3 rs6441961 CCR2_3 A derived 0.19
3 rs9811792 IL12A
IL12A,
G derived 0.18
3 rs17810546 SCHIP G derived 0.20
2 rs917997 IL18RAP A derived 0.27
4 rs13151961 IL2, IL21 A ancestral 0.31
3 rs1464510 LPP A derived 0.21
2 rs842647 REL A ancestral 0.46
1 rs2816316 RGS1 A derived 0.00
12 rs3184504 SH2B3 A derived 0.61*
6 rs1738074 TAGAP A ancestral 0.09
6 rs2327832 TNFAIP3 G derived 0.18
* Significant outlier (p <0.05) compared with an empirical genome-wide distribution
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Figure 2 Worldwide allele frequency distribution of rs3184504 in SH2B3. The
derived T allele is the CD risk allele that shows signature of recent selection.
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Figure 3 Altered response after LPS and MDP cytokine production of the 
SH2B3 genotypes. Differences between the SH2B3 genotype after 
lipopolysaccharide (LPS) stimulation show a moderately reduced IL-6 cytokine 
production in PBMCs isolated from individuals heterozygous for the celiac risk 
allele (A). After muramyl dipeptide (MDP) stimulation, a specific ligand of the 
NOD2 innate immune receptor, homozygous individuals carrying the risk allele 
showed an increased production of the IL-6 and IL l-ß  cytokines (B and C). IL-8 
production in these individuals also showed an elevated production of the 
cytokine (D). All data are presented as means and standard deviations (SD). The 
total numbers of individuals in each SH2B3 genotype are given under each bar 
and only the significant differences are included (Mann-Whitney U test).
l6 6
Evolutionary and functional analysis of celiac risk loci reveals SH2B3
been under selection pressure, SH2B3, contains an SH2 domain, which is common to 
master regulatory genes of innate immunity (such as SOCS genes)17. As we have 
shown SH2B3 was under positive selection in all the populations tested, we 
hypothesized that it might play a central role in the cytokine responses as well; these 
are one of the main host defense mechanisms during infections, which exert a major 
selective pressure on the genes of the immune system during history.
In order to assess the functional consequences of the SH2B3 variants, we stimulated 
human peripheral blood mononuclear cells (PBMCs) isolated from 56 individuals 
with known SH2B3 rs3184504 genotypes, with various bacterial components, to 
assess whether a differential response to bacteria could have caused the observed 
selection. Lipopolysaccharide (LPS) stimulation revealed a moderately decreased 
cytokine production in heterozygous rs3184504 individuals compared to individuals 
homozygous for the ancestral allele G (Fig. 3A). A much more striking difference in 
cytokine production was obtained after cell stimulation with muramyl dipeptide 
(MDP), a component of the peptidoglycans present in all bacteria cell walls: the 
production of the pro-inflammatory cytokines and IL1-ß was 3- to 5-fold higher in 
homozygous AA individuals, i.e. individuals homozygous for the CD risk allele, 
compared to individuals homozygous for the ancestral G allele (Fig. 3, B-C). A similar 
trend was observed for IL-6 and IL-8 (Fig. 3D). We observed a dose-response 
relationship of the derived A risk-allele with IL1ß production (p=0.034 for trend), 
meaning that IL1ß production was lowest in individuals carrying two ancestral G 
alleles and that it increased with each extra derived A risk-allele (Fig. 3B).
Molecules which contain an SH2 domain in their structure, like SH2B3, are known to 
modulate intermolecular interactions, and inhibit cytokine responses18. Stimulation 
of PBMCs with MDP, a specific ligand of the pattern recognition receptor NOD2, 
shows that cells isolated from individuals homozygous for the SH2B3 CD risk allele 
display an increased pro-inflammatory cytokine production. This suggests that the 
SH2B3 protein has an inhibiting function on the MDP-NOD2-RIP2 signaling pathway, 
and this inhibition is diminished in individuals carrying the SH2B3 risk allele. The 
increased cytokine production observed in these individuals is in line with the 
interaction of SH2B3 with the ERK1/2 and p38MAPK pathways19,20, which in turn 
mediates NOD2-induced IL1-ß production21. These functional consequences of
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different SH2B3 gene variants suggest, on the one hand, a possible mechanism of 
how this polymorphism contributes to the increased risk of developing immune- 
related diseases and, on the other hand, that the cause of the positive selection 
should be sought in improved host defense against infections. The improved 
response to bacterial ligands, followed by positive selection, is reminiscent of the 
similar observation reported on the selection of TIRAP/Mal variants, an important 
adaptor molecule for the innate immune responses22.
In summary, we have demonstrated signs of positive selection for three common loci 
associated to CD. Our study of SH2B3 reveals, for the first time, the function of the 
protein in the innate immune response and provides a possible explanation for its 
positive selection. It is tempting to speculate on the specific selective pressure that 
influenced the selective sweep of l,2OO-l,7OO years ago. We would note that one of 
the most important infectious diseases shaping human history in the Middle Ages 
was bubonic plague, NOD2 is known to be an important receptor for the agent of 
plague Yersinia pestis23, and we here show that SH2B3 variants strongly modulate 
NOD2-dependent immune responses.
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Materials and methods 
Celiac disease susceptibility alleles
Genome-wide association studies (GWAS) and follow-up studies have identified ten 
celiac disease (CD) susceptibility loci7-9. For this study we investigated whether the 
established CD susceptibility alleles (Table 1) showed signatures of recent selection 
in the human genome. For the analysis we selected a 4 Mb window around the most 
associated CD SNP for each of the ten loci. In the IL12A locus there were two SNPs 
independently associated to CD and these were both included in the analysis, giving 
a total of 11 SNPs for ten loci.
Study populations
We used the genotyping results from ongoing celiac GWA studies. The current study 
includes 4,533 cases and 10,750 controls, from four European populations (UK, the 
Netherlands, Italy and Finland) genotyped on Custom Illumina Human 670-Quad 
slides, includes Hap550 and 120k CNV probes) (detailed quality control steps 
described elsewhere, Dubois PC, et al., in preparation). The Sarahawi families with 
CD were genotyped on an Illumina Human 610-Quad platform. Only founder 
individuals from the Saharawi families were included in the analysis. The number of 
genotyped individuals from the five populations included in the analysis is indicated 
in Supplementary table 1.
HapMap phase II
Because large allele frequency differences between populations may be the result of 
differential selection pressures, we studied the allele frequency distribution of the 
CD risk alleles in HapMap phase II data. A total of 270 people are included in the 
HapMap II database: 30 trios of US residents with Northern and Western European 
ancestry (CEU), 30 trios of Yoruba people from Ibadan, Nigeria (YRI), 45 unrelated 
Japanese individuals from the Tokyo area (ASN), and 45 unrelated Chinese 
individuals from Beijing (ASN)24. The founders were included in the analyses. We did
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not use HapMap III populations, because not all the susceptibility SNPs were 
genotyped in all of them.
Imputation
Imputation was performed using Plink as described elsewhere25. We used the 
HapMap2 CEU genotypes as a reference panel. Only SNPs with an information score 
above 0.8 and imputed in more than 80% of individuals were included in further 
analysis. Similar results were observed in both genotyped and imputed datasets.
Data analysis
Regions of 4 Mb around the CD susceptibility alleles were extracted from the 
genotyped datasets. The Beagle software program was used to phase haplotypes 
from genotypes26. Based on chimpanzee alignment, we assigned an ancestral state 
to all the SNPs in the data files; all the CD susceptibility alleles had known ancestral 
states.
Integrated Haplotype Score (iHS)
We used the iHS software (available online at http://hgdp.uchicago.edu/) to 
calculate extended haploblocks around the CD susceptibility loci in the genome-wide 
SNP datasets. iHS is a statistic that was developed to detect evidence of recent 
positive selection (< 30,000 years ago) at a locus, and is based on the differential 
levels of linkage disequilibrium surrounding a positively selected allele compared to 
the background allele at the same position12. An extremely positive iHS score means 
that haplotypes on the ancestral allele background are longer than the derived allele 
background, whereas an extremely negative iHS score means that the haplotypes on 
the derived allele background are longer than the haplotypes associated with the 
ancestral allele.
We standardized the iHS values using derived frequency bins in a set of _5,000 
randomly chosen SNPs surrounding the CD susceptibility regions and located at least 
500 kb away from the associated SNP. The standardization was performed 
separately in each population using control datasets for the European populations 
and all the founder samples for the Saharawi population. After standardization, the
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¡HS distribution was normal with a mean of 0.00015 and a standard deviation of 
0.9996. We calculated the p value with a two-sided test based on the normal 
distribution of the iHS values. To study signs of recent selection around the CD 
susceptibility loci in HapMap phase II, we used a web-based tool, Haplotter 
(http://hg-wen.uchicago.edu/selection/haplotter.htm)12. Per SNP we checked 
whether the ancestral allele was correctly assigned as the ancestral allele in 
Haplotter and if it was incorrect we changed the output accordingly.
In the Saharawi population, the iHS score could be calculated for 9/11 SNPs. The iHS 
values could not be calculated for rs13151961 (IL2/IL21 locus) or rs17810546 (IL12A 
locus) due to a low allele frequency and extended haplotype homozygosity (EHH).
Estimating the age of the selective sweep
We calculated the extended haplotype homozygosity (EHH) to obtain a crude 
estimate of the age of expansion of the derived variant as a result of recent 
selection, the so-called selective sweep. For this analysis we assumed a star 
phylogeny of the haplotypes. The recombination distance r is the distance in 
cM/Mbp between EHH = x to the left and to the right of the core SNP. For a chosen 
x, r can be obtained from the data. As both x and r are then known, the generation 
time g can be calculated as g = (ln x / -r )  * 100. Assuming an average generation 
length of 25 years, the age of the selective sweep equals 25g. For this study, we 
calculated r using EHH = 0.30 (support interval EHH = 0.25 -  EHH = 0.35).
Fixation index (Fst)
When a genetic variation is under positive selection, it increases in prevalence in a 
population. Because diet, climate and pathogen load vary across the world, there are 
population differences in selective pressure resulting in global allele frequency 
variations. Therefore, allele frequency differences between populations could 
indicate that the alleles were under selection in a certain population (although it 
could also point towards a population bottleneck). The Fst is a measure of 
population differentiation based on data of genetic variation and the statistic 
compares the genetic variability within and between populations13.
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Under neutral selection, Fst is determined by genetic drift and will therefore affect 
all loci in the genome in a similar way. We study the Fst values of the celiac 
susceptibility loci in the HapMap II populations and compared these values with an 
empirical genome-wide distribution16.
Functional studies
For the functional studies of assessing monocyte release of pro-inflammatory 
cytokines, we used 56 Caucasian individuals from the Netherlands. We obtained an 
informed consent from all the participants.
Venous blood was drawn from the cubital vein of volunteers in 10 ml EDTA tubes 
(Monoject). Peripheral blood mononuclear cells (PBMC) were isolated by density 
centrifugation on Ficoll-Hypaque (Amersham Biosciences, Diegem, Belgium). After 
isolation, the PBMCs were resuspended in RPMI medium 1640, counted (Coulter 
Electronics) and the number was adjusted to 5x106 cells/ml. A volume of 100 y I was 
added to round-bottom 96-well plates (Greiner) and incubated with 100 y I of culture 
medium (negative control) or various stimuli. Stimuli added to the PBMCs were 
lipopolysaccharide (LPS, 10 ng/ml), or muramyl dipeptide (MDP, 10 Yg/ml), Pam3Cys 
(10 Yg/ml). IL-6 and IL-8 and IL1-_ were measured by commercial ELISA kits (Sanquin, 
Amsterdam, the Netherlands).
The genotype frequencies were tested for Hardy-Weinberg equilibrium by x 2 
analysis. Association between genotypes (as the independent variable) and IL-6, IL-8 
and IL1_ production (as dependent variables) was determined using the Mann­
Whitney U test. We also performed trend analyses to test a dose-response effect for 
the CD risk alleles. For this analysis, we used log-transformed data, because the 
cytokine production levels were not normally distributed among the tested 
individuals.
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Supplemental tables and figures
gene population RS ID N ind Allele Frq IHSnoncorrected IHScorrected pvalue
CCR3 FIN cases is6441961 647 0,3 -0,997 -0,865 0,387
CCR3 FIN controls is6441961 1829 0,294 -0,688 0,056 0,955
CCR3 It cases is6441961 497 0,347 0,337 1,329 0,184
CCR3 It controls is6441961 543 0,324 0,234 1,562 0,118
CCR3 N cases is6441961 803 0,379 -0,691 -0,381 0,704
CCR3 N controls is6441961 846 0,31 -0,789 -0,534 0,594
CCR3 Sahaiaw is6441961 195 0,249 -1,221 -0,422 0,673
CCR3 UK3 cases is6441961 1849 0,322 -0,892 -0,652 0,514
CCR3 UK3 cortrols is6441961 4936 0,297 -0,939 -0,728 0,467
CCR3 HapMapCEU is6441961 60 0,317 -0,025
CCR3 HapMapYRI is6441961 60 0,075 1,431
CCR3 HapMapAZN is6441961 89 0,339 -0,757
IL12A FIN cases is9811792 647 0,501 -1,219 -1,774 0,076
IL12A FIN controls is9811792 1829 0,475 -1,239 -1,595 0,111
IL12A It cases is9811792 497 0,472 -1,288 -1,540 0,124
IL12A It contiols is9811792 543 0,42 -1,159 -1,342 0,180
IL12A N cases is9811792 803 0,498 -1,202 -1,401 0,161
IL12A N controls is9811792 846 0,444 -1,218 -1,424 0,154
IL12A Sahaiaw is9811792 195 0,344 -1,373 -1,174 0,240
IL12A UK3 cases is9811792 1849 0,487 -1,048 -1,134 0,257
IL12A UK3 controls is9811792 4936 0,46 -1,063 -1,157 0,247
IL12A HapMapCEU is9811792 60 0,525 -0,937
IL12A HapMapYRI is9811792 60 0,3 -0,556
IL12A HapMapAZN is9811792 89 0,61 -2,187
IL12A FIN cases is17810546 647 0,132 -2,784 -2,924 0,0035
IL12A FIN cortols is17810546 1829 0,101 -2,792 -2,936 0,0033
IL12A It cases is17810546 497 0,112 -2,641 -3,224 0,0013
IL12A It contiols is17810546 543 0,067 -2,729 -2,923 0,0035
IL12A N cases is17810546 803 0,169 -2,622 -3,004 0,0027
IL12A N cortols is17810546 846 0,118 -2,874 -3,434 0,0006
IL12A Sahaiaw 195 0,06 rot calaJated
IL12A UK3 cases is17810546 1849 0,137 -2,753 -3,221 0,0013
IL12A UK3 cortols is17810546 4936 0,128 -2,811 -3,321 0,0009
IL12A HapMapCEU is17810546 60 0,1 -2,492
IL12A HapMapYRI is17810546 60 rot present r/a
IL12A HapMapAZN is17810546 89 rot present r/a
IL18RAP FIN cases is917997 647 0,221 -1,809 -1,775 0,076
IL18RAP FIN cortols is917997 1829 0,192 -1,822 -1,383 0,167
IL18RAP It cases is917997 497 0,245 -1,841 -2,026 0,043
IL18RAP It cortols is917997 543 0,23 -1,847 -2,036 0,042
IL18RAP N cases is917997 803 0,287 -1,921 -2,013 00 44
IL18RAP N cortols is917997 846 0,216 -1,859 -1,911 0,056
IL18RAP Sahaiaw is917997 195 0,154 -2,562 -1,703 0,089
IL18RAP UK3 cases is917997 1849 0,262 -1,897 -2,070 0,038
IL18RAP UK3 cortols is917997 4936 0,238 -1,877 -2,036 0,042
IL18RAP HapMapCEU is917997 60 0,233 -1,739
IL18RAP HapMapYRI is917997 60 0,067 -0,450
IL18RAP HapMapAZN is917997 89 0,406 -2,115
IL2 FIN cases is13151961 647 0,088 -1,171 -0,004 0,997
IL2 FIN cortols is13151961 1829 0,115 -1,167 -0,334 0,738
IL2 It cases is13151961 497 0,084 -1,132 -0,235 0,814
IL2 It cortols is13151961 543 0,12 -1,046 -0,483 0,629
IL2 N cases is13151961 803 0,127 -1,223 -0,617 0,537
IL2 N cortols is13151961 846 0,194 -1,164 -0,516 0,606
IL2 Sahaiaw 195 0,02 rot calcJated
IL2 UK3 cases is13151961 1849 0,127 -1,162 -0,486 0,627
IL2 UK3 cortols is13151961 4936 0,167 -1,182 -0,521 0,603
IL2 HapMapCEU is13151961 60 0,192 -1,976
IL2 HapMapYRI is13151961 60 0,017 rot calcJated
IL2 HapMapAZN is13151961 89 rot present r/a
LPP FIN cases is1464510 647 0,6 0,215 -0,055 0,956
LPP FIN cortols is1464510 1829 0,547 0,265 0,416 0,677
LPP It cases is1464510 497 0,517 0,127 0,250 0,802
LPP It cortols is1464510 543 0,471 0,186 0,722 0,470
LPP N cases is1464510 803 0,531 0,111 0,228 0,819
LPP N cortols is1464510 846 0,493 0,112 0,560 0,576
LPP Sahaiaw is1464510 195 0,313 0,079 1,104 0,270
LPP UK3 cases is1464510 1849 0,495 0,066 0,187 0,852
LPP UK3 cortols is1464510 4936 0,435 0,099 0,668 0,504
LPP HapMapCEU is1464510 60 0,425 -0,673
LPP HapMapYRI is1464510 60 0,183 -0,629
LPP HapMapAZN is1464510 89 0,511 0,794
REL FIN cases is842647 647 0,322 -0,994 -0,860 0,390
REL FIN cortols is842647 1829 0,323 -0,989 -0,852 0,394
REL It cases is842647 497 0,223 -1,111 -0,839 0,401
REL It cortols is842647 543 0,263 -1065 -0,764 0,445
REL N cases is842647 803 0,294 -1,134 -0,719 0,472
REL N cortols is842647 846 0,346 -1,152 -1,100 0,271
REL Sahaiaw is842647 195 0,136 -1,685 -0,512 0,608
REL UK3 cases is842647 1849 0,307 -1,117 -1,014 0,311
REL UK3 cortols is842647 4936 0,348 -1,122 -1,022 0,307
REL HapMapCEU is842647 60 0,3 -0,516
REL HapMapYRI is842647 60 0,475 -1,793
REL HapMapAZN is842647 89 0,828 -0,279
Supplementary table 1. Distribution 
of iHS values in European CD cases 
and controls and in the Saharawi 
population.
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RGS1 FIN cases rs2816316 647 0,875 0,800 0,044 0,965
RGS1 FIN controls rs2816316 1829 0,857 0,701 -0,110 0,912
RGS1 It cases rs2816316 497 0,87 0,684 0,070 0,944
RGS1 It contro Is rs2816316 543 0,831 0,752 0,184 0,854
RGS1 N cases rs2816316 803 0,752 -0,212 -0,951 0,342
RGS1 Nl controls rs2816316 846 0,711 -0,081 -0,756 0,450
RGS1 Saharawi rs2816316 195 0,756 0,657 0,106 0,915
RGS1 UK3 cases rs2816316 1849 0,865 0,747 0,031 0,975
RGS1 UK3 controls rs2816316 4936 0,822 0,754 0,042 0,966
RGS1 HapMapCEU rs2816316 60 0,783 0,695
RGS1 HapMapYRI rs2816316 60 0,733 -0,334
RGS1 HapMapAZN rs2816316 89 0,767 1,039
SH2B3 F  I N cases rs3184504 647 0,463 -1,738 -2,424 0,015
SH2B3 F  IN controls rs3184504 1829 0,398 -1,766 -2,129 0,033
SH2B3 I t cases rs3184504 497 0,542 -1,915 -2,754 0,006
SH2B3 It controls rs3184504 543 0,494 -1,977 -2,597 0,009
SH2B3 N cases rs3184504 803 0,524 -1,708 -2,597 0,009
SH2B3 Nl controls rs3184504 846 0,465 -1,680 -2,114 0,035
SH2B3 Saharawi rs3184504 195 0,151 -2,209 -1,224 0,221
SH2B3 UK3 cases rs3184504 1849 0,525 -1,689 -2,451 0,014
SH2B3 UK3 controls rs3184504 4936 0,468 -1,736 -2,214 0,027
SH2B3 HapMapCEU rs3184504 60 0,408 -2,756
SH2B3 HapMapYRI rs3184504 60 rot present n'a
SH2B3 HapMapAZN rs3184504 89 rot present n'a
TAGAP FIN cases rs1738074 647 0,569 -1,140 -1,658 0,097
TAGAP FIN controls rs1738074 1829 0,58 -1,150 -1,673 0,094
TAGAP It cases rs1738074 497 0,537 -1,125 -1,592 0,111
TAGAP It contro ls rs1738074 543 0,587 -1,029 -1,450 0,147
TAGAP N cases rs1738074 803 0,555 -1,170 -1,761 0,078
TAGAP Nl controls rs1738074 846 0,605 -1,042 -2,059 0,039
TAGAP Saharawi rs1738074 195 0,531 -1,141 -1,425 0,154
TAGAP UK3 cases rs1738074 1849 0,532 -1,056 -1,499 0,134
TAGAP UK3 controls rs1738074 4936 0,577 -1,056 -1,499 0,134
TAGAP HapMapCEU rs1738074 60 0,508 -1,287
TAGAP HapMapYRI rs1738074 60 0,283 -1,275
TAGAP HapMapAZN rs1738074 89 0,339 0,637
TNFAIP3 FIN cases rs2327832 647 0,224 -1,374 -1,065 0,287
TNFAI P3 FIN controls rs2327832 1829 0,185 -1,420 -0,740 0,460
TNFAI P3 It cases rs2327832 497 0,222 -1,465 -1,415 0,157
TNFAI P3 It contro ls rs2327832 543 0,157 -1,475 -1,220 0,222
TNFAI P3 N cases rs2327832 803 0,233 -1,540 -1,387 0,166
TNFA P3 Nl controls rs2327832 846 0,205 -1,566 -1,430 0,153
TNFA P3 Saharawi rs2327832 195 0,249 -1,354 -0,616 0,538
TNFA P3 UK3 cases rs2327832 1849 0,253 -1,579 -1,522 0,128
TNFA P3 UK3 controls rs2327832 4936 0,23 -1,584 -1,531 0,126
TNFA P3 HapMapCEU rs2327832 60 0,175 -1,491
TNFA P3 HapMapYRI rs2327832 60 0,108 -0,544
TNFA P3 HapMapAZN rs2327832 89 0,006 rot calculated
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Supplementary table 2. Estimation of the age of the selective sweep in European 
populations, with different EHH thresholds.
a
IL12A threshold EHH
FIN cases 
FIN controls 
IT cases 
IT controls 
NL cases 
NL controls 
UK cases 
UK controls
b
IL18RAP threshold EHH
FIN cases 
FIN controls 
IT cases 
IT controls 
NL cases 
NL controls 
UK cases 
UK controls
c________
SH2B3 threshold EHH
FIN cases 
FIN controls 
IT cases 
IT controls 
NL cases 
NL controls 
UK cases 
UK controls
0,25 0,3 0,35
2302 2104 2012
2248 2303 2054
2545 3770 3305
2479 3381 3446
2531 2960 3378
2231 2297 2182
2423 2198 2107
2423 2410 2107
0,25 0,3 0,35
5702 5461 6822
6282 5560 6822
7751 7824 6887
7481 7700 6822
8188 7111 6200
7606 7111 6200
7136 6834 6200
7136 7111 6200
0,25 0,3 0,35
1253 1528 1418
1248 1608 1502
1761 1551 1438
1727 1525 1339
1756 1525 1355
1756 1541 1374
1756 1533 1425
1756 1525 1370
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Supplementary figure 1. EHH plot of derived and ancestral haplotypes.
a. rsl7810546 SNP in IL12A locus (1 Mb left and right from rsl7810546)
b. rs917997 SNP in IL18RAP locus (500 kb left and right from rs917997)
c. rs3184504 SNP in SH2B3 locus (1.4 Mb left and right from rs3184504 are 
included).
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Summary and general discussion
Innate immunity represents our first line of defence against pathogenic 
microorganisms. Understanding the factors that alter the innate immune response 
can therefore give important insights in the pathogenesis of infections. During recent 
years, important advances have been made in understanding the innate immune 
signal pathways. Seminal studies have established that several classes of pathogen 
recognition receptors (PRRs) are involved in microbial recognition and induction of 
the innate immune response. In addition, it has been hypothesized that genetic 
polymorphisms in the genes of the innate immune system have an important 
contribution to the host susceptibility to infections.
During the last decade, a wealth of studies has investigated whether genetic 
variation in genes of the innate immunity in general, and PRRs in particular, 
influence susceptibility to infections. Genetic polymorphisms in the genes of the 
TLR4 pathway have been suggested to have important effects for the susceptibility 
to Gram-negative and fungal infections13, while polymorphisms in TLR2 have been 
proposed to influence infections with mycobacteria and Gram-positive infections4. 
Similarly, a premature stop codon of the flagellin receptor TLR5 has been claimed to 
increase susceptibility to Legionella pneumonia5,6. However, almost all these studies 
describe the influence of these polymorphisms in relative small numbers of 
individuals in one population, and do not explain the wide genetic variation in innate 
immunity genes between human populations in different geographic locations. The 
main hypothesis of this thesis is that the variation in genetic polymorphisms of 
innate immunity genes in populations of various ethnic and geographical origin has 
been moulded by evolutionary pressures exerted by local infections. In the present 
thesis, I have investigated this hypothesis from the perspective of several important 
recognition pathways in innate immunity: recognition of lipopolysaccharide of Gram­
negative bacteria by the TLR4/Mal pathway, recognition of fungal b-glucans by 
dectin-1, and the modulation of host defense by the modulatory genes caspase-12 
and SH2B3. The data presented here demonstrate that polymorphisms in innate
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immune genes correlate with functional differences. This implies that local infectious 
pressure can have an important consequences on the prevalence of functional 
polymorphisms in these genes in the various populations around the globe. One of 
the most difficult challenges remains to understand which infectious pathogens 
could have been responsible for the evolutionary pressure on these genes.
In the first part of this thesis, I studied how polymorphisms of the important PRR 
TLR4 and the enzyme Caspase-12 impact susceptibility to infections, and how this 
may explain the breadth of genetic variation in the innate immune system in various 
populations. In these studies, we have focused on the role of the genetic variation 
during bacterial sepsis. Chapter 2 shows that the impact of two TLR4 
polymorphisms, namely Asp299Gly and Thr399Ile, on the susceptibility to infections 
is inconsistent in the literature. The various studies assessing the role of TLR4 
Asp299Gly and Thr399Ile polymorphisms in human disease employ three types of 
methodology: i. genetic association studies; ii. functional stimulation experiments; 
and iii. cloning and transfection of the wild-type and variant TLR4 molecules. Our 
review of the literature demonstrates the inconsistencies of the conclusions drawn 
using different methodologies. In most studies using transfection of variant TLR4 
alleles into cell lines, a reduced recognition and cytokine signalling in the presence of 
the TLR4 polymorphisms is reported. However, studies employing this methodology 
are particularly prone to in-vitro artefacts: the use of modified cell lines, disruption 
of the receptors during the transfection, and overfeeding of the system all 
contribute to these possible artefacts. Therefore, transfections are not the ideal tool 
to determine the phenotypic consequence of TLR4 polymorphisms.
These observations are confirmed and extended by the studies reported in the 
Chapter 3 of the thesis. We approached the differences between genotypes and 
phenotypes in TLR4 from an evolutionary point of view. Firstly, we compared the 
TLR4 Asp299Gly and Thr399Ile polymorphisms in different populations from Africa, 
Asia and Europe and this comparison revealed the co-segregation of the TLR4 
Asp299Gly and Thr399Ile in Europe, and the low frequency of the Thr399Ile 
polymorphism in Africa. Thus, there are important differences in the TLR4 genotype
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between various populations. The most common cause of genetic variation between 
populations is represented by SNPs, i.e., a single mutation in the gene of interest. 
Once such a mutation occurs in a population, its frequency can change in time 
through processes like recombination, migration, demography, selection, and 
random drift. By investigating the evolutionary selection on TLR4 polymorphisms, it 
is possible to identify changes in the innate immune response that affect the fitness. 
The combination of evolutionary genetic tests and the translation into a phenotype 
with changed immunological function is the ideal starting point for our 
understanding how genetic variations influence susceptibility to infections. 
Application of this evolutionary approach to the TLR4 Asp299Gly and Thr399lle 
polymorphism revealed that white blood cells of the TLR4 Asp299Gly genotype 
stimulated by LPS produced more pro-inflammatory cytokines, and such enhanced 
production may have a deleterious influence on mortality during a Gram-negative 
sepsis. It was hypothesized that the low frequency of the TLR4 299Gly allele in 
Europe was due to negative selection of this gene by high pressure exerted by Gram­
negative bacterial infections through history. However, functional assessment of the 
co-segregated Asp299Gly and Thr399lle TLR4 genotype did not show any change in 
the phenotype upon challenge of white blood cells with LPS or Gram-negative 
microorganisms. The lack of association between Asp299Gly/Thr399Ile haplotype 
and either susceptibility to sepsis or the severity of sepsis confirmed this conclusion. 
Interestingly, it was recently published that TLR4 indeed shows signatures of 
purifying selection in African and East-Asian populations7.
In conclusion, in Chapter 3 we demonstrate that the differences in the effect of the 
TLR4 Asp299Gly and Thr399lle polymorphisms on the phenotype are caused by the 
strong linkage between these two polymorphisms in Europe, and the presence of a 
subgroup of individuals bearing only the Asp299Gly in Africa. The differential 
representation of these functional haplotypes was unfortunately not considered in 
many studies in the literature, which can explain several inconsistencies reported 
previously. We conclude that there is a fundamental difference between the TLR4 
haplotypes in Europe and Africa, with important consequences for the function of 
the receptor. Moreover, these data imply that assessment of the TLR4 Asp299Gly
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SNP must always be performed in tandem with the Thr399lle TLR4 polymorphism, in 
order to determine the correct genotype.
In Chapter 4, l investigated the TLR4 recognition pathway by assessing the effect of a 
Mal/TIRAP polymorphism on cytokine production and susceptibility to infection. 
Mal/TIRAP is an important adaptor molecule that transmits the intracellular signals 
from TLR4 through MyD88, leading to gene transcription. From this study we 
conclude that the Mal polymorphism rs8177374 (that leads to a change of a serine 
into a leucine) increases the resistance of individuals that are heterozygous for the 
variant allele to infections. In addition, in an experimental model in which human 
volunteers receive an infusion with bacterial endotoxin (LPS) and are monitored 
during a period of 6 hours, heterozygosity of Mal/TIRAP had a strong impact on 
cytokine production capacity, and this may indicate an increase of resistance to 
infection.
In addition to its role in the recognition of Gram-negative bacteria, the TLR4 pathway 
is instrumental in the recognition of other bacteria, e.g., Mycobacterium tuberculosis
[8]. To evaluate the effect of the TLR4 Asp299Gly genotype on the susceptibility to 
tuberculosis, we assessed its effect in an African cohort of patients with this 
infection. In Chapter 5, I concluded that individuals bearing the TLR4 299Gly allele 
had a greater risk of developing active tuberculosis. Secondly, in this study it was 
found that a genetic variation in the innate immune system may have consequences 
for the adaptive immune response as it led to a reduction in the CD4 T-lymphocyte 
count. Functional studies have to be conducted to fully understand the mechanism 
behind the effect of the TLR4 Asp299Gly genotype on the CD4 counts during HIV 
infection.
Altogether, Chapters 2 to 5 demonstrate that the evaluation of genetic variation in 
the innate immune system through an evolutionary approach has the potential to 
elucidate the phenotypic difference that plays a role in the susceptibility to 
microorganisms, and thereby contributes to the understanding of the pathogenesis 
of these infections. Functional stimulation tests for genetic variants in both TLR4 and
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Mal/TIRAP indicate modulation of proinflammatory cytokine production by SNPs in 
these genes. Low production of proinflammatory cytokines during the initial phase 
of the infection can lead to an inefficient clearance and higher chance to develop 
severe sepsis9, while overwhelming cytokine release during the late phase of the 
infection can also have deleterious effects through induction of septic shock. 
Interestingly, the heterozygous state of the Mal Ser180Leu polymorphism shows 
signatures of a selective advantage10, suggesting that a well-balanced cytokine 
release is protective in sepsis, while both too low or very high cytokine release has 
deleterious effects.
Caspase-12 is a cysteine protease thought to play an important role in inhibiting 
caspase-1 and NOD2/RIP innate immune signalling pathways11-13. In Chapter 6 I have 
investigated the functional consequences of caspase-12 polymorphisms. Recent 
studies have demonstrated the existence of two forms of the molecule in the 
population, one that is biologically active and is thought to lead to the inhibition of 
the caspase-1 and NOD2/RIP signalling pathways, and a second inactive truncated 
form. The active form of caspase-12 is only found in African populations. The second 
variant of the molecule is biologically inactive due to an early stop codon mutation in 
the caspase-12 gene, is found in all populations studies, although it is fixated in 
Europe and Asia. Evolutionary research of the caspase-12 gene has shown that the 
differences of the observed active caspase-12 frequency and lack of it in European 
and Asian populations was the result of evolutionary selection14,15, and the selection 
on the inactive caspase-12 should therefore be an indication that there is a 
substantial fitness difference between the inactive and active caspase-12 in humans. 
Functional research on the active caspase-12 suggested that this genotype had a 
lower proinflammatory cytokine production during Gram-negative infections 
compared to the inactive caspase-12 phenotype13. This led to the hypothesis that 
the inactive caspase-12 genotype was selected in Europe and Asia by a severe 
epidemic of the relatively recent history12,15. One such epidemic that exerted strong 
evolutionary selection was the plague epidemics of the Middle Ages. To gain more 
insight whether caspase-12 genotype results in a different immune response to 
Yersinia pestis, the causative agent of plague, I investigated the response of
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leukocytes isolated from individuals with various caspase-12 genotypes to Y. pestis. 
Our analysis of the phenotypic consequences of caspase-12 genotype in African 
populations from Mali shows that neither the caspase-1 nor the NOD2/RIP pathways 
are inhibited by active caspase-12. Thus, the functional data obtained during 
stimulation with either LPS or Y. pestis do not support the hypothesis that plague or 
other Gram-negative infections explain the profound fitness difference in the 
prevalence of the inactive form of caspase-12.
The loss of the active form of caspase-12 in European populations, while caspase-12 
remains active in a sizable proportion of African populations, could indicate that 
caspase-12 may also have an alternative beneficial effect in the African setting, 
possibly due to a specific infectious pressure. In Africa, malaria is one of the 
infections that probably exert the most profound selective pressure on the human 
genome. In Chapter 7 I investigated the potential effect of caspase-12 on the 
susceptibility and severity to malaria in two West-African populations from endemic 
areas. In addition, these studies were completed by functional investigations on the 
role of caspase-12 in the response to malaria of cells isolated from uninfected 
individuals. In both these clinical and immunological studies, we did not observe any 
evidence for a major role of the active caspase-12 in the pathogenesis of malaria, 
although a possible effect of active caspase-12 on the outcome of pregnancy in 
malaria-infected mothers was reported. However, this observation has to be 
carefully considered and should be replicated in additional studies, in order to verify 
its biological relevance.
Overall, Chapters 6 and 7 show that despite a relatively strong genetic evidence of 
selection on caspase-12 genotypes, no definitive conclusions could be drawn 
regarding the physiological role of this enzyme. In the case of caspase-12, this is 
particularly remarkable, as the early truncation leading to an inactive form of 
caspase-12 could relatively easily result in a phenotypic difference. These results 
may have two alternative explanations: either caspase-12 has a role different from 
what was previously reported in the literature, or the function of caspase-12 is
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completely redundant and can be fully compensated by other components of the 
innate immune system.
In the first part of this thesis, a combination between genetic data (genotype) and 
functional data (phenotype) was employed in order to gain insights in the 
differences in susceptibility to infections between individuals and populations. A first 
step was to use an evolutionary approach, in order to understand the genetic 
variability that determines susceptibility to Gram-negative sepsis. A second step in 
this approach was to translate the genetic variations into phenotypic differences. 
The studies on the genetic variations in the TLR4 receptor and the signalling 
molecule Mal/TIRAP indicate that a proper design of functional studies and genetic 
association studies can be successful in determining the corresponding genotypes 
and phenotypes responsible for differences in susceptibility to infections. The 
importance of functional studies to complement the genetic methodologies is 
apparent also from our studies on the role of caspase-12. While the genetic studies 
have suggested an important role of caspase-12 for the inflammatory reaction, 
cytokine stimulation experiments revealed that the proposed function of caspase-12 
was not confirmed. This suggests a redundant non-essential role of caspase-12, 
similar to that reported recently for the flagellin receptor TLR5. While the TLR5 
392stop mutation in European populations is relatively frequent (up to 20-23% of 
the population), the loss of TLR5 by the 392stop mutation is not correlated with a 
major increase of infections caused by flagellated bacteria. A similar situation 
appears to be true in the case of the inactive caspase-12.
In the second part of the thesis, we took a step further in order to assess the 
relationship between genetic variation and susceptibility to infections: one starting 
from a clinical problem, and one employing an evolutionary approach. On the one 
hand, clinical translational research starts from a clinical observation of one or more 
patients with a particular presentation of the disease. The phenotype of the patients 
represents the starting point for the reconstruction of the pathophysiology of the 
disease. Eventually, genetic variation in a specific gene could be the cause of the 
observed phenotypic difference. On the other hand, the evolutionary approach
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starts from the observation that a genotype difference is present between 
populations, and this difference is caused by selection. These signatures of selection 
point to a functional difference between the different genotypes. Understanding 
these functional differences will lead to insight in those genetic variants in the innate 
immune system that had a substantial contribution to altered susceptibilities to 
infections.
Chapter 8 demonstrates an example of the clinical approach. This study was initially 
prompted by the observation that cells isolated from a patient with recurrent 
vulvovaginal candidiasis and onychomycosis responded with a defective cytokine 
release upon stimulation with Candida albicans beta-glucans. Dectin-1 is the 
recognition receptor for beta-glucans, and its role in the pathogenesis of fungal 
infections has been demonstrated in mice and humans16,17. The defective response 
to beta-glucans led us to hypothesize that a defective dectin-1 function may be the 
cause of the clinical symptoms. Sequencing of the dectin-1 gene of the patient 
revealed the presence of an early stop mutation (Tyr238Stop mutation) in 
homozygous state. Sequencing of the family of the patient revealed that both 
parents were heterozygous, while the two other female siblings were homozygous 
for the dectin-1 stop mutation. All three siblings and the mother suffered from 
chronic onychomycosis, while two of the sisters had recurrent vulvovaginal 
candidiasis. Functional tests to determine the immunologic consequences of the 
dectin-1 stop mutation showed the lack of dectin-1 expression on white blood cells 
of the dectin-1 deficient patients, and reduced cytokine production after 
stimulations with C  albicans. The phagocytosis and fungicidal capacity of neutrophils 
from individuals with the dectin-1 mutations was normal. Overall, these experiments 
showed that the dectin-1 receptor plays an important role in the antifungal mucosal 
defence. Interestingly, assessment of the dectin-1 stop mutation in human 
populations revealed that the haplotype with the dectin-1 stop mutation was not 
uncommon, and future research has to clarify whether (partial) loss of dectin-1 may 
also have positive consequences that could explain its high prevalence in the 
population.
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The evolutionary approach towards understanding innate immunity is employed in 
Chapter 9. The human genome has been shaped by positive natural selection, 
meaning that beneficial traits tend to increase in frequency in the population over 
time. On the other hand, deleterious traits tend to disappear from the population. In 
contrast to this general rule, genetic traits that induce susceptibility to 
immunological disorders are commonly present in the population, despite their 
negative influence on human health. As a consequence, the worldwide rate of 
immunological diseases suggests that the process of natural selection may have 
favoured in the past the genes underlying these (present) deleterious traits. In this 
study we investigated the evolutionary origin of genes underlying celiac disease (CD), 
a common immunological disease. Signatures of selection were found for 10 
confirmed CD susceptibility loci in several populations from Europe and North Africa, 
with consistent signs of positive selection for three CD-associated derived alleles: 
IL12A, IL18RAP and SH2B3. All these three genes that showed signatures of selection 
are involved in the innate immunity. While IL-12A and IL-18RAP are known to 
modulate Th1-type responses, the function of the SH2B3 is not well understood. We 
therefore investigated the possible cause responsible for the selection of the SH2B3 
variants found in CD, by studying the effect of bacterial ligands stimulations on 
cytokine production in cells isolated from individuals bearing different SH2B3 
genotypes. We show that cells isolated from individuals homozygous for the SH2B3 
CD risk allele display increased proinflammatory cytokine production. This suggests 
that SH2B3 is a master regulator of immune responses to infections, and suggests 
that this particular locus has been selected because of its protective effects against 
bacterial infection. This study demonstrates that a rational approach with 
evolutionary tools can identify important novel genes for the pathophysiology of 
human diseases such as immune disorders or infections.
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The aim of the studies presented in this thesis was to provide additional insights into 
the role of evolutionary processes for shaping our immune system as a result of 
environmental pressures exerted by infections. On the one hand, several genetic 
variants in the innate immune system were investigated, and their role for 
influencing susceptibility to both Gram-negative bacteria and fungal infections was 
demonstrated. On the other hand, these studies provided additional proof for the 
complexity of the immune responses, and for the multiple levels of redundancy that 
insure an appropriate response to the pathogens. This redundancy has important 
implications for the understanding of the impact of genetic variation on human 
pathology, and points to the importance of the methodology used to evaluate the 
effect of genetic variation. An additional conclusion that can be drawn from these 
studies is that the complementary use of evolutionary, immunological and clinical 
methodological approaches can lay a stronger foundation for a better understanding 
of the relationship between the genotype and phenotype of genes of innate 
immunity.
Although we have been able to discern the global distribution of the various genetic 
polymorphisms, and have been able to give a critical appraisal on the functional 
aspects in terms of mediator response, we have not been able to establish which 
infections were exerting the selective pressure during history of mankind. Further 
investigations are needed to elucidate the exact nature of the plagues that have 
determined the evolutionary pressures leading to the changes of our host defence 
genes.
In conclusion, genetic variation strongly influences human susceptibility to infection. 
Due to the complexity and redundancy of the innate immune system mechanisms, a 
complex approach employing genetic, immunological and clinical methodologies is 
warranted in order to obtain an integrated view of host-pathogen interaction during 
infections.
Summary and general discussion
Final conclusion
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Het menselijk aangeboren afweersysteem is van belang voor onze eerstelijns 
verdediging tegen ziekteverwekkende micro-organismen. Kennis en begrip van de 
factoren die deze aangeboren afweer kunnen veranderen, geven belangrijk inzicht in 
het ontstaan en verloop van infecties. In de afgelopen jaren zijn belangrijke inzichten 
verworven in de werking en functie van de aangeboren afweer "signal pathways", 
waarbij eiwitten elkaar kunnen aan- of uitschakelen en daarmee de fysiologie van 
een cel beïnvloeden. Meerdere studies hebben aangetoond dat verschillende 
pathogeen herkennende receptoren (Pathogen Recognition Receptors, afgekort met 
PRRs) betrokken zijn bij de herkenning van ziekteverwekkende micro-organismen en 
daarmee de aangeboren afweer "signal pathways" induceren. Algemeen wordt 
aangenomen dat genetische polymorfismen in genen van de aangeboren afweer 
deze signalering beïnvloedt en hierdoor een belangrijke bijdrage kan hebben in 
verschillende gevoeligheid tussen mensen voor infecties.
Tijdens het laatste decennium is in een veelvoud aan studies onderzocht of 
genetische polymorfismen in genen van de aangeboren afweer in het algemeen en 
PRRs in het bijzonder, de gevoeligheid voor infecties beïnvloedt. Genetisch 
polymorfisme in het gen van de toll-like receptor 4 (TLR4) heeft belangrijke gevolgen 
voor de gevoeligheid voor Gram-negatieve en schimmel infecties1-3, terwijl genetisch 
polymorfisme in TLR2 invloed op de gevoeligheid van mycobacteriën en Gram- 
positieve infecties lijkt te hebben4. Tevens is er een voortijdig stopcodon van de 
flagellin receptor TLR5 die de gevoeligheid verhoogt voor Legionella pneumonie5,6. 
Echter, bijna al deze studies beschrijven de invloed van genetische polymorfismen in 
een relatief klein aantal individuen afkomstig uit dezelfde populatie en houden geen 
rekening met de grote genetische variatie in aangeboren afweergenen tussen 
menselijke populaties van verschillende geografische locaties. De belangrijkste 
hypothese van dit proefschrift is dat polymorfismen in genen behorende tot het 
menselijk aangeboren afweersysteem in populaties met een verschillende etnische 
en geografische herkomst veroorzaakt kunnen zijn door evolutionaire druk van
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lokaal voorkomende infecties. In dit proefschrift hebben we deze hypothese 
onderzocht vanuit het perspectief van een aantal belangrijke herkennings 
"pathways" die deel uitmaken van de aangeboren afweersysteem, namelijk: 
herkenning van lipopolysaccharide (LPS) van Gram-negatieve bacteriën door de 
TLR4/Mal "pathway", herkenning van schimmel bèta -glucanen door dectin-1, en de 
modulering van de gastheer tegen pathogenen door de "pathway" modulerende 
eiwitten caspase-12 en SH2B3. De in dit proefschrift gepresenteerde gegevens laten 
zien dat genetische polymorfismen in genen van het aangeboren afweersysteem 
correleren met functionele verschillen. Dit houdt in dat lokaal voorkomende 
infecties belangrijke oorzaken zouden kunnen zijn van het voorkomen van 
functionele genetische polymorfismen in aangeboren afweersysteem genen tussen 
verschillende bevolkingsgroepen. Één van de moeilijkste uitdagingen blijft echter om 
te achterhalen welke infectieuze micro-organismen verantwoordelijk zijn geweest 
voor deze evolutionaire druk op de genen.
In het eerste deel van dit proefschrift bestudeerden we hoe genetische 
polymorfismen van de belangrijke PRR TLR4 en het enzym Caspase-12 effect hebben 
op de gevoeligheid voor infecties, en hoe deze genetische polymorfismen in het 
aangeboren afweersysteem tussen verschillende populaties verklaard kunnen 
worden. In deze studies hebben we ons gericht op de rol van genetische 
polymorfismen tijdens bacteriële sepsis. Hoofdstuk 2 laat zien dat het effect van 
twee genetische polymorfismen in TLR4, namelijk Asp299Gly en Thr399Ile, op de 
gevoeligheid voor infecties onjuist worden onderzocht in de literatuur. De 
verschillende studies beoordelen de rol van de genetische polymorfismen Asp299Gly 
en Thr399Ile in TLR4 en de functionele verschillen tussen mensen met behulp van 
drie methodieken namelijk: i. genetische associatie studies; ii. functionele stimulatie 
experimenten, en iii. klonen en transfectie van de TLR4 receptor die de genetische 
variatie bevat. Onze literatuur review geeft een overzicht van de tegenstrijdigheden 
in de conclusies over de invloed van de genetische polymorfismen in TLR4 in relatie 
met de verschillen in gevoeligheid voor sepsis. Het laat tevens zien dat de reden voor 
de verschillende conclusies sterk beïnvloed is door de keuze van de onderzoeks 
methoden. In de meeste studies die de verschillende TLR4 allelen in cellijnen
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transfecteren hebben de genetische polymorfismen van TLR4 een verlaagde 
herkenning en cytokine productie. Nadeel van de methode is dat deze bijzonder 
gevoelig is voor in-vitro artefacten zoals: i. het gebruik van gemodificeerde cellijnen 
ii. verstoring van de receptoren door de transfectie en iii. een overvoeding van de 
TLR4 receptoren tijdens het experiment. Deze drie artefacten dragen bij aan een 
mogelijk verkeerde interpretatie van de gevolgen die de TLR4 genetische 
polymorfismen kunnen hebben op de functie. Transfecties zijn daarom niet de ideale 
manier om de fenotypische gevolgen van de genetische polymorfismen in TLR4 te 
bepalen.
Deze conclusies worden bevestigd en uitgebreid door de studie in hoofdstuk 3. Daar 
benaderden we de verschillen tussen genotypen en fenotypen in TLR4 vanuit een 
evolutionair perspectief. Ten eerste hebben wij de TLR4 Asp299Gly en Thr399lle 
genetische varianten tussen verschillende populaties uit Afrika, Azië en Europa 
vergeleken. Deze vergelijking liet het voorkomen zien van een co-segregatie van de 
TLR4 Asp299Gly en Thr399lle in Europa en een lage frequentie van de Thr399lle TLR4 
variant in Afrika. De populatie verdeling van de Asp299Gly en Thr399lle TLR4 
varianten liet dus zien dat er belangrijke verschillen in de TLR4 genotype tussen de 
verschillende bevolkingsgroepen zijn. De meest voorkomende oorzaak van deze 
genetische varianten tussen populaties wordt gevormd door mutaties van een 
enkele nucleotide (Single Nucleotide Polymorphisme, afgekort SNP) in het 
desbetreffende gen. Wanneer een mutatie optreedt in een populatie, kan de 
frequentie daarvan veranderen in de tijd door processen zoals recombinatie, 
migratie, demografie, selectie en willekeurige drift. Bij het onderzoek naar de 
evolutionaire selectie van TLR4 genetisch polymorfisme, is het mogelijk om 
veranderingen in het aangeboren afweersysteem die invloed hebben op de fitness te 
identificeren. De combinatie van evolutionaire genetische tests en de vertaling in 
een fenotype met gewijzigde immunologische functie is het ideale startpunt voor het 
begrip hoe genetische polymorfismen invloed kunnen hebben op de gevoeligheid 
voor infecties.
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Toepassing van deze evolutionaire benadering op de functionele gevolgen voor het 
TLR4 Asp299Gly en Thr399lle genetisch polymorfisme liet zien dat witte bloedcellen 
van het TLR4 Asp299Gly genotype gestimuleerd met LPS meer pro-inflammatore 
cytokinen produceren. Deze verhoogde productie kan een nadelige invloed hebben 
op de mortaliteit gedurende een Gram-negatieve sepsis. Verondersteld werd dat de 
lage frequentie van het TLR4 299Gly allel in Europa te wijten was aan negatieve 
selectie van dit gen door een verhoogde druk van Gram-negatieve bacteriële 
infecties gedurende de geschiedenis. Echter, functionele beoordeling van het 
genotype met de Asp299Gly en Thr399lle TLR4 in co-segregatie, die met name in 
Europa voorkomt, toonde geen verandering in het fenotype bij stimulatie van de 
witte bloedcellen met LPS of Gram-negatieve micro-organismen. Het ontbreken van 
een associatie tussen het Asp299Gly/Thr399lle haplotype en de gevoeligheid voor 
sepsis of ernst van sepsis bevestigen deze conclusie. Interessant is een recentelijk 
gepubliceerd onderzoek over TLR4 dat inderdaad tekenen van selectie aantoonde in 
Afrikaanse en Oost-Aziatische populaties, maar niet in Europa7.
Tot slot laat hoofdstuk 3 zien dat de verschillen in het effect op het fenotype van de 
genetische varianten Asp299Gly en Thr399lle in TLR4 het resultaat zijn van de sterke 
segregatie van deze genetische varianten in Europa in vergelijking met de 
aanwezigheid van een subgroep van personen met alleen de Asp299Gly in Afrika. 
Het verschil in de TLR4 fenotypen door genotypisch polymorfisme is in veel studies 
helaas niet in acht genomen en kan de inconsistentie tussen de invloed van de TLR4 
genotypen op de gevoeligheid voor Gram-negatieve bacteriële sepsis verklaren. We 
concluderen dan ook dat er een belangrijk fundamenteel verschil is tussen de TLR4 
haplotypen in Europa en Afrika met belangrijk gevolgen voor de functie van de 
receptor. Hierbij is het van belang dat voor het fenotype van de TLR4 Asp299Gly SNP 
deze altijd moet worden onderzocht in combinatie met de Thr399lle TLR4 variant.
In hoofdstuk 4, onderzochten we de TLR4 receptor door het effect van genetisch 
polymorfisme in Mal/TlRAP op de cytokine productie en de gevoeligheid voor 
infecties te bepalen. Het Mal/TlRAP adapter molecule is een belangrijk eiwit dat de 
intracellulaire signalen van TLR4 via het MyD88 eiwit overbrengt, wat leidt tot gen
Samenvatting en algemene discussie
199
transcriptie van onder andere pro-inflammatore cytokinen. In een experimenteel 
model waarin menselijke vrijwilligers een infuus met bacteriële endotoxinen (LPS), 
gedurende een gecontroleerde periode van 6 uur, kregen toegediend zagen wij een 
sterke invloed op de cytokine productiecapaciteit bij personen die heterozygoot 
waren voor de Mal/TIRAP rs8177374 SNP. Uit dit onderzoek concludeerden we dat 
de genetische variant van een Mal SNP rs8177374 (een SNP dat leidt tot vervanging 
van een serine door een leucine in het eiwit) de weerstand verhoogd van 
heterozygote individuen die één allel hebben met de leucine mutatie en één zonder 
de mutatie. Door de betere aangeboren afweer reactie van deze personen verklaard 
deze bevinding een de minder heftige ziekteverschijnselen bij Gram-negatieve 
bacteriële infecties.
Naast de herkenning van Gram-negatieve bacteriën, is de TLR4 receptor ook 
betrokken bij de herkenning van andere bacteriën, zoals Mycobacterium 
tuberculosis8, veroorzaker van tuberculose . Evaluatie van het effect van het TLR4 
Asp299Gly genotype op de gevoeligheid voor actieve tuberculose, is bestudeerd in 
een Afrikaanse patiënten groep met deze infectie. In hoofdstuk 5, concludeerden we 
dat individuen die het TLR4 299Gly allel dragen een groter risico hebben op het 
ontwikkelen van actieve tuberculose. Op de tweede plaats bleek uit dit onderzoek 
dat een genetisch polymorfisme in TLR4 van het aangeboren afweersysteem 
gevolgen kan hebben voor het verworven afweersysteem en leiden tot een verlaging 
van de CD4 T-lymfocyten. Uitvoering van functionele studies zijn nog gewenst voor 
een volledig begrip van het mechanisme achter het effect van het TLR4 299Gly 
genotype op de CD4-tellingen tijdens een HIV-infectie.
Samen tonen hoofdstukken 2 tot 5 aan dat de evaluatie van genetische 
polymorfismen in het aangeboren afweersysteem door middel van een evolutionaire 
benadering de potentie heeft om fenotypische verschillen, die een rol spelen bij de 
gevoeligheid voor micro-organismen te verduidelijken, en daarmee bijdraagt tot het 
begrip van de invloed van genetische polymorfismen op de pathogenese van 
infecties. De functionele stimulaties van witte bloedcellen met de genetische 
varianten in zowel TLR4 en Mal/TIRAP lieten een verandering van het fenotype zien
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in de productie van pro-inflammatore cytokinen door de aanwezigheid van SNPs in 
deze genen. Lage productie van de pro-inflammatore cytokinen tijdens de eerste 
fase van een infectie kan leiden tot een inefficiënte klaring en een hogere kans op 
ernstige sepsis 9, terwijl een hoge cytokine productie tijdens de latere fase van een 
infectie ook schadelijke effecten kan hebben door het induceren van een septische 
shock. Interessant is dat de heterozygote toestand van de Mal Serl80Leu genetische 
variant een selectief voordeel laat zien10, wat erop duidt dat een evenwichtige 
cytokine productie beschermend is bij sepsis, terwijl zowel een te lage als ook een te 
hoge cytokine productie schadelijke gevolgen voor de gastheer kan hebben.
Verondersteld wordt dat Caspase-12, een cysteïne protease, een belangrijke rol 
speelt bij het remmen van de caspase-1 en NOD2/RIP signalerings "pathway"11-13. In 
hoofdstuk 6 hebben we onderzoek gedaan naar de functionele gevolgen van één 
genetische variant in caspase-12. Recente studies hebben namelijk aangetoond dat 
er door één genetische variant twee vormen van het caspase-12 eiwit in de 
populatie bestaan namelijk een biologisch actief eiwit dat leidt tot de remming van 
het caspase-1 en de NOD2/RIP signaal "pathway" en een tweede inactieve verkorte 
vorm. De actieve variant van caspase-12 is alleen te vinden in de Afrikaanse 
bevolking. De inactieve verkorte variant van het eiwit is biologisch inactief door een 
stopcodon veroorzaakt door een mutatie van het caspase-12 gen, die te vinden is in 
alle onderzochte populaties, hoewel gefixeerd in populaties in Europa en Azië. 
Evolutionair onderzoek van het caspase-12 gen toonde aan dat de verschillen in 
voorkomen van de actieve caspase-12 frequenties en het ontbreken daarvan in de 
Europese en Aziatische bevolking het gevolg van evolutionaire selectie was14,15. De 
positieve selectie van met name het inactieve caspase-12 geeft daarom een indicatie 
dat er een wezenlijk verschil is tussen de fitness van individuen met inactief en actief 
caspase-12. Functioneel onderzoek naar het actieve caspase-12 enzym suggereerde 
dat dit genotype een lagere pro-inflammatore cytokine productie tijdens Gram- 
negatieve infecties had dan het inactieve caspase-1213. Dit leidde tot de hypothese 
dat het inactieve caspase-12 genotype in Europa en Azië geselecteerd was door een 
ernstige bacteriële epidemie gedurende de relatief recente menselijke 
geschiedenis12,15. Een epidemie die een sterke evolutionaire selectie veroorzaakt kan
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hebben was de pest gedurende de Middeleeuwen. Om meer inzicht erin te krijgen of 
het caspase-12 genotype ook resulteert in een andere afweerresponse bij een 
infectie met Yersinia pestis, de verwekker van pest, onderzochten en vergeleken we 
de reactie van leukocyten, geïsoleerd uit personen met verschillende caspase-12 
genotypen, op stimulatie met Y. Pestis en LPS. Uit onze analyse van de fenotypische 
verschillen van het caspase-12 genotype in de Afrikaanse bevolking van Mali bleek 
dat noch de voorgestelde caspase-1, noch het voorgestelde NOD2/RIP "pathway" 
werden geremd door de aanwezigheid van het actieve caspase-12. Onze stimulaties 
met Y. pestis of LPS ondersteunen daarom niet de hypothese dat pest of andere 
Gram-negatieve bacteriële infecties de oorzaak waren van de voorgestelde 
evolutionaire selectie op één van de caspase-12 genotypen en dat een andere uitleg 
moet gevonden moet worden voor de prevalentie van de inactieve vorm van 
caspase-12.
Het verlies van de actieve vorm van caspase-12 in Europese populaties, terwijl de 
caspase-12 actief blijft in een aanzienlijk deel van de Afrikaanse populaties, kan er 
ook op duiden dat het actieve caspase-12 een alternatief gunstig effect in de 
Afrikaanse omgeving heeft, mogelijk als gevolg van een specifieke infectieuze druk 
aldaar. In Afrika is malaria één van de infecties waarvan duidelijk is bewezen dat het 
menselijk genoom de infectieuze selectieve druk ervan heeft ondergaan. In 
hoofdstuk 7 onderzochten we de mogelijke gevolgen van caspase-12 op de 
gevoeligheid en de ernst van malaria in twee West-Afrikaanse populaties uit 
endemische malaria gebieden. Bovendien bevat deze studie functionele 
onderzoeken over de rol van actief en inactief caspase-12 en het gevolg voor de 
cytokine productie op stimulaties met malaria van cellen geïsoleerd uit niet- 
geïnfecteerde personen. In deze klinische en immunologische onderzoeken, hebben 
we niet kunnen waarnemen dat actieve caspase-12 in de pathogenese van malaria 
een grote rol speelt op de aangeboren afweer. Hoewel er wel een mogelijk effect 
van actief caspase-12 op het resultaat van zwangerschap in de met malaria 
geïnfecteerde moeders kon worden waargenomen. Deze bevinding moet echter 
zorgvuldig worden geïnterpreteerd en aanvullende studies zullen nodig zijn om dit te 
controleren en de biologische relevantie te onderzoeken.
Samenvatting en algemene discussie
202
Samenvatting en algemene discussie
Samengevat tonen de hoofdstukken 6 en 7 aan dat ondanks een relatief sterke 
genetische selectie op de caspase-12 genotypen, geen definitieve conclusies kunnen 
worden getrokken over de fysiologische rol van dit enzym. In het geval van caspase- 
12 is dit bijzonder opmerkelijk omdat de mutatie leidt tot een inactieve vorm van 
caspase-12 die relatief gemakkelijk kan resulteren in fenotypische verschillen. Het 
niet kunnen bevestigen van deze verschillen kan twee verklaringen hebben: of 
caspase-12 heeft een rol die totaal verschilt van wat eerder werd gemeld in de 
literatuur, of de functie van caspase-12 is volledig overbodig in het aangeboren 
afweer en kan volledig worden gecompenseerd door andere componenten van dit 
systeem.
In het eerste deel van dit proefschrift werd een combinatie van genetische gegevens 
(genotype) en functionele gegevens (fenotype) gebruikt om inzicht te verkrijgen in 
de verschillen tussen gevoeligheid voor infecties van individuen en 
bevolkingsgroepen. Hierbij is in eerste instantie een evolutionaire benadering 
gebruikt om inzicht te krijgen in de genetische variabiliteit die ten grondslag kan 
liggen aan de gevoeligheid voor Gram-negative sepsis tussen individuen. Vervolgens 
is er gekeken naar de vertaling van deze polymorfismen in mogelijke functionele 
verschillen. Uit de studies van de genetische polymorfismen in TLR4 en het 
signalerings eiwit Mal/TIRAP bleek dat een goed ontwerp van functionele en 
genetische associatie studies succesvol kan zijn bij het bepalen van de 
overeenkomstige genotypen en fenotypen die verantwoordelijk zijn voor verschillen 
in gevoeligheid voor infecties. Het belang van functionele studies als aanvulling op 
de genetische methoden komt ook naar voren uit onze studies over de rol van 
caspase-12. Hoewel de genetische studies een belangrijke rol van caspase-12 voor 
de ontstekingsreactie hebben verondersteld konden stimulatie experimenten de 
vermeende functie van caspase-12 niet bevestigen. Dit suggereert een niet- 
essentiële rol van caspase-12 die vergelijkbaar is met de flagellin receptor TLR5. Voor 
TLR5 is namelijk een 392stop mutatie beschreven in de Europese bevolking met een 
relatief hoge frequentie (tot wel 20-23% van de bevolking). Ondanks het verlies van 
de TLR5 door de 392stop mutatie gaat dit niet gepaard met een grote toename van
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infecties veroorzaakt door bacteriën. In het geval van caspase-12 lijkt het om een 
soortgelijke situatie te gaan.
In het tweede deel van dit proefschrift hebben we een iets ander benadering 
gebruikt om de relatie tussen genetische polymorfismen en de gevoeligheid voor 
infecties te begrijpen: ten eerste een aanpak vanuit de klinische visie en ten tweede 
een aanpak die gebaseerd is op een evolutionaire benadering. De klinische 
translationele aanpak gaat uit van de observatie in de kliniek waarbij één of meer 
patiënten met een bijzondere presentatie van een ziekte het uitgangspunt vormen. 
Hierbij is het fenotype van de patiënten het uitgangspunt voor de reconstructie van 
de pathofysiologie van de ziekte. Uiteindelijk leidt dit ertoe dat genetisch 
polymorfisme in een specifiek gen de oorzaak is van de waargenomen fenotypische 
verschillen. Bij de evolutionaire benadering is het beginpunt de constatering dat een 
genotypisch verschil aanwezig is tussen bevolkingsgroepen, en dat dit verschil 
veroorzaakt wordt door selectie. Deze tekenen van selectie in het menselijk genoom 
geven functionele verschillen tussen de verschillende genotypen. Inzicht in deze 
functionele verschillen kan leiden tot het begrijpen van genetische varianten in het 
aangeboren afweersysteem, die een substantiële bijdrage hebben geleverd aan de 
veranderde gevoeligheid voor infecties.
Hoofdstuk 8 beschrijft een voorbeeld van de klinische aanpak. Deze studie werd in 
eerste instantie ingegeven door de observatie dat cellen geïsoleerd uit een patiënt 
met recidiverende vulvovaginale candidiasis en schimmelnagels een defecte cytokine 
response hadden op stimulatie met bèta-glucanen van de schimmel Candida 
albicans. Dectin-1 is de receptor van de aangeboren afweer die bèta-glucanen 
herkend, en een belangrijke rol in de pathogenese van schimmelinfecties heeft. De 
betrokkenheid van dectin-1 in deze herkenning is uitvoerig onderzocht en 
aangetoond in muizen en mensen studies16,17. De gebrekkige respons van de 
patiënten op bèta-glucanen van C  albicans heeft ons geleid tot de hypothese dat er 
een gebrekkige dectin-1 functie ten grondslag ligt aan de klinische symptomen. DNA 
sequentieanalyse van het dectin-1 gen van de patiënt toonde de aanwezigheid van 
een vroege stop mutatie (Tyr238Stop) in homozygote staat aan. Sequencing van de
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familie van de patiënt toonde aan dat beide ouders heterozygoot waren, terwijl de 
twee andere vrouwelijke nakomelingen ook homozygoot waren voor de dectin-1 
stop mutatie. Alle drie de nakomelingen en moeder leden aan chronische 
schimmelnagels, terwijl twee ook recidiverende vulvovaginale candidiasis hadden. 
Functionele testen voor het bepalen van de immunologische gevolgen van de dectin- 
1 stop mutatie toonden aan dat de expressie van de dectin-1 receptor op de witte 
bloedcellen van de dectin-1-deficiënte patiënten ontbrak en dat zij een verminderde 
productie van cytokines vertoonden na stimulatie met C. Albicans. In tegenstelling 
daarmee waren de fagocytose en fungicide capaciteit van neutrofielen met de 
dectin-1-mutaties normaal. Algemeen tonen deze experimenten aan dat de dectin-1 
receptor een belangrijke rol speelt in de schimmeldodende mucosale verdediging. 
Interessant is dat onderzoek naar het voorkomen van de dectin-1 stop mutatie in 
menselijke populaties liet zien dat de mutatie niet zeldzaam is. Toekomstig 
onderzoek kan inzicht geven of het gedeeltelijk verlies van de dectin-1 functie ook 
mogelijk positieve gevolgen zou kunnen hebben, waardoor de hoge prevalentie in de 
populatie verklaard kan worden.
Het toepassen van de evolutionaire aanpak om de aangeboren afweer te begrijpen 
wordt toegepast in hoofdstuk 9. Het menselijk genoom is gevormd door positieve 
natuurlijke selectie, wat betekent dat na mutaties gunstige eigenschappen 
geselecteerd worden en deze na verloop van tijd een hogere frequentie in de 
bevolking hebben. Aan de andere kant kunnen negatieve eigenschappen door 
selectie in de loop van de tijd uit de populatie verdwijnen. In tegenstelling met deze 
algemene regel kunnen genetische eigenschappen die tot gevoeligheid leiden voor 
immunologische stoornissen vaak nog aanwezig zijn in de bevolking, ondanks dat 
deze een negatieve invloed op de menselijke gezondheid hebben. Het wereldwijde 
percentage van immunologische ziekten suggereert dat het proces van natuurlijke 
selectie de betrokken genen in het verleden om andere redenen kan hebben 
bevoordeeld, met als gevolg daarvan dat genen die ten grondslag liggen aan de 
(huidige) schadelijke gevolgen nog steeds in de menselijke populatie aanwezig zijn. 
Daarom hebben we in deze studie onderzocht of er een evolutionaire oorsprong van 
de onderliggende genen bij coeliakie (CD), een veelvoorkomende immunologische
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ziekte, was. Tekenen van selectie werden gevonden voor tien genen betrokken bij 
CD in verschillende populaties uit Europa en Noord-Africa. Consistente tekenen van 
selectie waren er voor drie mutaties in de CD geassocieerde allelen van de IL12A, 
IL18RAP en SH2B3 genen. Al deze drie genen die tekenen van selectie vertoonden 
maken onderdeel uit van het aangeboren afweer systeem. Van IL-12A en IL-18RAP is 
bekend dat zij betrokken zijn bij de Th1 afweer response, de functie van SH2B3 is 
niet goed begrepen. Daarom hebben wij onderzoek gedaan naar de mogelijke 
oorzaak die verantwoordelijk is voor de selectie van de SH2B3 variant, een CD risico 
allel. Dit is gedaan door bestudering van het effect van verschillende bacteriële 
stimuli op cellen die geïsoleerd waren uit individuen met verschillende SH2B3 
genotypen. Stimulaties toonden aan dat cellen van individuen die homozygoot voor 
het SH2B3 CD risico allel waren een verhoogde productie van pro-inflammatore 
cytokinen gaven. Dit suggereert dat SH2B3 een regulator functie heeft tijdens de 
afweerresponse op infecties. Ook suggereert dit dat het specifieke CD risico allel 
waarschijnlijk is geselecteerd vanwege de beschermende effecten tegen bacteriële 
infecties. Deze studie toont aan dat een rationele benadering met evolutionaire 
aanpak belangrijke nieuwe genen kan identificeren voor de pathofysiologie van 
ziekten bij de mens zoals immuun aandoeningen of infecties.
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Het doel van de studies in dit proefschrift was om meer inzicht te geven in de rol van 
evolutionaire processen voor de vorming van ons aangeboren afweersysteem als 
gevolg van infectieuze druk door onze omgeving. Ten eerste werden verschillende 
genetische varianten in het aangeboren afweersysteem onderzocht en de rol 
aangetoond die zij hebben voor het beïnvloeden van de gevoeligheid voor zowel 
Gram-negatieve bacteriën en schimmelinfecties. Ten tweede lieten de studies de 
complexiteit en plasticiteit van de menselijke aangeboren afweersysteem reactie 
zien die ten grondslag liggen aan een goede afweerreactie tegen ziekteverwekkers. 
Deze complexiteit en plasticiteit hebben belangrijke implicaties voor het begrip van 
de invloed van genetische polymorfismen op de menselijke afweer tegen 
ziekteverwekkers, en wijst op het belang van de methoden die worden gebruikt om 
het effect van genetische polymorfismen te evalueren. Hierbij laten deze studies zien 
dat een integraal gebruik van een evolutionaire, immunologische en klinisch 
methodologische benadering een sterker fundament kan leggen voor een beter 
begrip van de relatie tussen het genotype en fenotype van genen die deel uitmaken 
van ons aangeboren afweersysteem.
Hoewel we in staat zijn geweest de wereldwijde distributie van de verschillende 
genetische polymorfismen te onderscheiden, en in staat waren om een kritische 
beoordeling van de functionele aspecten te geven waren we niet in staat een 
specifiek antwoord te geven op de vraag, welk pathogenen verantwoordelijk waren 
voor de selectieve druk tijdens de geschiedenis van de mensheid. Verdere 
onderzoeken zullen nodig zijn om opheldering te verschaffen over de vraag welke 
infecties en epidemieën ten grondslag lagen aan evolutionaire druk welke geleid 
heeft tot veranderingen van onze genen die betrokken zijn bij de afweer.
Kortom, genetische polymorfismen beïnvloeden sterk de menselijke gevoeligheid 
voor infecties. Vanwege de complexiteit en de redundantie van de werking van het 
aangeboren afweersysteem zijn een complex genetische, immunologische en
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klinische aanpak noodzakelijk om een correct beeld te krijgen van de interacties 
tussen de gastheer en pathogeen tijdens infecties.
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Tot slot misschien wel het meest gelezen onderdeel van een proefschrift: het 
dankwoord. Onderzoek is en blijft een samenwerking met vele personen en kent ook 
hoogte en diepte punten. Gelukkig waren er veel mensen die tijdens mijn 
promotieonderzoek een enorme steun en inspiratie zijn geweest.
Beste Mihai, als eerste wil ik je bedanken voor het vertrouwen dat je in me had in de 
beginperiode van mijn promotietraject. Ons eerste gesprek op je kamer kan ik me 
nog goed herinneren: Ik kwam voor mijn gevoel voor een oriëntatiegesprek en stond 
na 5 minuten alweer op de gang met de mededeling dat ik de volgende dag al kon 
beginnen. Onder jou begeleiding heb ik in de afgelopen jaren mijn eerste stappen in 
de immunologie gezet en ik had geen betere top-onderzoeker kunnen treffen. Jouw 
brede kennis en enthousiasme is ongeëvenaard en een bron van inspiratie. Bruggen 
bouwen doe je niet alleen tussen de kliniek en het lab maar ook tussen verschillende 
onderzoeksgebieden. Je bent een grensverleggende onderzoeker die oprecht een 
"homo universalis" genoemd kan worden. Het was één groot avontuur en het einde 
is nog lang niet in zicht. Ik zal me aan de science belofte houden.
Beste Jos, jij hebt voor mij, met mijn biologische achtergrond, met enthousiasme en 
ongeëvenaarde kennis mijn ogen geopend voor de medische biologie. Jou 
commentaar en adviezen waren altijd scherp en de sterke link tussen de kliniek en 
het laboratorium waren van onschatbare waarde. Ik ben trots dat ik onder jou 
begeleiding mag promoveren.
Natuurlijk wil ik iedereen van het lab interne experimentele geneeskunde bedanken. 
Leo, als hoofd van dit lab, heb je geen makkelijke taak. Jou vrolijkheid en inzet voor 
de afdeling is groot en dragen bij aan de positieve sfeer die er heerst. Al begrijp ik 
dat de focus op de cellulaire experimenten ligt, toch hoop ik wel dat je een mogelijke 
uitbreiding van het PCR hok niet zult vergeten. Anneke en Johanna, ik wil jullie als 
eerste bedanken omdat jullie mij wegwijs hebben gemaakt in het lab en mij lieten
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zien hoe jullie de genetische analyses in Nijmegen deden. Liesbeth en Trees, jullie 
vormen echt een eenheid in ervaring en kennis over de PBMC stimulaties en 
cytokine metingen en ik vond het altijd enorm gezellig om met jullie te werken. Zoals 
jullie met zijn tweeën in het lab aan het werk waren is uniek. Ook was het enorm fijn 
om samen met jou, Liesbeth, het over de nieuwste muziek ontwikkelingen te 
hebben. Bedankt voor de tips die ik nog vaak luister. Ineke en Jan, bedankt voor de 
korte periode dat ik in Nijmegen bij jullie heb mogen wonen. Ik vond het een plezier 
om toen ook éénmaal in de week voor jullie te koken. Helga, Magda, Heidi en Cor, 
bedankt voor de gezellige momenten. Alle analisten van de afdeling zijn in mijn ogen 
de stabiele factor geweest, die voor de continuïteit en kennis van het lab voor 
onschatbare waarde zijn (ook voor de verhalen tijdens de koffiepauzes). Natuurlijk 
wil ik ook alle PhD, AIO, junior onderzoekers en studenten bedanken. Berry, Jeroen, 
Anna, Evelien, Rinke, Frank, Edwin, Tim, Theo, Monique, James, Louis, Hendry, 
Diana, Sanne, Nico, Karlijn, Laury, Mihai Iona en Oana, bedankt voor alle gesprekken, 
adviezen en samenzweringen gedurende de afgelopen periode. In het bijzonder wil 
ik Matthew bedanken. Matthew, het was een ongelooflijk fijne periode om intensief 
met jou samen te werken en je bent letterlijk de rode draad geweest tijdens mijn 
periode aan de Radboud. Ik weet zeker dat dit niet voorbij zal zijn en we elkaar nog 
vaak zullen treffen, misschien wel in Afrika. Tot slot, Gerben, wil ik jou bedanken. Ik 
heb het onvergetelijk gevonden om samen met jou onderzoek te doen. Onze 
persoonlijke cytokine overleg zal zeker voortgezet worden en er zullen nog mooie 
dingen uit voortkomen. Je breedte en veelvoud aan ideeën zijn uniek en ondanks dat 
je jezelf wel eens de Fransje van Dusschoten van de wetenschap hebt genoemd weet 
ik wel beter. Ik ben ook trots dat je tijdens de verdediging aan mijn zijde staat als 
paranimf.
Ik wil ook iedereen bedanken die in de hoofdstukken door het proefschrift heen als 
auteurs worden genoemd. Hierbij wil ik met name André en Wil bedanken voor de 
samenwerking. Het was voor mij extra bijzonder omdat jullie waren betrokken bij 
mijn allereerste wetenschappelijke publicatie. Quirijn, bedankt voor de vele 
momenten waarop ik even je kamer binnenkwam en we over van alles en niets 
praatten. Ik voelde me ook vereerd dat ik bij een onderzoek van jou betrokken was.
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Beste Reinout, de populatie die ¡k van jou gebruikt hebt is misschien wel één van de 
bijzonderste geweest. Ik denk dat je daarom ook nog niet van me af bent. Bedankt 
Peter Pickkers en Bart Ramakers, jullie doen fantastisch onderzoek met een uniek 
model. Het heeft zeker mijn ogen geopend hoe je op een andere manier naar 
evolutionaire effecten kan kijken van sepsis. Gert Vriend en Hanka, ik wil jullie ook 
bedanken. Hanka, ik ben je enorm dankbaar voor je hulp, zeker toen je vertelde dat 
je bezig was met je eigen project en toch nog de tijd vrijmaakte om mij te helpen. 
Beste Cisca Wijmenga en Sasha, bedankt voor de enorm prettige samenwerking 
tijdens de laatste periode van mijn promoveren.
I would also like to thank some international researchers that have been very 
important during my PhD. First, I would like to thank Concepcion de la Rúa and 
Santos Alonso. You do great work on ancient Basque human genetics and I am 
honoured to have been working with you. Also, I would like to thank Evangelos, 
Maria and Paul. Evangelos and Maria, you came together to our lab and I had the 
privilege to work with you. Evangelos, your enthusiasm is unique, I know that this is 
not going to end and I am looking forward to future work. Dear Gordon and Janet, 
thank you very much for the opportunity to come to your laboratory. Both your 
experimental expertise and skills have impressed and inspired me. Also, I would like 
to thank Cristal and Matti from your former department. They have been a great 
help during my visit in South Africa. Finally I would like to thank Jaume Bertrantpetit 
and David Comas. Your work on the human evolution and migration are exceptional 
and I had a great time during my stay at your laboratory in the great city of 
Barcelona. I hope that in the future this collaboration will result in a long lasting 
adventure. Also, I would like to thank everybody from the department of Jaume.
Ook wil ik de mensen bedanken tijdens mijn studie periode op de VU. Jeroen, als 
eerste wil ik jou bedanken voor alle gesprekken die we gedurende de studie biologie 
hadden. Ik zal ook nooit vergeten hoe we samen het vak ontwikkelingsbiologie 
hebben overleefd. Daarnaast wil ik Nico van Straalen, Stefan K(ools) en Martijn 
T(immermans) van de afdeling dierecologie bedanken. In mijn mening hebben jullie 
aan de basis gestaan van dit proefschrift omdat jullie mij enthousiast gemaakt
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hebben voor wetenschappelijk onderzoek. Nico, bedankt dat ik tijdens mijn studie 
op jouw afdeling, onder jou supervisie, mijn stages heb mogen lopen. Stefan K, het 
was een vernieuwende ervaring voor mij hoe wij samen af en toe het gras knipte van 
je microkosmossen. Martijn, de reis die we tijdens jou promotieonderzoek gemaakt 
hebben op jacht naar Orchasella cincta waren de basis om verder te gaan met 
moleculaire technieken.
Beste Stefan en Sietse, ik wil jullie bedanken voor de steun die ik gehad heb tijdens 
mijn promotieonderzoek. We begonnen alledrie aan de docentenopleiding en ik 
kwam er als laatste bij om het 'all stars' team compleet te maken. Tijdens het 
promotieonderzoek heb ik veel aan jullie gehad en ik heb het zeker gewaardeerd om 
met jullie over meer dan het onderzoek alleen te filosoferen. Sietse, ik vind het ook 
heel gaaf dat je tijdens de verdediging naast mij zult staan. Na alle gesprekken die 
we hadden, vond ik het super om te horen dat je naar de kunstacademie ging. Ik voel 
me zeer vereerd dat jij en Lieke de voorkant van mijn proefschrift hebben gemaakt. 
Maarten, Ook jou wil ik bedanken voor de steun en het luisterend oor. Ik blijf het 
uniek vinden hoe alles in Terschelling begon.
Ed en Lotte, bedankt voor jullie steun en medeleven. Ik heb er erg veel aan gehad 
om van jullie te horen hoe het er in de andere wetenschappen aan toe gaat. Al moet 
ik wel bekennen dat ik blij ben dat ik een proefschrift aan de medische faculteit heb 
geschreven en niet aan de geschiedenis faculteit. Aan 493 pagina's (klein letter 
formaat, regelafstand 0.5) kan ik niet tippen. Lieve Elisabeth en Fabien, bedankt voor 
de Bourgondische afleiding in jullie tuin tijdens het promoveren.
Lieve papa en mama, bedankt dekt de lading niet. Jullie hebben mij met liefde 
opgevoed en stonden altijd voor mij klaar. Zoals in de biologie gezegd wordt zijn 
deze "nature" en "nurture" enorm belangrijk en ik heb geen betere kunnen wensen. 
Hoe jullie voor me klaar stonden en me hebben gesteund is bijzonder geweest en 
getuigt van veel liefde. Judith en Lourens, Jelle en Sarah, Gerben en Roos, ik wil jullie 
allemaal bedanken voor de vele keren dat ik even bij jullie langskwam. Al was het in 
Haarlem, Nijmegen of Washington DC, het was altijd zo vertrouwd dat het voelde als
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thuiskomen. Ik heb het ook bijzonder gevonden dat naarmate we ouder werden we 
steeds meer naar elkaar toe gegroeid zijn. Maar dit heeft misschien te maken met 
het Bartje zijn. Natuurlijk ook bedankt aan al mijn nichtjes en neefjes.
Allerliefste Clara, als allerlaatste wil ik jou bedanken. Jij bent het mooiste wat mij 
tijdens mijn promotie is overkomen. Omdat je zelf ook bezig bent met promoveren 
weet je hoe lastig het soms kan zijn en ik heb erg veel gehad aan jouw steun. Ik kijk 
uit naar de avonturen die we samen tegemoet gaan. Ik hou van je.
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